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1.1 Introduction 
1.1.1 Cancer 
Cancer is a collective term used for a group of diseases that are characterized by the 
loss of control of the growth, division, and spread of a group of cells, leading to a 
primary tumor that invades and destroys adjacent tissues. The continuous proliferation 
of cancer cells develops into tumour tissues and may spread across to other organs via 
circulatory systems resulting in metastasis, which is the cause of 90% of cancer 
deaths. There are two types of tumours: those demonstrating the properties described 
above, known as malignant tumours, which result in cancer; and those without 
malignant properties, which are self-limiting, noninvasive and do not metastasise, 
known as benign tumours. Cancer remains one of the most difficult diseases to treat 
and is responsible for about 13% of all deaths worldwide. Cancer may affect humans 
of all ages. According to statistics from the American Cancer Society (ACS), cancer 
is the third most lethal disease after cardiovascular diseases and infectious and 
parasitic diseases1,2. 
Cancer occurs when genetic mutations accumulate in cells during the replication of 
genetic material, allowing cells to undergo transformation. The mutations of three 
major types of genes: oncogenes, tumour suppressor genes and DNA repair genes, 
play an important role in tumourgenesis. Tumorigenic events include small-scale 
changes in DNA sequences, such as point mutations; larger-scale chromosomal 
aberrations, such as translocations, deletions, and amplifications; and changes that 
affect the chromatin structure and are associated with dysfunctional epigenetic 
control, such as aberrant methylation of DNA or acetylation of histones.3 About 
2,000–3,000 proteins may have a potential role in the regulation of gene transcription 
and in the complex signal-transduction cascades that regulate the activity of these 
regulators. Cancer is not only a cell disease, but also a tisular disease in which the 
normal relationships between epithelial cells and their underlying stromal cells are 
altered.4  
 
1.1.2 Cell cycle and regulation5 
The cell cycle is represented in Figure 1 the cycle is divided into four main parts. The 
g1 or gap1 phase is the period when a newly created cell is born. The period of time a 
cell remains in the G1 phase depends on the tissue type and whether it is a normal 
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phase and tumor cell. If the cell is proliferating cell, it will quickly move into the S or 
synthesis phase. It is during this period that nuclear DNA is replicated, and at the end 
of the S phase, two copies of DNA are present in cell. The next phase is G2 or Gap2 
period and this phase is largely a time during which preparations are made for the 
final cell cycle phase, the M phase or mitosis. The time between mitoses is the cell 
cycle time, although this time can vary depending mainly on the duration of G1 phase. 
There are two major control points in the cell cycle. One of these is at G1/S when cell 
commit to replicate. The second is at G2/M when cell commit to divide. Of the two 
major points in the cell cycle, the G1/S phase is of major importance in understanding 
cancer and cancer treatment. 
During the G1 phase a cell can take one of three routes. First, the cell may enter the s 
phase. Second, a cell in G1 phase may enter into fifth phase called G0 or Gap0. Cell in 
G0 are termed quiescent. Third, the cell may terminally differentiate and die. In 
normal cell populations cell may be proliferating, quiescent, or terminally 
differentiating such that there is no net change in the number of cell. However, in 
tumors, the fraction of cell proliferating increases at the expense of quiescent or 
terminally differentiating cell such that there is net increase in the number of cell. 
 
Figure 1 Cell cycle regulation  
1.1.3 Cancer Therapy 
The specific approach used to treat cancer depends upon the specific type, location, 
and stage of the cancer. Regardless of the specific details, there are several 
fundamental techniques available to treat cancer including surgery, radiation therapy, 
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immunological treatment, and chemical based approaches. In most therapeutic 
approaches to the treatment of cancer there will be chemical components.   
Surgery6   
Surgery, the oldest form of cancer treatment, is used in cancer treatment either to 
remove only the tumor, or the entire organ. In order for this approach to be effective, 
the cancer must still be in the primary tumor stage and there must be a high degree of 
confidence that the entire tumor can be excised. Surgery can also be used for 
diagnostic purposes and in combination with other approaches.  
Radiation therapy7 
Radiation therapy is used of ionizing radiation to kill cancer cells and shrink tumors. 
It can be administered externally (external beam radiotherapy) or internally 
(brachytherapy). It does so by causing damage to the DNA of the tumor cell so that 
they die.  Radiation therapy is not painful and anesthetics are not required for the 
procedure. Radiation is often used in combination with other treatments. 
Unfortunately, radiation can cause severe blood changes including drop in production 
of new blood cells, nausea, anemia and vomiting.  
Immunologic therapy8 
This is relatively new approach to the treatment of cancer. There are treatments that 
use the body's own natural defenses to fight cancer. Immunotherapy, also known as 
biotherapy or biological response modifiers, works on white blood cells - the body's 
first line of defense against disease. White blood cells can be stimulated in various 
ways to boost the body's immune response to cancer, with little or no effect on healthy 
tissue. Immunotherapy can also be used to lessen the side effects of other cancer 
treatments. Currently, therapy of this type primarily consists of the administration of 
highly purified interferons, especially interferon-2. 
Chemotherapy9 
Chemotherapy uses powerful drugs to kill cancer cells, control their growth, or relieve 
pain symptoms. Chemotherapy may involve one drug, or a combination of two or 
more drugs, depending on the type of cancer and its rate of progression. 
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Chemotherapeutics agents are complementary to either surgery or radiation therapy in 
that they are affective agents metastasized tumor or residual tumor after surgery or 
radiation therapy. In other words, they are useful for eliminating tumors that are small 
in size. They are certain drawbacks of chemotherapy, the lake of selectivity of the 
agents for normal verses malignant cells. Chemotherapeutics agents are basically 
cytotoxic and thy can kill both normal and malignant cell types. A consequence of 
this is patients undergoing chemotherapy suffer hair loss, depression of their immune 
system, and nausea or diarrhea. These effects typically disappear once chemotherapy 
has been discontinued.      
1.1.4 Classification of cytotoxic drug  
Cytotoxic drugs are usually classified according to their mechanism of action. The 
major classes of cytotoxic agents are shown below. The mechanism of action of 
cytotoxic drug is also summarized in figure 2 
1. Alkylating agents10: alkylating agents and related compounds, which act by 
forming covalent bonds with DNA and thus impeding replication. Such as 
Nitrogen mustard (e.g. Mechloethamine hydrochloride, Cyclophosphamide, 
Chlorambucil, Melphalan, Isofamide), ethyleneimines (e.g. Thiotepa), 
Triazenes (e.g. Dacarbazine), nitrosourea (e.g. Carmustine, Lomustine, 
Semustine, Streptozocin), alkyl sulfonates (e.g. Busulfan) 
2. Antimetabolites11: antimetabolites, which block or subvert one or more of the 
metabolic pathways involved in DNA synthesis. Purine antagonists (e.g. 6-
Mercaptopurine, Thioguanine), pyrimidine antagonists (e.g. Fluorouracil, 
Cytarabine, Fludarabine), folic acid antagonists (e.g. Methotrexate) 
3. Plants alkaloids12: Most of these derivatives specifically affect microtubule 
function and hence the formation of the mitotic spindle. Vinca alkaloids (e.g. 
Vinblastine, Vincristine, Vinorelbine, Vindesine), taxanes (e.g. Taxol, 
Docetaxol) 
4. Topoisomerase inhibitors13: Topoisomerases are essential enzymea that 
maintain the topology of DNA. Inhibition of type I and type II topoisomerases 
interferes with both transcription and replication of DNA by upsetting proper 
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DNA supercoiling. Type I topoisomerase inhibitors (e.g. Irinotecan, 
Topotecan), type II topoisomerase inhibitors (e.g. Amsacrine, Etoposide, 
Teniposide) 
5. Antibiotics14: These are substances of microbial origin that prevent 
mammalian cell division. Anthracyclines (e.g. Doxorubicin hydrochloride, 
Daunorubicin, Idarubicin, Bleomycin, Mitomycin)  
6. Hormonal agents15: Hormones, of which the most important are steroids, 
namely glucocorticoids, oestrogens and androgens, as well as drugs that 
suppress hormone secretion or antagonise hormone action. Estrogens, 
antiastrogenes (e.g. Tamoxifen cytrate, Estramustine phosphate sodium), 
androgens, antiandrogens (e.g. Flutamide), other (e.g. Glucocorticoid, 
Progestins, Octreotide acetate) 
7. Miscellaneous agents16: Miscellaneous agents that do not fit into the above 
categories. This group includes a number of recently developed drugs 
designed to affect specific tumor-related targets. Enzymes (L-asperagina), 
metal compounds (e.g Cisplatin, Carboplatine), other (e.g. Mitoxantrone 
Hydroxyurea, Procarbazine). 
8. Some newer agents do not directly interfere with DNA. These include 
monoconal antidodies and new tyrosine kinase inhibitors e.g. imatinib 
mesylate (gleevec or glivec) with directly targets a molecular abnormality in 
certain types of cancer (chronic myelogenous leukemia, gestrointestinal 
stromal tumors). 
1.2 DNA-alkylating agents 
DNA alkylating agents have played an important part in cancer chemotherapy. 
Alkylating agents, the oldest and most useful among the antineoplastic agents, can be 
defined as compounds capable of covalently binding an alkyl group to a biomolecule 
under physiological conditions (aqueous solution, 37°C, pH 7.4). Some of them 
especially nitrogen mustard (N-mustard), are used clinically for the treatment of 
cancer. 
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 Figure 2. Summary of the main sites of action of cytotoxic agents.     
The other DNA alkylating agents such as mechlorethamine (1), chlorambucil (2), 
melphalan (3), cyclophosphamide (4), estramustine (5), the anthramycine (6), 
cisplatin (7) and bismethanesulfonates (8) derivatives that are remain currently in 
clinical use. All of these drugs share the property of being the source of electrophiles 
that alkylate various nucleophilic groups such as phosphate, amino, hydroxyl, 
carboxyl and imidazole present in biomolecules such as proteins and nucleic acids. 
There are several nucleophilic groups in DNA such as N-1 and N-3 of adenine bases, 
N-3 of cystosine, and in particular N-7 of guanine. Drug with two alkylating groups 
can react with a guanine on each chain and cross-links the strand such that they 
disrupt the replication of transcription leading to the cell death.    
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1.2.1 Nitrogen mustards 
The nitrogen mustard represents the earliest and perhaps most extensively studied of 
the DNA interstrand cross-linking agents.17 The first nitrogen mustard was used in 
cancer therapy was mechlorethamine (1). N-mustards act through the alkylation of 
DNA and prevent cell division by cross-linking DNA, which leads to DNA breaks or 
abnormal base pairing, and subsequently to cell death.18 The overall process of DNA 
alkylation by N-mustard is a two-step process. At neutral or alkaline pH, 
bis(chloroethyl)amine (1) undergoes a first order SN1 intramolecular cyclization, with 
the release of chloride ion and formation of an aziridinium cation (2)19, which is 
highly reactive and unstable species. The strained three member ring of aziridinium 
cation can undergo nucleophilic addition by DNA nucleophile to form a mono 
alkylation adduct. These reactions can then be repeated with the other -CH2CH2Cl to 
give a cross-link. Cross-linking can occur either between two complementary strands 
of DNA (interstrand) or within a strand of DNA (intrastrand). The site specificity the 
mustard was originaly assigned as being the 5GpC3 sequence within B-form DNA.20 
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Despite their clinical importance, the usefulness of many DNA-alkylating drugs is 
often limited by a number of pharmacological deficiencies resulting from the intrinsic 
chemical reactivity of the agent. There are several drawbacks for using DNA 
alkylating agents as chemotherapeutic agents including: 
1. High chemical reactivity5 of conventional drug. This can result in loss of drug’s 
activity by reacting with other cellular nucleophiles such as proteins and low 
molecular weight thiols. These agents may be also induce cellular resistance 
mechanisms because of increasing high level of glutathione. 21, 22 
2. Lack of intrinsic DNA binding affinity of the alkylating pharmacophore requiring 
for cross-linking of DNA to reach fully cytotoxic. This can be resulted by formating 
high ratio of genotoxic mono-adducts to cross-links (20:1)23 and produce 
carcinogenicity9 or bone marrow toxicity. 
3. The major guanine N7 adduct formed by N-mustards is readily repaired and thus, 
may reduce drug efficacy by DNA repair mechanism.24  
There are several strategies to overcome the drawbacks of N-mustards. One of the 
effective strategies is to synthesize N-mustard prodrug to reduce the reactivity of the 
parent N-mustard pharmacophore. Another strategy is preparing N-mustard-DNA-
affinic molecule conjugates to increase sequence-specific Drug-DNA binding. 
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1.2.2 N-mustard Prodrug approaches 
Prodrug therapy provides an alternative approach to design less reactive and less 
cytotoxic form of anticancer drugs.25 Prodrugs can be defined as agents that are 
transformed after administration, either by metabolism or by spontaneous chemical 
breakdown, to form a pharmacologically active species. Prodrugs have been used to 
improve the solubility, transport properties, and pharmacokinetic properties of 
anticancer agents. Early work showed that cyclophosphamide (4), a N-mustards 
prodrug, is able to be activated by enzymatic oxidation to generate active N-mustard 
pharmacophore. This agent is currently widely used for treatment cancer patients.26-27 
In the last two decades, monoclon antibody and exogenous enzyme have been utilized 
for prodrug antibody therapy.28-30 Enzyme-activating prodrug therapy is a two-step 
approach. A drug-activating enzyme (usually antibody-enzyme fusion protein) is 
administered intravenously in the first step, which binds to specific antigen expressed 
on the tumor cell surface. A non-toxic prodrug is administered systemically in the 
second step and is converted to the cytotoxic drug by the pre-targeted enzyme.4-6 
Currently, delivery methods for an enzyme/prodrug strategy can be divided into two 
major classes: (a) delivery of genes that encode prodrug-activating enzymes into 
tumor tissues (GDEPT, VDEPT, etc.); and (b) delivery of active enzymes onto tumor 
tissues (ADEPT). 
Springer et al. have synthesized several N-mustard prodrugs, the phenyl N-mustard 
pharmacophore is linked to enzyme’s substrate moiety, L-glutamic acid, via a urea 
(13 and 14, Z = NH)31 carbamate (13 and 14, Z = O)31 , and carboxamide [15 
(CMDA)32, 33 and 16 (CJS 1050)34] linkage for antibody-directed enzyme prodrug 
therapy (ADEPT),35 or gene-directed enzyme prodrug therapy (GDEPT). After 
enzymatic cleavage by bacterial enzyme carboxypeptidase G2 (CPG2), they can be 
transformed into their corresponding active metabolite phenol or aniline N-mustard 
drugs. The amide analogue 13 (CMDA) was the first ADEPT prodrug evaluated 
clinically.36 
The prodrugs, 17,37 18,38 19,39 and 2039  were also synthesized by linking the aniline 
N-mustard to the trigger unit tyramine, 3-hydroxytyramine, catecholamine, and 4-
aminophenol respectively, via a urea or carbamate linker for melanocyte-directed 
Chapter 1                                                                                                Introduction….. 
  10 
enzyme prodrug therapy (MDEPT). Upon exposure to tyrosinase, these conjugates 
can also release the active aniline or phenol N-mustard. 
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Recently, pedersen et al. have synthesized prodrug 2140 and 2240 with both C16 and 
C18 ether chain and a choline and a glycerol phosphate headgroup, respectively. They 
studied biophysical and biological characterization of the synthesized chlorambucil 
prodrug (21, 22) with liposome formulation, particle size determination, and in 
particular sPLA2 activity. After hydrolysis of sn-2 ether bond by sPLA2, they can be 
released both the anticancer drug bound to sn-2 ether bond and an anticancer ether 
lipid (AFL). 
Various nitro containing derivatives, 5-aziridinyl-2,4-dinitrobenzamides (i.e., 23, CB 
1954),41,42 2,4-dinitrobenzamide 5-N-mustards (24)43,44 and related derivatives  were 
also synthesized for antibody-directed or gene-directed enzyme prodrug therapy. 
These prodrugs can be activated by co-treatment of E. coli nitroreductase (NTR), 
which are able to concert the electron-withdrawing para-NO2 function to NH2 
(electro-donating function) via reductive activation.45-49 compound 24 was superior to 
23 as an NTR substrate, with a 4-fold higher Kcat for purified enzyme50 and 2-3 fold 
faster reduction by NTR expressing mammalian cells.51 
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Similarly, 3,5-dinitrobenzamide nitrogen mustard PR-104 (25),52 which also can be 
activated by nitroreductase. This agent is a novel hypoxia-activated DNA cross-
linking agent with potent activity against human tumor xenografts (e. g., SiHa 
cervical, HT29 colon and H460 NSCLC), both as monotherapy and combined with 
radiotherapy and chemotherapy.52 It suggests that the urea or carbamate linker is 
capable of lowering the reactivity of aniline or phenol N-mustard pharmacophore 
resulting in formation of rather stable N-mustard derivatives. 
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1.2.3 DNA Directed Alkylating Agents 
Another strategy for overcome the drawbacks of DNA-alkylating agents is to 
construct “DNA-directed alkylating agents”. DNA-directed alkylating agents are 
synthesized by linking DNA-affinic molecules (carrier) to a N-mustard 
pharmacohpore (warhead, such as alkyl N-mustard or phenyl N-mustard). The 
generally useful DNA-affinic molecules are DNA-intercalating agents (e. g. 9-
anilinoacridines and acridines), binding agents (quinolines or quinazolines), and DNA 
minor groove binding agents (e. g. distamycin A and netropsin). Most of these carriers 
also exhibit anticancer activity by inhibiting Topoisomerases I and II.53 Most evidence 
shows that DNA-directed alkylating agents are more cytotoxic than the used carrier 
itself. Consequently, connecting DNA-affinic molecules to alkylating agents usually 
results in improved therapeutic efficacy and low toxicity in the compound.  
Creech et al. 54-57 have synthesized DNA-directed alkylating agents by using various 
heterocyclic nuclei such as quinazoline (e.g. 26), quinolone (e.g. 27, 28), 
benz[c]acridine (e.g. 29), and acridine (e.g. 30, 31) as carriers for the N-mustard 
pharmacophore, through aminoalkyl side chain or amide linkage for antitumor studies 
(Figure 8). It revealed that the presence of DNA-intercalating or binding nuclei 
improved the antitumor effectiveness of the mustard moiety against Ehrlich ascites 
tumors in vivo and compounds caused at least five-fold increase in survival time over 
that of the control mice. Treatment of mice bearing ascites tumors with these 
compounds caused at least five-fold increase in survival time over that of the control 
mice.  Based on these finding, the same research group have also synthesized sulfur 
mustard attached with various heterocyclic nuclei through aminoalkyl side chain or 
amide linkage for antitumor studies (e.g. 32, 33 and 34). A striking observation was 
that, the N-mustard conjugates have good anti-tumor activity then corresponding 
sulfur mustard. From this effort it becomes clear that initiatives to increase drug-
DNA-affinity often provide frameworks upon which to design and construct new 
drugs of higher efficacy or altered selectivity. 
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Prakash and co-workers have synthesized a series of phenyl N-mustard link to a 
various quinazoline (35) and 9-aminoacridine (36, 37) via alkyl chain of variable 
length58-60. These conjugates were extremely potent and have pronounced antitumor 
activity. It demonstrated that compound 35 is not a strong intercalator, but it may bind 
weakly at the major groove side. Compounds having a (CH2)n (36) and (CH2)nO (37)  
(n was variable from 2 to 5) were much greater potency (ILS 50-60% at an optimal 
doses of 20-30 mg/kg) than either chlorambucil (ILS 33% at an optimal dose of 225 
mg/kg) or any of the untargeted mustards, using a single-dose protocol. On the other 
hand, the thioether and sulfoxide derivatives of 37 showed only minimal in vivo 
activity.58 The DNA cross-linking studies demonstrate that the compound (36, 37 and 
thioether and sulfoxyde analog of 37) 5’-GT sequences was the most preferred sites at 
which N-7-guanine alkylation occurred. For analogues with longer chain lengths, the 
preference of 5’-GT sequence diminishes in favor of N-7-adenine alkylation at the 
complementary 5’-AC sequence. The thioether analog of 37 was found less reactive 
in vitro interstrand cross-linking than were 36 and 37. These studies suggest that the 
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quinazoline and 4-aminoacridine are also valuable carriers for building DNA-directed 
alkylating agents. Gravatt et. al. also utilized a carrier 4-anilinoquinoline for DNA-
directed alkylating agent (e.g. 38, 39).61 It was demonstrated that these compounds 
exhibited potent antiproliferative activity against human leukemia and various solid 
tumor cell growths in vitro and potent antitumor efficacy in vivo with a relatively low 
toxicity. Particularly, compound 39 bind in minor groove and alkylate both adenines 
and guanines at the N3 position at the 3’-ends of AT-rich sequences, with the most 
preferred sites being AT-tracts.62 These compounds are also efficient interstrand 
crosslinking agents. 
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DNA intercalating agents, 9-anilinoacridine-4-carboxamide [a topoisomerase II,63,64 
and used for treatment of adult leukemia65,66], was used as a carrier for constructing 
DNA-directed alkylating agents. The asymmetry of the 9-anilinoacridine-4-
carboxamide ‘DNA intercalating’ agents (40) makes it a potential regioselective 
carrier of alkylating agents. Recent crystallographic studies of 9-aminoacridine-4-
carboxamide (41) shows the carboxamide side chain binding in the major groove side. 
The mustard analog of 40, where the alkylating unit was attached either off the 4-
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carboxamide (42) or at the 1’-position of the 9-anilino ring (43)67, 68. At the optimal 
dose, these analogues achieved a smaller percentage increase of lifespan (%ILS) than 
the parent m-AMSA (40) in mice bearing murine leukemia p388.67 The 4-linked 
analogue 42 showed to have slightly higher in vivo antileukemic activity than their 
corresponding 1’-linked analogues (43), suggesting that the active side chain may be 
better to be linked to the acridine ring rather than to the aniline ring.  Incubation of 42 
and 43 with calf thymus DNA showed that 42 gave only one adduct, resulting from 
alkylation at guanine N-7 in the major groove. In contrast, the major adduct of 43 
resulted from alkylation at adenine N-3 in the minor groove.68 The studies suggested  
that the 9-anilinoacridine-4-carboxamide chromophore may be important ‘DNA-
threading agent’ with high region-specifity, placing the aniline side chain in the minor 
groove and the carboxamide chain in the major groove.       
 
In order to establish the higher sequence-selectivity, most of the recent work has used 
DNA minor groove binders as carriers to construct DNA-directed alkylating agents, 
because these may offer much higher region and sequence selectivity. Utilizing this 
approach, denny et. al. have synthesized phenyl N-mustard analoge using bis-
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benzimidazoles as a carrier for DNA-directed alkylating agents.69 Bis- benzimidazole 
are also well-characterized reversible minor groove binding ligands, with broad 
studies on the lead compound Hoechst 33258 (44)70-72. Analogues of 45 with aniline 
mustards attached by a variable-length polymethylene chain showed that these 
compounds exhibited potent antiproliferative activity and bound within the minor 
groove side. The C-3 analog of 45 exhibited efficiently cross-linked the cellular DNA 
and exhibited potent cytotoxicity (up to 85-fold more potent than chlorambucil), with 
IC50 value of 10 nM against the P388 cell culture. Further studies on bisbenzimidazole 
were altered by changing the heteroatoms, but the mustard was directly attached to the 
phenyl ring, revealed that analogues (46) retaining DNA-affinic H-bonding moieties 
had higher reversible binding and faster kinetics of alkylation.73      
 
In addition to increasing drug-to-target affinity, the oligopyrrole antibiotics netropsin 
and distamycin A was used as a carrier for nitrogen mustard. Distamycin A is also 
well-documented AT-specific reversible minor groove binders. On the basis of this, 
polypyrrole analogues of Distamycin A with mustard moieties was synthesized for 
antitumor evaluation, found to have a broad spectrum of antitumor activity in 
experimental tumor models and highly specific alkylation at adenines in runs of 
adenines.74-78 The benzoic mustard derivative tellimustine is a very sequence and 
regiospecific alkylator. Previous studies have shown that tallimustine (47) possess a 
high preference for alkylation of adenines located in the 5’-TTTTGA-3’ sequence.79,  
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80 The dibromo mustard analoge (48) of tallimustine was considerably 100-fold more 
cytotoxic than tallimustine against L1210 cell, but had similarly DNA selectivity.81 
The number of pyrroleamide units also affected the pattern of DNA alkylation. A 
dibromo pyrazole analoge (PNU 157977, 49) showed good potency and also superior 
to tellimustine against both L1210 murine leukaemia and M5076 solid tumors.82 
Compound 50 with the mustard attached directly to one of the pyrrole units were less 
sequence specific. Moreover, the other compound 51, 52 and 53 have also synthesized 
for their anti-tumor activity. Compound 51 did not produce detectable guanine N7 
alkylation, but alkylation specificity nearly identical to that found for the analogues 
polypyrrole compound, reacting at the same 5'-TTTTGPu sequence.  The other 
compound with the mustard attached by a more flexible ether chain (e.g. 52) showed 
extensive guanine N7 alkylation. Another analogue (MEN 10710, 53) was 10 to 100 
fold more cytotoxic then tallimustine against A2780/DDP (cisplatin-resistance 
ovarian carcinoma) xenograft.83 
 
However, tallimustine has represented an important pharmacophore for the designing 
new cytotoxic minor groove binders derived from distamycin. Among these, a 
Chapter 1                                                                                                Introduction….. 
  18 
cinnamoyl nitrogen mustard derivatives of distamycin A (PNU- 157911, 54)84 a 
vinylogue of tallimustine, shows very good antileukemic activity, significantly 
superior to that of tallimustine (IC50 = 7.2 ng/mL compared with 50.3 ng/mL for 
tallimustine against L1210 leukemia). Compound 54 appears significantly more 
cytotoxic than tallimustine in accordance with its increased chemical reactivity due to 
the long-range nitrogen-carbonyl conjugation via the vinylic double bond.84 Recently, 
baraldi et. al. have been synthesized a series of benzoyl and cinnamoyl mustard 
derivatives tallimustine modified at the amidino moiety for anti-tumor evaluation.85, 86 
It revealed that, these compounds has a good cytotoxicity and also interact with DNA 
with sequences selectivity for certain AT-rich sequences. Compound having a 
cinnamoyl mustard moiety (56) 22 fold more potent then (55). Benzohetrocyclic 
analogues of the tallimustine having cinnamoyl N-mustard (57) does not found any 
improvement in terms of cytotoxicity activity and DNA-binding capability. 
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Atwell et. al. have been synthesized a series of polybenzamide DNA minor groove 
binding ligands bearing either one or two monofunctional mustards for DNA directed 
nitrogen mustard.87 Polybenzamide are also known to be DNA minor groove binding 
moieties. The antitumor evaluation and DNA interaction study showed that these 
agents possessed significant cytotoxicity against murine p388 leukemia cells in 
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culture with high degree of DNA interstrand cross-linking ability.  Analogues with 
two alkylating functions (e.g. compounds 58 and 59) are the most cytotoxic, with 58 
being 1000-fold more potent than the clinicalmustard chlorambucil against P388 
leukemia in culture, as well as being more potent in vivo. In contrast, the other three 
monofunctional compounds (60b-d) are more than 10-fold less cytotoxic no different 
than the corresponding non-alkylating analogue 60a., These results support the 
concept that DNA-directed nitrogen mustard alkylating agents by attachment to DNA-
affinic carriers can greatly enhance cytotoxicity due to alkylation. 
 
 
 
1.4 Rational Drug Design 
Previously, Su et. al. have synthesized a series of 9-anilinoacridine-alkyl N-mustard 
conjugates by linking various lengths of linkers, such as methylene (CH2) or alkoxy 
[O(CH2)n] to the aniline, and/or acridine ring(s) (Figure 15).88-91 The results showed 
that all compounds exhibited potent in vitro cytotoxicity against human lymphoblastic 
leukemia cells (CCRF-CEM) in culture. These agents were about >100-fold more 
cytotoxic than the parent 3-(9-acridinylamino)-5-hydroxymethylaniline AHMA 
(61)92, which is a potent DNA-intercalating agent and Topoisomerase II inhibitor 
previously developed in Su’s laboratory. Studies on the structure-activity relationships 
of these N-mustards indicated that the antitumor activity was slightly affected by the 
length of the spacer and the location of the N-mustard pharmacophore. Of these 
conjugates, BO-0742 (64, Fig. 1) exhibited potent antitumor activity against various 
human tumor xenografts both in vitro and in vivo. Although complete tumor 
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remission (CR) was achieved against human breast MX-1 xenograft or significant 
suppression human T-cell acute lymphoblastic leukemia CCRF-CEM, colon 
carcinoma HCT-116, and ovarian adenocarcinoma SK-OV-3 tumor xenografts in 
animal models by BO-0742, this agent has a narrow therapeutic window and low 
bioavailability (chemical instability with a short half-life) in mice. The instability of 
BO-0742 may be due to the inductive effect of the alkoxy linker, increasing the 
reactivity of the N-mustard moiety. 
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To improve the poor bioavailability of BO-0742, kapuriya et. al. have synthesized a 
series of phenyl N-mustard-9-anilinoacridine conjugates linked via urea, carbamate or 
carbonate linkers for antitumor studies (Figure 15).93, 94 These conjugates possessed 
significant cytotoxicity with IC50 in submicro molar range in inhibiting human 
lymphoblastic leukemia (CCRF-CEM), breast carcinoma (MX-1), colon carcinoma 
(HCT-116) and human non-small cell lung cancer (H-1299) cell growth in vitro. Of 
these derivatives, 68 (BO-1051) and 69 (BO-1062) possessed potent therapeutic 
efficacy against human breast MX-1, human colon HCT-116 and human glioma 
xenografts in animal model. These agents are capable of inducing DNA interstrand 
cross-linking and found to be more stable than BO-0742 in i.v. injection vehicle and 
in rat plasma. For MX-1 xenograft, total tumor remission was achieved with only one 
cycle of treatment and no tumor relapse was found over 129 days in mice treated with 
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compound 69 (BO-1062). The urea, carbamate, and or carboxamide linkers were 
previously applied in antibody-directed enzyme prodrug therapy (ADEPT) and 
melenocyte directed enzyme prodrug therapy (MDEPT) of N-mustard derivatives.  It 
indicates that these spacers are able to stabilize the chemically reactive N-mustard 
moiety. 
Figure 16
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Based on these findings, Kakadiya et. al. have utilized quinolines as carriers to 
prepare a series of N-mustard-quinoline conjugates having a urea or 
hydrazinecarboxamide linker.95 Similarly, these conjugates possess potent antitumor 
activity against a variety of human tumor xenografts. Both linkers are also able to 
lower the reactivity of the N-mustard moiety, resulting in a longer half-life in rat 
plasma. Of these conjugates, compound 70, 71 and 72, 73 having urea and 
hydrazincarboxamide linker, respectively, are able to achieve complete tumor 
Chapter 1                                                                                                Introduction….. 
  22 
remission against breast carcinoma MX-1 xenograft in animal model with low 
toxicity. The linkers in these derivatives are attached to the C-4 position of the 4-
aminoquinolines, demonstrating that quinolines are also valuable carriers for building 
DNA-directed alkylating agents. 
 
 
 
These studies clearly suggested that the selection of N-mustard (alkyl or phenyl N-
mustards), DNA-affinic molecules and linker are important since they may affect the 
antitumor activity, DNA-drug interactions and stability of these DNA-directed 
alkylating agents. In general, alkyl N-mustards are very reactive and unstable due to 
the inductive effect of alkyl function leading to rapid generation of the reactive 
aziridium cation intermediate, which readily interacts with DNA forming interstrand 
cross-inking. While, the reactivity of phenyl N-mustards is relatively weaker than 
alkyl N-mustards due to the electron-withdrawing property of the phenyl ring. 
In order to discover new chemically stable DNA-directed alkylating agents, we 
therefore connected the phenyl N-mustard pharmacophore to quinazolines and 
quinolines moiety using a urea and carbamate as a linker. The newly synthesized 
DNA-directed alkylating agents are:  
1) Phenyl N-mustard-4-aminoquinazoline conjugate having a urea linker (74, Figure 
18)  
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2) Phenyl N-mustard-6-aminoquinazoline conjugates having a urea linker (75, Figure 
18) 
3) Phenyl N-mustard-6-hydroxyquinoline conjugates having a carbamate linker (76, 
Figure 18) 
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Figure 18  
These studies will give direction to understand whether these conjugates have 
improved water-solubility and cytotoxicity. It will also give a clue to realize whether 
the urea or carbamate spacers are able to reduce the reactivity of the reactive phenyl 
N-mustard pharmacophore.  
All the newly synthesized derivatives in this work were subjected to antitumor 
evaluation against a variety of human tumor cell growth in vitro, therapeutic efficacy 
in vivo, and their capability of DNA interstrand cross-linking. 
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2.1 Chemistry 
The synthesis of newly designed N-mustards-quinazoline conjugates having a 
urea linker were achieved by reacting of the known aniline N-mustard isocynate (81) 
with the corresponding 6-amino-4-anilinoquinazolines (87a-q) as shown in scheme 1. 
The aniline N-mustard isocynate (81) was prepared from the known N,N-bis(2-
chloroethyl)benzene-1,4-diamine dihydrochloride (80), which was prepared according 
to multi-step literature procedure96 with modification (Scheme 1). The commercially 
available 4-fluoronitrobenzene (77) was reacted with diethanolamine under refluxing 
to give 4-[N,N-bis(2-hydroxyethyl)amino]nitrobenzene (78), which was then 
converted to 4-[N,N-bis(2-chloroethyl)amino]nitrobenzene (79) by treating with 
thionyl chloride. Catalytic hydrogenation (10% Pd/C, H2) of compound 79 in ethyl 
acetate afforded N,N-bis(2-chloroethyl)benzene-1,4-diamine (80), which was 
immediately treated with 2.5M HCl in ethyl acetate to yield aniline N-mustard 
hydrochloride salt (80). The hydrochloride salt 80 was then converted to isocyanate 
8197 by treating with triphosgene in chloroform at –5 oC. The key starting materials, 
6-amino-4-anilinoquinazolines (86a-q), were prepared by following the literature 
methods.98 Briefly, the commercially available 5-nitroanthranilonitrile 82 was treated 
with dimethylformamide dimethylacetal (DMF-DMA) in acetic acid to give (E)-N-(2-
cyano-4-nitrophenyl)-N,N-dimethylformimidamide (83), which was then reacted with 
substituted anilines (84a-q) in acetic acid to afford 6-nitroquinazoline derivatives 
(85a-q). The nitro function in 85a-q was converted into the corresponding 6-
aminoquinazoline derivatives (86a-q) by treating with Fe/acetic acid. Reaction of 
86a-q with the freshly prepared 81 in the presence of triethylamine gave the desired 
N-mustard-6-aminoquinazoline conjugates (87a-q) bearing a urea linker. 
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2.2 Reaction Scheme 
Scheme 1. Synthetic route for the aniline N-mustard isocynate 
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Scheme 2. Synthetic route for the N-mustard-6-aminoquinazoline conjugates 
bearing a urea linker 
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Scheme 2. (a) DMF-dimethyl acetal/ref lux; (b) ArNH2/AcOH/ref lux; (c) Fe/AcOH/EtOH/H2O/ref lux;
(d) Et3N/THF, room temperature.
j: R = 3' -Br, 4' -F
k: R = 3' -CF3, 4' -Cl
l: R = 3' -Cl, 4' -OMe
m: R = 3' -OMe
n: R = 3' -OMe, 4' -OMe, 5' -OMe
o: R = 3' -Ethynyl
p: R = 4' -OPh
q: R = 3' -Cl, 4' -OCH2(2-pyridinyl)
a: R = 3' -F
b: R = 3' -Cl
c: R = 3' -Br
d: R = 3' -CF3
e: R = 4' -F
f: R = 4' -Br
g: R = 2' -F, 3' -Cl
h: R = 3' -Cl, 4' -F
i: R = 3' -Cl, 4' -Cl
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2.3 Physical data 
Table 1. Analytical data and yields of Substituted 6-Nitro-4-anilinoquinazolines 
(85a-q)  
 
 
Sr. 
No. 
Substitute R MF MW Yield % MP °C 2' 3' 4' 5' 
85a 
 H F H H C14H9FN4O2 284.25 83 255-256  
85b 
 H Cl H H C14H9ClN4O2 300.70 90 278-281 
85c 
 H Br H H C14H9BrN4O2 345.15 91 267-270 
85d 
 H CF3 H H C15H9F3N4O2 334.25 85 209-211 
85e 
 H H F H C14H9FN4O2 284.25 96 257-258 
85f 
 H H Br H C14H9BrN4O2 345.15 84 279-280 
85g 
 F Cl H H C14H8ClFN4O2 318.69 75 224-226 
85h 
 H Cl F H C14H8ClFN4O2 318.69 91 280-281 
85i 
 H Cl Cl H C14H8Cl2N4O2 335.14 87 297-298 
85j 
 H Br F H C14H8BrFN4O2 363.14 97 257-258 
85k 
 H CF3 Cl H C15H8ClF3N4O2 368.70 90 221-222 
85l 
 H Cl OMe H C15H11ClN4O3 330.73 90 290-291 
85m 
 H OMe H H C15H12N4O3 296.28 89 241-242 
85n 
 H OMe OMe OMe C17H16N4O5 356.33 68 274-275 
85o H 3-ethynyl H H C16H10N4O2 290.28 95 271-272 
85p 
 H H OPh H C20H14N4O3 358.35 73 296-298 
85q H Cl 
OCH2(2
-
pyridiny
l) 
H C20H14ClN5O3 407.81 89 241-242 
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Table 2. Analytical data and yields of Substituted 6-amino-4-anilinoquinazolines 
(86a-q)  
 
 
 
Sr. 
No. 
Substitute R MF MW Yield % MP °C 2' 3' 4' 5' 
86a 
 H F H H C14H11FN4 254.26 76 188-189 
86b 
 H Cl H H C14H11ClN4 270.72 78 175-176 
86c 
 H Br H H C14H11BrN4 315.17 78 204-206 
86d 
 H CF3 H H C15H11F3N4 304.27 63 174-175 
86e 
 H H F H C14H11FN4 254.26 97 185-186 
86f 
 H H Br H C14H11BrN4 315.17 88 210-211 
86g 
 F Cl H H C14H10ClFN4 288.71 67 257-258 
86h 
 H Cl F H C14H10ClFN4 288.71 83 255-256 
86i 
 H Cl Cl H C14H10Cl2N4 305.16 86 243-244 
86j 
 H Br F H C14H10BrFN4 333.16 63 225-226 
86k 
 H CF3 Cl H C15H10ClF3N4 338.71 56 265-266 
86l 
 H Cl OMe H C15H13ClN4O 300.74 69 235-237 
86m 
 H OMe H H C15H14N4O 266.30 76 182-183 
86n 
 H OMe OMe OMe C17H18N4O3 326.35 65 220-221 
86o H 3-ethynyl H H C16H12N4 260.29 63 110-111 
86p 
 H H OPh H C20H16N4O 328.37 64 89-90 
86q H Cl 
OCH2(2
-
pyridiny
l) 
H C20H16ClN5O 377.83 40 238-239 
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Table 3. Analytical data and yields of new N-mustard-quinazoline conjugates 
(87a-q) 
 
*decomposition temperature 
Sr. 
No. 
Substitute R MF MW Yield % MP °C 2' 3' 4' 5' 
87a 
 H F H H C25H23Cl2FN6O 513.39 50 190-191 (d)* 
87b 
 H Cl H H C25H23Cl3N6O 529.84 65 172-173 (d) 
87c 
 H Br H H C25H23BrCl2N6O 574.30 57 165-166 (d) 
87d 
 H CF3 H H C26H23Cl2F3N6O 563.40 51 210-211 (d) 
87e 
 H H F H C25H23Cl2FN6O 513.39 54 223-224 (d) 
87f 
 H H Br H C25H23BrCl2N6O 574.30 36 220-221 (d) 
87g 
 F Cl H H C25H22Cl3FN6O 547.84 69 210-211 (d) 
87h 
 H Cl F H C25H22Cl3FN6O 547.84 64 200-201 (d) 
87i 
 H Cl Cl H C25H22Cl4N6O 564.29 71 225-226 (d) 
87j 
 H Br F H C25H22BrCl2FN6O 592.29 17 175-176 (d) 
87k 
 H CF3 Cl H C26H22Cl3F3N6O 597.85 52 220-221 (d) 
87l 
 H Cl OMe H C26H25Cl3N6O2 559.87 69 168-169 (d) 
87m 
 H OMe H H C26H26Cl2N6O2 525.43 65 159-160 (d) 
87n 
 H OMe OMe OMe C28H30Cl2N6O4 585.48 66 154-155 (d) 
87o 
 H 
3-
ethyny
l 
H H C27H24Cl2N6O 519.43 52 164-165 (d) 
87p 
 H H OPh H C31H28Cl2N6O2 587.50 33 143-144 (d) 
87q H Cl 
OCH2(2-
pyridinyl
) 
H C31H28Cl3N7O2 636.96 56 156-157 (d) 
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2.4 Experimental Section 
General methods and materials 
Compound solvents and reagents were reagent grade and used without purification 
unless otherwise noted. The melting points were recorded on a Fargo melting point 
apparatus and are uncorrected. Column chromatography was carried out on silica gel 
G60 (70-230mesh, ASTM; Merck and 230-400 mesh, silicycle inc.). Reaction 
progress was monitored using analytical thin-layer chromatography (TLC) on 
0.25mmMerck F-254 silica gel glass plates. Visualization was achieved by UV light 
(254 nm). 1H NMR spectra were recorded with a Bruker AVANCE 600 DRX and 400 
MHz spectrometer; Chemical shifts are reported in parts per million (δ) using 
tetramethylsilane as the internal standard with coupling constants (J) reported in hertz 
(Hz). The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; dd, double doublet; brs, broad singlet. Elemental analyses were 
performed on a Heraeus CHN-O Rapid analyzer. High performance liquid 
chromatography analysis for checking purity of synthesized compounds were 
recorded on a Hitachi D-2000 Elite instrument: column, Mightysil RP-18 GP 250-4.6 
(5µL) mobile phase, MeCN/THF (70:30 v/v); flow rate, 1 mL/min; injected sample 
10µL, column temp, 27°C; wavelength, 254nm. The purity of all compounds was > 
95 % based on analytical HPLC. 
Synthesis of Aniline Nitrogen mustard 
2-[(2-Hydroxyethyl)-(4-nitrophenyl)amino]ethanol (78).77 A mixture of p-flouro 
nitrobenzene (77, 28.0 g, 198 mmol) and diethanolamine (30.0 g, 285 mmol) was 
heated at 120 oC for 2 h. The reaction mixture was cooled to 60 oC and an aqueous 
solution of 0.6 % NaOH (900 mL) was added slowly into the mixture. The separated 
yellow precipitate was collected by filtration, washed well with water, and dried to 
give 78, yield: 42.6 g (95%); mp 104–105 oC (lit.77 103–104 oC); 1H NMR (CHCl3-d6) 
 3.55–3.62 (8H, m, 4CH2), 4.88 (2H, t, J = 4.4 Hz, exchangeable 2OH), 6.81 (2H, 
d, J = 9.5 Hz, 2ArH), 8.01 (2H, d, J = 9.5 Hz, 2ArH).  
Bis(2-chloroethyl)-(4-nitrophenyl)amine (79).77 To a mixture of 2-[(2-hdroxyethyl)-
(4- nitrophenyl)amino]ethanol (78, 16.0 g, 71 mmol) in dry dichloromethane (200 
mL) containing dry pyridine (10.0 mL) was added dropwise thionylchloride (14.0 
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mL) at 0 oC. The reaction mixture was heated with stirring at refluxed for 3 h and then 
cooled to room temperature.  The mixture was diluted with dichloromethane (100 
mL), carefully washed with water, 10% KHSO4 solution (100 mL) and brine (100 
mL). The organic layer was dried over Na2SO4, and evaporated to dryness under 
reduce pressure to give 79, yield 16.7 g (89%); mp 91–93 oC (lit.77 92–94 oC) 1H 
NMR (CHCl3-d6)  3.81 (4H, t, J = 6.6 Hz, 2CH2), 3.89 (4H, t, J = 6.6 Hz, 2CH2), 
6.93 (2H, d, J = 9.5 Hz, 2ArH), 8.07 (2H, d, J = 9.5 Hz, 2ArH). 
N,N-Bis(2-chloroethyl)benzene-1,4-diamine hydrochloride (80).77 A mixture bis(2-
chloroethyl)-(4-nitrophenyl)amine (79, 10.0 g, 38 mmol) in ethyl acetate (100 mL) 
and 10 % Pd/C (1.0 g) was sonicated for 5 min.  The mixture was then hydrogenated 
(H2) at 35 psi for 2 h. and monitored by TLC (SiO2, ethyl acetate/Hexane: 1:1 v/v). 
After completion of reaction, the reaction mixture was filtered through a pad of celite 
and the filtrate was cooled to 0 oC.  A solution of HCl in ethyl acetate (20.0 mL) was 
slowly added into the filtrate with stirring. The white solid separated was collected by 
filtration and dried to give 80, yield: 9.18 g (80%), mp 212–214 oC (lit.77 213–215 
oC); 1H NMR(DMSO-d6)  3.92 (8H, s, 4CH2), 6.83 (2H, d, J = 8.8 Hz, 2ArH), 
7.24 (2H, d, J = 8.8 Hz, 2ArH), 10.2 (2H, brs, exchangeable, NH2). 
4-[N,N-Bis(2-chloroethyl)amino]phenylisocyanate (81). To a suspension of N,N-
bis(2-chloroethyl)benzene-1,4-diamine hydrochloride  (80, 1.683 g, 5.4 mmol) in dry 
chloroform (30 mL) was added triethylamine (2.5 mL) at room temprature. The clear 
solution obtained was then added dropwise into a solution of triphosgene (0.623 g, 2.1 
mmol) in dry chloroform (10 mL) at -50°C. The reaction mixture was allowed to 
stand at room temperature. After being stirred for 30 min, the reaction mixture was 
evaporated to dryness under reduced pressure. The solid residue was triturated with 
dry THF (100 mL), filtered, and washed with small amount of THF. The combined 
filtrate and washings was evaporated to dryness to give the crude isocyanate 81 which 
was used directly for the next reaction without further purification. 
(E)-N'-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide (83)  
5-Nitroanthranilonitrile 82 (20.0 g, 122.5 mmol) was suspended in 
dimethylformamide dimethylacetal (43 mL, 360.0 mmol). The mixture was heated up 
to reflux temperature for 1.5 h. The resulting mixture was cooled to room temperature 
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and refrigerated overnight. The yellow precipitated was filtered, washed with ethyl 
ether to give 83, 25.0 g (96 %); mp 153–154 °C (lit.17 153–155 °C); 1H NMR 
(DMSO-d6) δ 3.09 (3H, s, Me), 3.17 (3H, s, Me), 7.36–7.39 (1H, m, ArH), 8.25–8.28 
(2H, m, 2 × ArH), 8.47–8.48 (1H, m, ArH). Anal. (C7H5N3O2): C, H, N 
Synthesis of 6-nitro-4-anilinoquinazoline (85a-q) 
N-(3-Fluorophenyl)-6-nitroquinazolin-4-amine (85a). To a solution of (E)-N-(2-
cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (6.0 g, 2.7 mmol) and acetic 
acid (45 mL) was added 3-Fluoroaniline (84a, 3.3 g, 3.0 mmol) at room temperature. 
The reaction mixture was heated up to reflux temperature for 1 hour.  After 
completion of the reaction, the resulting mixture was cooled to room temperature. The 
solid separated was filtered and washed with ether to give 85a, 6.5 g (83 %); mp 255–
256 °C; 1H NMR (DMSO-d6) δ 6.98–7.03 (1H, m, ArH), 7.43–7.48 (1H, m, ArH), 
7.68 (1H, d, J = 9.2 Hz, ArH), 7.89–7.95 (2H, m, 2 × ArH), 8.55 (1H, dd, J = 2.2 Hz, 
J = 9.2 Hz,  ArH), 8.77 (1H, s, ArH), 9.65 (1H, d, J = 2.2 Hz, ArH), 10.48 (1H, s, 
exchangeable, NH). Anal. (C14H9FN4O2): C, H, N. 
By following the same procedure as that for 85a the following compounds were 
synthesized. 
N-(3-Chlorophenyl)-6-nitroquinazolin-4-amine (85b). Compound 85b was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (5.0 
g, 2.2 mmol) and 3-chloroaniline (84b, 3.2 g, 2.5 mmol) in acetic acid (40 mL): Yield 
6.2 g (90 %); mp 285–286 °C; 1H NMR (DMSO-d6) δ 7.22–7.47 (1H, m, ArH), 7.43–
7.47 (1H, m, ArH), 7.83–7.85 (1H, m, ArH), 7.95 (1H, d, J = 9.2 Hz,  ArH), 8.07–
8.08 (1H, m, ArH), 8.56 (1H, dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.78 (1H, s, ArH), 
9.65 (1H, d, J = 2.2 Hz, ArH), 10.48 (1H, s, exchangeable, NH). Anal. 
(C14H9ClN4O2): C, H, N. 
N-(3-Bromophenyl)-6-nitroquinazolin-4-amine (85c). Compound 85c was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (5.0 
g, 2.2 mmol) and 3-bromoaniline (84c, 4.3 g, 2.5 mmol) in acetic acid (40 mL): Yield 
7.2 g (91 %); mp 282–283 °C; 1H NMR (DMSO-d6) δ 7.35–7.41 (2H, m, 2 × ArH), 
7.90–7.92 (1H, m, ArH), 7.94 (1H, d, J = 9.1 Hz, ArH), 8.18–8.19 (1H, m, ArH), 8.56 
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(1H, dd, J = 2.2 Hz, J = 9.1 Hz, ArH), 8.77 (1H, s, ArH), 9.64 (1H, d, J = 2.2 Hz, 
ArH), 10.46 (1H, s, exchangeable, NH). Anal. Calcd. for (C14H9BrN4O2): C, H, N. 
N-(3-(Trifluoromethyl)phenyl)-6-nitroquinazolin-4-amine (85d). Compound 85d 
was synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 
(5.0 g, 2.2 mmol) and 3-(trifluoromethyl)aniline (84d, 4.0 g, 2.5 mmol) in acetic acid 
(40 mL): Yield 6.5 g (85 %); mp 210–211 °C; 1H NMR (DMSO-d6) δ 7.52–7.54 (1H, 
m, ArH), 7.65–7.69 (1H, m, ArH), 7.97 (1H, d, J = 9.1 Hz, ArH), 8.25–8.29 (2H, m, 2 
× ArH), 8.59 (1H, dd, J = 2.2 Hz, J = 9.1 Hz, ArH), 8.79 (1H, s, ArH), 9.67 (1H, d, J 
= 2.2 Hz, ArH), 10.61 (1H, s, exchangeable, NH). Anal. (C15H9F3N4O2): C, H, N. 
N-(4-Fluorophenyl)-6-nitroquinazolin-4-amine (85e). Compound 85e was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (4.0 
g, 1.5 mmol) and 4-fluoroaniline (84e, 2.2 g, 2.0 mmol) in acetic acid (30 mL): Yield 
5.0 g (96 %); mp 257–258 °C; 1H NMR (DMSO-d6) δ 7.28–7.32 (2H, m, 2 × ArH), 
7.84–7.88 (2H, m, 2 × ArH), 7.96 (1H, d, J = 9.2 Hz, ArH), 8.58 (1H, dd, J = 2.5 Hz, 
J = 9.2 Hz, ArH), 8.72 (1H, s, ArH), 9.66 (1H, d, J = 2.5 Hz, ArH), 10.51 (1H, s, 
exchangeable, NH). Anal. (C14H9FN4O2): C, H, N. 
N-(4-Bromophenyl)-6-nitroquinazolin-4-amine (85f). Compound 85f was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (3.0 
g, 1.3 mmol) and 4-bromoaniline (84f, 2.6 g, 1.5 mmol) in acetic acid (25 ml): Yield 
4.0 g (84 %); mp 279–280 °C; 1H NMR (DMSO-d6) δ 7.62–7.65 (2H, m, 2 × ArH), 
7.86–7.89 (2H, m, 2 × ArH), 7.97 (1H, d, J = 9.2 Hz, ArH), 8.57–8.60 (1H, dd, J = 
2.4 Hz, J = 9.2 Hz, ArH), 8.76 (1H, s, ArH), 9.67 (1H, d, J = 2.4 Hz, ArH), 10.51 
(1H, s, exchangeable, NH). Anal. (C14H9BrN4O2): C, H, N. 
N-(2-Fluoro-3-chlorophenyl)-6-nitroquinazolin-4-amine (85g). Compound 85g 
was synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 
(5.0 g, 2.2 mmol) and 2-fluoro-3-chloroaniline (84g, 3.6 g, 2.5 mmol) in acetic acid 
(35 mL): Yield 5.5 g (75 %); mp 224–226 °C; 1H NMR (DMSO-d6) δ 7.30–7.34 (1H, 
m, ArH), 7.52–7.56 (2H, m, 2 × ArH), 7.74–8.01 (1H, m, ArH), 8.57–8.65 (2H, m, 2 
× ArH), 9.55 (1H, s, ArH), 10.73 (1H, s, exchangeable, NH). Anal. (C14H8ClFN4O2): 
C, H, N. 
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N-(3-Chloro-4-fluorophenyl)-6-nitroquinazolin-4-amine (85h). Compound 85h 
was synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 
(3.0 g, 1.3 mmol) and 3-chloro-4-fluoroaniline (84h, 2.2 g, 1.5 mmol) in acetic acid 
(20 mL): Yield 4.0 g (91 %); mp 280–281 °C; 1H NMR (DMSO-d6) δ 7.45–7.50 (1H, 
m, ArH), 7.81–7.83 (1H, m, ArH), 7.94 (1H, d, J = 9.2 Hz,  ArH), 8.14–8.17 (1H, m, 
ArH), 8.55 (1H, dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.74 (1H, s, ArH), 9.60 (1H, d, J = 
2.2 Hz, ArH), 10.50 (1H, s, exchangeable, NH). Anal. (C14H8ClFN4O2): C, H, N.  
N-(3,4-Dichlorophenyl)-6-nitroquinazolin-4-amine (85i). Compound 85i was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (6.0 
g, 2.7 mmol) and 3,4-dichloroaniline (84i, 4.9 g, 3.0 mmol) in acetic acid (45 mL): 
Yield 8.0 g (86 %); mp 297–298 °C; 1H NMR (DMSO-d6) δ 7.65–7.67 (1H, m, ArH), 
7.89–7.96 (2H, m, 2 × ArH),  8.27–8.28 (1H, m, ArH), 8.54–8.57 (1H, m, ArH), 8.79 
(1H, s, ArH), 9.61–9.62 (1H, m, ArH), 10.49 (1H, s, exchangeable, NH). Anal. 
(C14H8Cl2N4O2): C, H, N. 
N-(3-Bromo-4-fluorophenyl)-6-nitroquinazolin-4-amine (85j). Compound 85j was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (4.0 
g, 1.5 mmol) and 3-bromo-4-fluoroaniline (84j, 4.0 g, 2.0 mmol) in acetic acid (30 
mL): Yield 6.0 g (90 %); mp 260–261 °C; 1H NMR (DMSO-d6) δ 7.43–7.47 (1H, m, 
ArH), 7.88–7.89 (1H, m, ArH), 7.95 (1H, d, J = 9.2 Hz, ArH), 8.25–8.26 (1H, m, 
ArH), 8.56 (1H, dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.75 (1H, s, ArH), 9.61 (1H, d, J = 
2.2 Hz, ArH), 10.48 (1H, s, exchangeable, NH). Anal. (C14H8BrFN4O2): C, H, N. 
N-(4-Chloro-3-(trifluoromethyl)phenyl)-6-nitroquinazolin-4-amine(85k). 
Compound 85k was synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-
dimethylformimidamide 83 (3.0 g, 1.3 mmol) and 4-chloro-3-(trifluoromethyl)aniline 
(84k, 2.8 g, 1.4 mmol) in acetic acid (30 mL): Yield 4.5 g (90 %); mp 221–222 °C; 1H 
NMR (DMSO-d6) δ 7.77–7.79 (1H, m, ArH), 7.98 (1H, d, J = 9.2 Hz, ArH), 8.32–
8.34 (1H, m, ArH), 8.43–8.44 (1H, m, ArH), 8.58 (1H, dd, J = 2.2 Hz, J = 9.2 Hz, 
ArH), 8.81 (1H, s, ArH), 9.63 (1H, s, J = 2.2 Hz, ArH), 10.53 (1H, s, exchangeable, 
NH). Anal. (C15H8ClF3N4O2): C, H, N. 
N-(3-Chloro-4-methoxyphenyl)-6-nitroquinazolin-4-amine (85l). Compound 85l 
was synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 
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(5.0 g, 2.2 mmol) and 3-chloro-4-methoxyaniline (84l, 3.9 g, 2.5 mmol) in acetic acid 
(40 mL): Yield 6.8 g (91 %); mp 290–291 °C; 1H NMR (DMSO-d6) δ 3.90 (3H, s, 
Me), 7.21–7.23 (1H, m, ArH), 7.75–7.77 (1H, m, ArH), 7.91 (1H, d, J = 9.2 Hz, 
ArH), 7.99–8.00 (1H, m, ArH), 8.52 (1H, dd, J = 2.4 Hz, J = 9.2 Hz, ArH), 8.70 (1H, 
s, ArH), 9.60 (1H, d, J = 2.4 Hz, ArH), 10.38 (1H, s, exchangeable, NH). Anal. 
(C15H11ClN4O3): C, H, N. 
N-(3-Methoxyphenyl)-6-nitroquinazolin-4-amine (85m). Compound 85m was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (5.0 
g, 2.2 mmol) and 3-methoxyaniline (84m, 3.0 g, 2.5 mmol) in acetic acid (35 mL): 
Yield 6.0 g (89 %); mp 241–242 °C; 1H NMR (DMSO-d6) δ 3.82 (3H, s, Me), 6.78–
6.81 (1H, m, ArH), 7.32–7.37 (1H, m, ArH), 7.49–7.53 (2H, m, 2 × ArH), 7.93 (1H, 
d, J = 9.2 Hz, ArH), 8.54–8.57 (1H, dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.74 (1H, s, 
ArH), 9.66 (1H, d, J = 2.2 Hz, ArH), 10.38 (1H, s, exchangeable, NH). Anal. 
(C15H12N4O3): C, H, N. 
N-(3,4,5-Trimethoxyphenyl)-6-nitroquinazolin-4-amine (85n). Compound 85n was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (5.0 
g, 2.2 mmol) and 3,4,5-trimethoxyaniline (84n, 4.6 g, 2.5 mmol) in acetic acid (40 
mL): Yield 5.5 g (68 %); mp 274–275 °C; 1H NMR (DMSO-d6) δ 3.81 (3H, s, Me), 
3.69 (6H, s, 2 × Me), 7.27 (2H, s, 2 × ArH), 7.93 (1H, d, J = 9.2 Hz, ArH), 8.56 (1H, 
dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.72 (1H, s, ArH), 9.64 (1H, d, J = 2.2 Hz, ArH), 
10.32 (1H, s, exchangeable, NH). Anal. (C17H16N4O5): C, H, N. 
N-(3-Ethynylphenyl)-6-nitroquinazolin-4-amine (85o). Compound 85o was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (3.0 
g, 1.3 mmol) and 3-ethynylaniline (84o, 1.6 g, 1.3 mmol) in acetic acid (30 mL): 
Yield 3.8 g (95 %); mp 271–272 °C; 1H NMR (DMSO-d6) δ 4.25 (1H, s, CH), 7.30–
7.32 (1H, m, ArH), 7.44–7.48 (1H, m, ArH), 7.92–7.95 (2H, m, 2 × ArH), 8.05–8.06 
(1H, m, ArH), 8.54–8.57 (1H, m, ArH), 8.76 (1H, s, ArH), 9.65–9.66 (1H, m, ArH), 
10.48 (1H, s, exchangeable, NH). Anal. (C16H10N4O2·0.5): C, H, N. 
N-(4-Phenoxyphenyl)-6-nitroquinazolin-4-amine (85p). Compound 85p was 
synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylformimidamide 83 (5.0 
g, 2.2 mmol) and 4-phenoxyaniline (84p, 4.6 g, 2.5 mmol) in acetic acid (40 mL): 
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Yield 6.0 g (73 %); mp 296–298 °C; 1H NMR (DMSO-d6) δ 7.06–7.08 (2H, m, 2 × 
ArH), 7.11–7.13 (2H, m, 2 × ArH), 7.17–7.19 (1H, m, ArH), 7.42–7.46 (2H, m, 2 × 
ArH), 7.85–7.87 (2H, m, 2 × ArH), 7.94 (1H, d, J = 9.2 Hz, ArH), 8.57 (1H, dd, J = 
2.4 Hz, J = 9.2 Hz, ArH), 8.71 (1H, s, ArH), 9.67 (1H, d, J = 2.4 Hz, ArH), 10.55 
(1H, s, exchangeable, NH). Anal. (C20H14N4O3): C, H, N. 
N-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-6-nitroquinazolin-4-amine (85q). 
Compound 85q was synthesized from (E)-N-(2-cyano-4-nitrophenyl)-N, N-
dimethylformimidamide 83 (3.0 g, 1.3 mmol) and 3-chloro-4-(pyridine-2-
ylmethoxy)aniline (84q, 3.2 g, 1.3 mmol) in acetic acid (30 mL): Yield 5.0 g (89 %); 
mp 241–242 °C; 1H NMR (DMSO-d6) δ 5.32 (2H, s, CH2), 7.30–7.33 (1H, m, ArH), 
7.39–7.40 (1H, m,  ArH), 7.60–7.62 (1H, m, ArH), 7.74–7.75 (1H, m, ArH), 7.88–
7.95 (2H, m,  2 × ArH), 8.04–8.05 (1H, m, ArH), 8.55–8.57 (1H, m, ArH), 8.62–7.63 
(1H, m, ArH), 8.73 (1H, s, ArH), 9.62–9.63 (1H, m, ArH), 10.43 (1H, s, 
exchangeable, NH). Anal. (C20H14ClN5O3·2H2O): C, H, N. 
Synthesis of 6-amino-4-anilinoquinazoline (86a-q) 
N4-(3-Fluorophenyl)quinazolin-4,6-diamine(86a). A mixture of N-(3-fluorophenyl)-
6-nitroquinazolin-4-amine 85a (6.0 g, 21.1 mmol) and iron (8.13 g, 147.8 mmol) were 
suspended in aqueous ethanol (600 mL, 70% v/v) containing acetic acid (16.3 mL, 
295.4 mmol). The mixture was heated up to reflux temperature for 2 h. After 
completion of the reaction, the reaction mixture was cooled to room temperature and 
alkalinized by addition of concentrated ammonia solution (120 mL). The insoluble 
material was removed by filtration through celite, and the filtrate was evaporated 
under reduce pressure. The resulting solid was washed with 10% K2CO3 solution and 
finally with water and dried to give 86a, 4.0 g, (75 %); mp 188–189 °C; 1H NMR 
(DMSO-d6) δ 5.62 (2H, s, exchangeable, NH2), 6.84–6.88 (1H, m, ArH), 7.25–7.28 
(1H, m, ArH), 7.35–7.40 (2H, m, 2 × ArH), 7.54–7.56 (1H, m, ArH), 7.67–7.69 (1H, 
m, ArH), 7.93–7.96 (1H, m, ArH), 8.39 (1H, s, ArH), 9.47 (1H, s, exchangeable, NH). 
Anal. (C14H11FN4·0.8H2O): C, H, N. 
By following the same procedure as that for 86a the following compound were 
synthesized. 
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N4-(3-Chlorophenyl)quinazolin-4,6-diamine (86b). Compound 86b was synthesized 
from N-(3-chlorophenyl)-6-nitroquinazolin-4-amine 85b (5.0 g, 16.6 mmol) and iron 
(6.3 g, 116.2 mmol) in aqueous ethanol (400 mL, 70% v/v) containing acetic acid 
(13.3 mL, 232.4 mmol): Yield 3.5 g (78 %); mp 175–176 °C; 1H NMR (DMSO-d6) δ 
5.62 (2H, s, exchangeable, NH2), 7.09–7.11 (1H, m, ArH), 7.25–7.28 (1H, m, ArH), 
7.34–7.39 (2H, m, 2 × ArH), 7.54–7.56 (1H, m, ArH), 7.82–7.85 (1H, m, ArH), 8.12–
8.13 (1H, m, ArH), 8.39 (1H, s, ArH), 9.46 (1H, s, exchangeable, NH). Anal. 
(C14H11ClN4): C, H, N. 
N4-(3-Bromophenyl)quinazolin-4,6-diamine (86c). Compound 86c was synthesized 
from N-(3-bromophenyl)-6-nitroquinazolin-4-amine 85c (6.0 g, 17.3 mmol) and iron 
(6.69 g, 121.7 mmol) in aqueous ethanol (600 mL, 70% v/v) containing acetic acid 
(13.9 mL, 243.4 mmol): Yield 4.2 g (78 %); mp 204–206 °C; 1H NMR (DMSO-d6) δ 
5.62 (2H, s, exchangeable, NH2), 7.22–7.35 (4H, m, 4 × ArH), 7.54–7.56 (1H, m, 
ArH), 7.88–7.90 (1H, m, ArH), 8.24–8.25 (1H, m, ArH), 8.38 (1H, s, ArH), 9.44 (1H, 
s, exchangeable, NH). Anal. (C14H11BrN4): C, H, N. 
N4-(3-(Trifluoromethyl)phenyl)quinazolin-4,6-diamine (86d). Compound 86d was 
synthesized from N-(3-(trifluoromethyl)phenyl)-6-nitroquinazolin-4-amine 85d (6.0 
g, 17.9 mmol) and iron (6.9 g, 125.0 mmol) in aqueous ethanol (600 mL, 70% v/v) 
containing acetic acid (14.3 mL, 250.0 mmol): Yield 3.4 g (63 %); mp 174–175 °C; -
1H NMR (DMSO-d6) δ 5.66 (2H, s, exchangeable, NH2), 7.29–7.31 (1H, m, ArH), 
7.39–7.42 (2H, m, 2 × ArH), 7.58–7.63 (2H, m, 2 × ArH), 8.24–8.26 (1H, m, ArH), 
8.37–8.38 (1H, m, ArH), 8.42 (1H, s, ArH), 9.62 (1H, s, exchangeable, NH). Anal. 
(C15H11F3N4): C, H, N. 
N4-(4-Fluorophenyl)quinazolin-4,6-diamine (86e). Compound 86e was synthesized 
from N-(4-fluorophenyl)-6-nitroquinazolin-4-amine 85e (4.0 g, 14.0 mmol) and iron 
(5.4 g, 98.5 mmol) in aqueous ethanol (400 mL, 70% v/v) containing acetic acid (11.2 
mL, 196.0 mmol): Yield 3.5 g (97 %); mp 185–186 °C; 1H NMR (DMSO-d6) δ 5.60 
(2H, s, exchangeable, NH2), 7.30–7.32 (2H, m, 2 × ArH), 7.40–7.56 (3H, m, 3 × 
ArH), 7.71–7.73 (2H, m, 2 × ArH), 8.30 (1H, s, ArH), 9.29 (1H, s, exchangeable, 
NH). Anal. (C14H11FN4·1.3H2O): C, H, N. 
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N4-(4-Bromophenyl)quinazolin-4,6-diamine (86f). Compound 86f was synthesized 
from N-(4-bromophenyl)-6-nitroquinazolin-4-amine 85f (4.0 g, 11.5 mmol) and iron 
(4.4 g, 80.5 mmol) in aqueous ethanol (400 mL, 70% v/v) containing acetic acid (5 
mL, 162.0 mmol): Yield 3.2 g (88 %); mp 210–211 °C; 1H NMR (DMSO-d6) δ 5.63 
(2H, s, exchangeable, NH2), 7.27–7.29 (2H, m, 2 × ArH), 7.53–7.56 (3H, m, 3 × 
ArH), 7.90–7.92 (2H, m, 2 × ArH), 8.38 (1H, s, ArH), 9.45 (1H, s, exchangeable, 
NH). Anal. (C14H11BrN4·0.2H2O): C, H, N. 
N4-(2-Fluoro-3-chlorophenyl)quinazolin-4,6-diamine (86g). Compound 86g was 
synthesized from N-(2-fluoro-3-chlorophenyl)-6-nitroquinazolin-4-amine 85g (5.0 g, 
15.7 mmol) and iron (6.0 g, 110.0 mmol) in aqueous ethanol (500 mL, 70% v/v) 
containing acetic acid (12.5 mL, 219.0 mmol): Yield 3.0 g (67 %); mp 257–258 °C; -
1H NMR (DMSO-d6) δ 5.65 (2H, s, exchangeable, NH2), 7.25–7.27 (3H, m, 3 × ArH), 
7.43–7.44 (1H, m, ArH), 7.54–7.56 (2H, m, 2 × ArH), 8.24 (1H, s,  ArH), 9.42 (1H, s, 
exchangeable, NH). Anal. (C14H10ClFN4): C, H, N. 
N4-(3-Chloro-4-fluorophenyl)quinazolin-4,6-diamine (86h). Compound 86h was 
synthesized from N-(3-chloro-4-fluorophenyl)-6-nitroquinazolin-4-amine 85h (2.0 g, 
6.2 mmol) and iron (2.4 g, 44.0 mmol) in aqueous ethanol (200 ml, 70%v/v) 
containing acetic acid (5 mL, 57.9 mmol):Yield 1.4 g (83 %); mp 255–256 °C; 1H 
NMR (DMSO-d6) δ 5.62 (2H, s, exchangeable, NH2), 7.24–7.27 (1H, m, ArH), 7.34–
7.35 (1H, m , ArH), 7.38–7.43 (1H, m, ArH), 7.53–7.54 (1H, m, ArH), 7.83–7.84 
(1H, m, ArH), 8.22–8.22 (1H, m,  ArH), 8.36 (1H, s, ArH), 9.50 (1H, s, exchangeable, 
NH). Anal. (C14H10ClFN4): C, H, N. 
N4-(3,4,-Dichlorophenyl)quinazolin-4,6-diamine (86i). Compound 86i was 
synthesized from N-(3,4,-dichlorophenyl)-6-nitroquinazolin-4-amine 85i (7.0 g, 20.8 
mmol) and iron (8.0 g, 146.2 mmol) in aqueous ethanol (600 mL, 70% v/v) containing 
acetic acid (16.6 mL, 291.0 mmol): Yield 5.5 g (86 %); mp 243–244 °C; 1H NMR 
(DMSO-d6) δ 5.66 (2H, s, exchangeable, NH2), 7.27–7.30 (1H, m, ArH), 7.34–7.35 
(1H, m, ArH), 7.56–7.61 (2H, m, 2 × ArH), 7.91–7.93 (1H, m, ArH), 8.34–8.35 (1H, 
m, ArH), 8.42 (1H, s, ArH), 9.55 (1H, s, exchangeable, NH). Anal. (C14H10Cl2N4): C, 
H, N. 
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N4-(3-Bromo-4-fluorophenyl)quinazolin-4,6-diamine (86j). Compound 86j was 
synthesized from N-(3-bromo-4-fluorophenyl)-6-nitroquinazolin-4-amine 85j (6.0 g, 
16.5 mmol) and iron (6.36 g, 115.0 mmol) in aqueous ethanol (600 mL, 70% v/v) 
containing acetic acid (13.2 mL, 231.0 mmol): Yield 3.5 g (64 %); mp 225–226 °C; -
1H NMR (DMSO-d6) δ 5.61 (2H, s, exchangeable, NH2), 7.25–7.27 (1H, m, ArH), 
7.31–7.32 (1H, m, ArH), 7.35–7.40 (1H, m, ArH), 7.53–7.55 (1H, m, ArH), 7.88–7.89 
(1H, m, ArH), 8.30–8.31 (1H, m, ArH), 8.36 (1H, s, ArH), 9.45 (1H, s, exchangeable, 
NH). Anal. (C14H10BrFN4): C, H, N. 
N4-(4-Chloro-3-(trifluoromethyl)phenyl)quinazolin-4,6-diamine (86k). Compound 
86k was synthesized from N-(4-chloro-3-(trifluoromethyl)phenyl)-6-nitroquinazolin-
4-amine 85k (4.0 g, 10.8 mmol) and iron (4.2 g, 75.8 mmol) in aqueous ethanol (400 
mL, 70% v/v) containing acetic acid (8.6 mL, 151.0 mmol): Yield 2.0 g (56 %); mp 
265–266 °C; 1H NMR (DMSO-d6) δ 5.67 (2H, s, exchangeable, NH2), 7.27–7.29 (1H, 
m, ArH), 7.33–7.34 (1H, m, ArH), 7.56–7.58 (1H, m, ArH), 7.68–7.70 (1H, m, ArH), 
8.29–8.31 (1H, m, ArH), 8.40–8.41 (1H, m, ArH), 8.48 (1H, s, ArH), 9.69 (1H, s, 
exchangeable, NH). Anal. (C15H10ClF3N4): C, H, N. 
N4-(3-Chloro-4-methoxyphenyl)quinazolin-4,6-diamine (86l). Compound 86l was 
synthesized from N-(3-chloro-4-methoxyphenyl)-6-nitroquinazolin-4-amine 85l (6.0 
g, 18.0 mmol) and iron (6.9 g, 126.0 mmol) in aqueous ethanol (600 mL, 70% v/v) 
containing acetic acid (14.4 mL, 252.0 mmol): Yield 3.7 g (69 %); mp 235–237 °C; -
1H NMR (DMSO-d6) δ 3.58 (3H, s, Me), 5.57 (2H, s, exchangeable, NH2), 7.15–7.16 
(1H, m, ArH), 7.24–7.26 (1H, m, ArH), 7.33–7.34 (1H, m, ArH), 7.52–7.54 (1H, m, 
ArH), 7.73–7.54 (1H, m, ArH), 8.02–8.03 (1H, m, ArH), 8.32 (1H, s, ArH), 9.32 (1H, 
s, exchangeable, NH). Anal. (C15H13ClN4O): C, H, N. 
N4-(3-Methoxyphenyl)quinazolin-4,6-diamine (86m). Compound 86m was 
synthesized from N-(3-methoxyphenyl)-6-nitroquinazolin-4-amine 85m (5.5 g, 18.5 
mmol) and iron (7.2 g, 130.0 mmol) in aqueous ethanol (600 mL, 70% v/v) containing 
acetic acid (14.8 mL, 260.0 mmol): Yield 3.2 g (75 %); mp 182–183 °C; 1H NMR 
(DMSO-d6) δ 3.77 (3H, s, Me), 5.57 (2H, s, exchangeable, NH2), 6.63–6.66 (1H, m, 
ArH), 7.23–7.27 (2H, m, 2 × ArH), 7.36–7.37 (1H, m, ArH), 7.49–7.58 (3H, m, 3 × 
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ArH), 8.35 (1H, s, ArH), 9.28 (1H, s, exchangeable, NH). Anal. (C15H14N4O·0.2H2O): 
C, H, N. 
N4-(3,4,5-Trimethoxyphenyl)quinazolin-4,6-diamine (86n). Compound 86n was 
synthesized from N-(3,4,5-trimethoxyphenyl)-6-nitroquinazolin-4-amine 85n (5.0 g, 
14.0 mmol) and iron (5.4 g, 98.3 mmol) in aqueous ethanol (500 mL, 70% v/v) 
containing acetic acid (11.2 mL, 196.5 mmol): Yield 2.9 g (64 %); mp 220–221 °C; -
1H NMR (DMSO-d6) δ 3.66 (3H, s, Me), 3.79 (6H, s, 2 × Me),  5.54 (2H, s, 
exchangeable, NH2), 7.22–7.25 (1H, m, ArH), 7.34–7.35 (3H, m, 3 × ArH), 7.51–7.53 
(1H, m, ArH), 8.33 (1H, s,  ArH), 9.19 (1H, s, exchangeable, NH). Anal. 
(C17H18N4O3): C, H, N. 
N4-(3-Ethynylphenyl)quinazolin-4,6-diamine(86o). Compound 86o was synthesized 
from N-(3-ethynylphenyl)-6-nitroquinazolin-4-amine 85o (4.5 g, 15.5 mmol) and iron 
(5.9 g, 108.0 mmol) in aqueous ethanol (450 mL, 70% v/v) containing acetic acid 
(12.4 mL, 217.0 mmol): Yield 2.5 g (62 %); mp 110–111 °C; 1H NMR (DMSO-d6) δ 
4.17 (1H, s, CH),  5.60 (2H, s, exchangeable, NH2), 7.16–7.18 (1H, m, ArH), 7.24–
7.27 (1H, m, ArH), 7.35–7.39 (2H, m, 2 × ArH), 7.53–7.56 (1H, m, ArH), 7.90–7.92 
(1H, m, ArH), 8.08–8.09 (1H, m, ArH), 8.37 (1H, s, ArH), 9.39 (1H, s, exchangeable, 
NH). Anal. (C16H12N4·1.2H2O): C, H, N. 
N4-(4-Phenoxyphenyl)quinazolin-4,6-diamine (86p). Compound 86p was 
synthesized from N-(4-phenoxyphenyl)-6-nitroquinazolin-4-amine 85p (6.0 g, 16.7 
mmol) and iron (6.4 g, 117.0 mmol) in aqueous ethanol (600 mL, 70% v/v) containing 
acetic acid (13.3 mL, 233.0 mmol): Yield 4.2 g (64 %); mp 100–101 C; 1H NMR 
(DMSO-d6) δ 5.40 (2H, s, exchangeable, NH2), 6.97–6.99 (2H, m, 2 × ArH), 7.09–
7.11 (2H, m, 2 × ArH), 7.30–7.39 (3H, m, 3 × ArH), 7.47–7.49 (2H, m, 2 × ArH), 
7.67–7.78 (3H, m, 3 × ArH), 8.51 (1H, s, ArH), 9.50 (1H, s, exchangeable, NH). 
Anal. (C20H16N4O): C, H, N. 
N4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)quinazolin-4,6-diamine (86q). 
Compound 86q was synthesized from N-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-6-
nitroquinazolin-4-amine 85q (6.0 g, 14.7 mmol) and iron (5.6 g, 103.0 mmol) in 
aqueous ethanol (600 mL, 70% v/v) containing acetic acid (11.7 mL, 205.0 mmol): 
Yield 2.5 g (40 %); mp 238–239 °C; 1H NMR (DMSO-d6) δ 5.28 (2H, s, CH2), 5.57 
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(2H, s, exchangeable, NH2), 7.23–7.24 (2H, m, 2 × ArH), 7.31–7.37 (2H, m, 2 × 
ArH), 7.51–7.53 (1H, m, ArH), 7.58–7.60 (1H, m, ArH), 7.71–7.73 (1H, m, ArH), 
7.86–7.88 (1H, m, ArH), 8.06–8.07 (1H, m, ArH), 8.32–8.33 (1H, m, ArH), 8.60 (1H, 
s, ArH), 9.33 (1H, s, exchangeable, NH). Anal. (C20H16ClN5O): C, H, N. 
Synthesis of N-mustard-quinazoline conjugates  (87a-q) 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-fluorophenylamino)quinazolin-6-
yl)urea(87a). To a solution of N4-(3-fluorophenylamino)quinazolin-4,6-diamine (86a, 
0.99 g, 3.9 mmol) in dry THF (40 mL) containing triethylamine (2.7 mL) was added a 
solution of isocyanate 81 (freshly prepared from 80, 3.00 g, 9.7 mmol) in dry THF (15 
mL) at room temperature. After being stirred for 1 h at room temperature, the solid 
was filtered and washed with dry THF. The filtrate was evaporated to dryness in 
vacuo. The residue was purified by column chromatography using CHCl3/MeOH 
(100:2 v/v) as an eluent. The fractions containing the main product were combined 
and evaporated to dryness. The residue was recrystallized from CHCl3 to give 87a, 
0.99 g, (50 %); mp 190–191 °C (dec); 1H NMR (DMSO-d6) δ 3.69–3.71 (8H, m, 4 × 
CH2), 6.73 (2H, d, J = 9.0 Hz, 2 × ArH), 6.89–6.94 (1H, m, ArH), 7.34 (2H, d, J =9.0 
Hz, 2 × ArH), 7.37–7.43 (1H, m, ArH), 7.66–7.67 (1H, m, ArH), 7.75–7.77 (1H, m, 
ArH), 7.87–7.92 (2H, m, 2 × ArH), 8.45–7.46 (1H, m, ArH), 8.55 (1H, s, ArH), 8.57, 
8.83, 9.85 (each 1H, s, exchangeable, 3 × NH). Anal. (C25H23Cl2FN6O·H2O): C, H, N. 
By following the same procedure as that for 87a the following compound were 
synthesized. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-chlorophenylamino)quinazolin-6-
yl)urea (87b). Compound 87b was synthesized from 81 (freshly prepared from 80, 
2.00 g, 6.5 mmol) and N4-(3-chlorophenyl)quinazolin-4,6-diamine (86b, 0.70 g, 2.6 
mmol) in dry THF (35 mL) containing triethylamine (1.8 mL): Yield 0.90 g (65 %); 
mp 172–173 °C (dec);  1H NMR (DMSO-d6) δ 3.69–3.71 (8H, m, 4 ×  CH2), 6.73 
(2H, d, J = 8.8 Hz, 2 × ArH), 7.14–7.17 (1H, m, ArH), 7.34 (2H, d, J = 8.8 Hz, 2 × 
ArH), 7.38–7.42 (1H, m, ArH), 7.76 (1H, d, J = 9.1 Hz, ArH), 7.81–7.83 (1H, m, 
ArH), 7.89 (1H, dd, J = 2.2 Hz, J = 9.1 Hz, ArH), 8.06–8.07 (1H, m, ArH), 8.46 (1H, 
d, J = 2.2 Hz ArH), 8.55 (1H, s, ArH), 8.59, 8.85, 9.83 (each 1H, s, exchangeable, 3 × 
NH). Anal. (C25H23Cl3N6O·H2O): C, H, N. 
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1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-bromophenylamino)quinazolin-6-
yl)urea (87c). Compound 87c was synthesized from 81 (freshly prepared from 80, 
2.00 g, 6.5 mmol) and N4-(3-bromophenyl)quinazolin-4,6-diamine (86c, 0.82 g, 2.6 
mmol) in dry THF (35 mL) containing triethylamine (1.8 mL): Yield 0.80 g (57 %); 
mp 165–166 °C (dec); 1H NMR (DMSO-d6) δ 3.71–3.73 (8H, m, 4 ×  CH2), 6.75–
6.77 (2H, m, 2 × ArH), 7.32–7.38 (4H, m , 4 × ArH), 7.77–7.79 (1H, m, ArH), 7.91–
7.94 (2H, m, 2 × ArH), 8.21–8.22 (1H, m, ArH), 8.48–8.49 (1H, m, ArH), 8.57 (1H, s, 
ArH), 8.61, 8.87, 9.85 (each 1H, s, exchangeable, 3 × NH). Anal. 
(C25H23BrCl2N6O·1.5H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-(trifluoromethyl)phenylamino) 
quinazolin-6-yl)urea(87d). Compound 87d was synthesized from 81 (freshly 
prepared from 80, 2.00 g, 6.5 mmol) and N4-(3-(trifluoromethyl)phenyl)quinazolin-
4,6-diamine (86d, 0.79 g, 2.6 mmol) in dry THF (35 mL) containing triethylamine 
(1.8 mL): Yield 0.75 g (51 %); mp 210–211 °C (dec); 1H NMR (DMSO-d6) δ 3.70–
3.71 (8H, m, 4 × CH2), 6.74 (2H, d, J = 8.8 Hz, 2 × ArH), 7.34 (2H, d, J = 8.8 Hz, 2 × 
ArH), 7.43–7.45 (1H, m, ArH), 7.60–7.64 (1H, m, ArH), 7.76–7.78 (1H, m, ArH), 
7.87–7.89 (1H, m, ArH), 8.20–8.22 (1H, m, ArH), 8.29–8.31 (1H, m, ArH), 8.50–8.51 
(1H, m, ArH), 8.56 (1H, s, ArH), 8.58, 8.85, 9.98 (each 1H, s, exchangeable, 3 × NH). 
Anal. (C26H23Cl2F3N6O·0.5H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(4-fluorophenylamino)quinazolin-6-
yl)urea(87e). Compound 87e was synthesized from 81 (freshly prepared from 80, 
3.00 g, 9.7 mmol) and N4-(4-fluorophenyl)quinazolin-4,6-diamine (86e, 0.99 g, 3.9 
mmol) in dry THF (40 mL) containing triethylamine (2.7 mL): Yield 1.0 g (53 %); 
mp 223–224 °C (dec); 1H NMR (DMSO-d6) δ 3.69–3.71 (8H, m, 4 × CH2), 6.74 (2H, 
d, J = 9.0 Hz, 2 × ArH), 7.19–7.24 (2H, m, 2 × ArH), 7.34 (2H, d, J = 9.0 Hz, 2 × 
ArH), 7.73 (1H, d, J = 9.0 Hz, ArH), 7.80–7.83 (2H, m, 2 × ArH), 7.88 (1H, dd, J = 
2.0 Hz, J = 9.0 Hz, ArH), 8.42 (1H, d, J = 2.0 Hz, ArH), 8.46 (1H, s, ArH) 8.56, 8.79, 
9.75 (each 1H, s, exchangeable, 3 × NH). Anal. (C25H23Cl2FN6O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(4-bromophenylamino)quinazolin-6-
yl)urea (87f). Compound 87f was synthesized from 81 (freshly prepared from 80, 
1.50 g, 4.8 mmol) and N4-(4-bromophenyl)quinazolin-4,6-diamine (86f, 0.61 g, 1.9 
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mmol) in dry THF (30 mL) containing triethylamine (1.3 mL): Yield 0.40 g (36 %); 
mp 220–221 °C (dec);  1H NMR (DMSO-d6) δ 3.69–3.71 (8H, m, 4 × CH2), 6.73 (2H, 
d, J = 9.0 Hz, 2 × ArH), 7.33 (2H, d, J = 9.0 Hz, 2 × ArH), 7.56 (2H, d, J = 8.8 Hz, 2 
× ArH), 7.74 (1H, d, J = 9.0 Hz, ArH), 7.84 (2H, d, J = 8.8 Hz, 2 × ArH), 7.89 (1H, 
dd, J = 9.0 Hz, J = 2.0 Hz, ArH), 8.47 (1H, d, J = 2.0 Hz, ArH), 8.50 (1H, s, ArH), 
8.59, 8.84, 9.80 (each 1H, s, exchangeable, 3 × NH). Anal. 
(C25H23BrCl2N6O·1.5H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(2-fluoro-3-chlorophenylamino) 
quinazolin-6-yl)urea(87g). Compound 87g was synthesized from 81 (freshly 
prepared from 80, 2.00 g, 6.5 mmol) and N4-(2-fluoro-3-chlorophenyl)quinazolin-4,6-
diamine (86g, 0.75 g, 2.6 mmol) in dry THF (35 mL) containing triethylamine (1.8 
mL): Yield  0.97 g (69 %); mp 210–211 °C (dec); 1H NMR (DMSO-d6) δ 3.68–3.71 
(8H, m, 4 × CH2), 6.73 (2H, d, J = 9.0 Hz, 2 × ArH), 7.25–7.29 (1H, m, ArH), 7.33 
(2H, d, J = 9.0 Hz, 2 × ArH), 7.45–7.54 (2H, m, 2 × ArH), 7.72–7.73 (1H, m, ArH), 
7.82–7.84 (1H, m, ArH), 8.41–8.42 (1H, m, ArH), 8.46 (1H, s, ArH) 8.58, 8.87, 9.86 
(each 1H, s, exchangeable, 3 × NH). Anal. (C25H22Cl3FN6O·0.5H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-chloro-4-fluorophenylamino) 
quinazolin-6-yl)urea (87h). Compound 87h was synthesized from 81 (freshly 
prepared from 80, 0.53 g, 1.7 mmol) and N4-(3-chloro-4-fluorophenyl)quinazolin-4,6-
diamine 86h (0.20 g, 0.6 mmol) in dry THF (20 ml) containing triethylamine (0.5 
mL): Yield 0.14 g (37 %); mp 200–201 °C (dec); 1H NMR (DMSO-d6) δ 3.67–3.75 
(8H, m, 4 × CH2), 6.73 (2H, d, J = 9.0 Hz, 2 × ArH), 7.34 (2H, d, J = 9.0 Hz, 2 × 
ArH), 7.41–7.46 (1H, m, ArH), 7.74–7.88 (3H, m, 3 × ArH), 8.14–8.17 (1H, m, ArH), 
8.45–8.46 (1H, m, ArH), 8.52 (1H, s, ArH), 8.57, 8.83, 9.85 (each 1H, s, 
exchangeable, 3 × NH). Anal. (C25H22Cl3FN6O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3,4-dichlorophenylamino) 
quinazolin-6-yl)urea(87i). Compound 87i was synthesized from 81 (freshly prepared 
from 80, 1.00 g, 3.2 mmol) and N4-(3,4,-dichlorophenyl)quinazolin-4,6-diamine (86i, 
0.40 g, 1.3 mmol) in dry THF (25 mL) containing triethylamine (0.9 mL): Yield 0.55 
g (71 %); mp 225–226 °C (dec); 1H NMR (DMSO-d6) δ 3.67–3.73 (8H, m, 4 × CH2), 
6.74 (2H, d, J = 8.8 Hz, 2 × ArH), 7.34 (2H, d, J = 8.8 Hz, 2 × ArH), 7.61–7.63 (1H, 
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m, ArH), 7.75–7.77 (1H, m, ArH), 7.87–7.90 (2H, m, 2 × ArH), 8.28–8.29 (1H, m, 
ArH), 8.47–8.48 (1H, m, ArH), 8.57 (1H, s, ArH) 8.58, 8.86, 9.91 (each 1H, s, 
exchangeable, 3 × NH). Anal. (C25H22Cl4N6O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-bromo-4-fluorophenylamino) 
quinazolin-6-yl)urea(87j). Compound 87j was synthesized from 81 (freshly prepared 
from 80, 2.00 g, 6.5 mmol) and N4-(3-bromo-4-fluorophenyl)quinazolin-4,6-diamine 
(86j, 0.87 g, 2.6 mmol) in dry THF (35 mL) containing triethylamine (1.8 mL): Yield 
0.25 g (17 %); mp 175–176 °C (dec); 1H NMR (DMSO-d6) δ 3.73–3.75 (8H, m, 4 × 
CH2), 6.76 (2H, d, J = 8.8 Hz, 2 × ArH), 7.36 (2H, d, J = 8.8 Hz, 2 × ArH), 7.41–7.43 
(1H, m, ArH), 7.77 (1H, d, J = 9.2 Hz, ArH),  7.87–7.90 (2H, m, 2 × ArH), 8.26 (1H, 
dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.48 (1H, d, J = 2.2 Hz ArH), 8.54 (1H, s, ArH), 
8.63, 8.89, 9.86 (each 1H, s, exchangeable, 3 × NH). Anal. 
(C25H22BrCl2FN6O·1.5H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(4-chloro-3-(trifluoromethyl) 
phenylamino)quinazolin-6-yl)urea(87k). Compound 87k was synthesized from 81 
(freshly prepared from 80, 2.00 g, 6.5 mmol) and N4-(4-chloro-3-
(trifluoromethyl)phenyl)quinazolin-4,6-diamine (86k, 0.80 g, 2.6 mmol) in dry THF 
(35 mL) containing triethylamine (1.8 mL): Yield  0.80 g (52 %); mp 220–221 °C 
(dec); 1H NMR (DMSO-d6) δ 3.67–3.73 (8H, m, 4 × CH2), 6.73 (2H, d, J = 8.8 Hz, 2 
× ArH), 7.34 (2H, d, J = 8.8 Hz, 2 × ArH), 7.71–7.73 (1H, m, ArH), 7.76–7.92 (1H, 
m, ArH), 7.85–7.88 (1H, m, ArH), 8.27–8.31 (1H, m, ArH),  8.43–8.44 (1H, m, ArH), 
8.51–8.52 (1H, m, ArH), 8.56 (1H, s, ArH)  8.57, 8.87, 10.05 (each 1H, s, 
exchangeable, 3 × NH). Anal. (C26H22Cl3F3N6O·0.5H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-chloro-4-methoxyphenylamino) 
quinazolin-6-yl)urea(87l). Compound 87l was synthesized from 81 (freshly prepared 
from 80, 2.00 g, 6.5 mmol) and N4-(3-chloro-4-methoxyphenyl)quinazolin-4,6-
diamine (86l, 0.78 g, 2.6 mmol) in dry THF (35 mL) containing triethylamine (1.8 
mL): Yield  1.0 g (69 %); mp 168–169 °C (dec); 1H NMR (DMSO-d6) δ 3.69–3.72 
(8H, m, 4 × CH2), 3.87 (3H, s, Me), 6.73 (2H, d, J = 8.6 Hz, 2 × ArH), 7.17–7.19 (1H, 
m, ArH), 7.34 (2H, d, J = 8.6 Hz, 2 × ArH), 7.72–7.73 (2H, m, 2 × ArH), 7.85–7.87 
(1H, m, ArH), 7.96–7.97 (1H, m, ArH),  8.42–8.43 (1H, m, ArH), 8.47 (1H, s, ArH) 
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8.56, 8.79, 9.70 (each 1H, s, exchangeable, 3 × NH). Anal. (C26H25Cl3N6O2·H2O): C, 
H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-methoxyphenylamino)quinazolin-
6-yl)urea(87m). Compound 87m was synthesized from 81 (freshly prepared from 80, 
2.50 g, 8.1 mmol) and N4-(3-methoxyphenyl)quinazolin-4,6-diamine (86m, 0.87 g, 
3.2 mmol) in dry THF (35 mL) containing triethylamine (2.2 mL): Yield 1.1 g (65 %); 
mp 159–160 °C (dec); 1H NMR (DMSO-d6) δ 3.69–3.71 (8H, m, 4 × CH2), 3.78 (3H, 
s, Me), 6.68–7.70 (1H, m, ArH), 6.73 (2H, d, J = 9.0 Hz, 2 × ArH), 7.26–7.28 (1H, m, 
ArH), 7.33 (2H, d, J = 9.0 Hz, 2 × ArH), 7.45–7.46 (1H, m, ArH), 7.52–7.53 (1H, m, 
ArH), 7.73 (1H, d, J = 9.0 Hz, ArH), 7.90 (1H, dd, J = 2.1 Hz, J = 9.0 Hz, ArH), 8.42 
(1H, d, J = 2.1 Hz, ArH), 8.50 (1H, s, ArH) 8.57, 8.81, 9.65 (each 1H, s, 
exchangeable, 3 × NH). Anal. (C26H26Cl2N6O2·H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3,4,5-trimethoxyphenylamino) 
quinazolin-6-yl)urea(87n). Compound 87n was synthesized from 81 (freshly 
prepared from 80, 1.00 g, 3.2 mmol) and N4-(3,4,5-trimethoxyphenyl)quinazolin-4,6-
diamine (86n, 0.42 g, 1.3 mmol) in dry THF (25 mL) containing triethylamine (0.9 
mL): Yield 0.49 g (66 %); mp 154–155 °C (dec); 1H NMR (DMSO-d6) δ 3.33 (3H, s, 
Me), 3.67–3.72 (8H, m, 4 × CH2), 3.80 (6H, s, 2 × Me), 6.74 (2H, d, J = 9.0 Hz, 3 × 
ArH), 7.28 (2H, s , 2 × ArH), 7.34 (2H, d, J = 9.0 Hz, 2 × ArH), 7.73 (1H, d, J = 8.9 
Hz, ArH), 7.85–7.88 (1H, dd, J = 2.0 Hz, J = 8.9 Hz, ArH),  8.42 (1H, d, J = 2.0 Hz, 
ArH), 8.49 (1H, s, ArH) 8.56, 8.81, 9.58 (each 1H, s, exchangeable, 3 × NH). Anal. 
(C28H30Cl2N6O4·H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-ethynylphenylamino)quinazolin-6-
yl)urea(87o). Compound 87o was synthesized from 81 (freshly prepared from 80, 
2.00 g, 6.5 mmol) and N4-(3-ethynylphenyl)quinazolin-4,6-diamine (86o, 0.68 g, 2.6 
mmol) in dry THF (35 mL) containing triethylamine (1.8 mL): Yield  0.75 g (52 %); 
mp 164–165 °C (dec); 1H NMR (DMSO-d6) δ 3.67–3.73 (8H, m, 4 × CH2), 4.19 (1H, 
s, CH), 6.73 (2H, d, J = 8.8 Hz, 2 × ArH), 7.20–7.21 (1H, m, ArH), 7.34 (2H, d, J = 
8.8 Hz, 2 × ArH), 7.37–7.41 (1H, m, ArH), 7.73–7.76 (1H, m, ArH), 7.88–7.90 (2H, 
m, 2 × ArH), 8.03–8.04 (1H, m, ArH), 8.44–8.45 (1H, m, ArH), 8.52 (1H, s, ArH)  
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8.58, 8.82, 9.78 (each 1H, s, exchangeable, 3 × NH). Anal. (C27H24Cl2N6O·H2O): C, 
H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(4-phenoxyphenylamino)quinazolin-
6-yl)urea(87p). Compound 87p was synthesized from 81 (freshly prepared from 80, 
2.00 g, 6.5 mmol) and N4-(4-phenoxyphenyl)quinazolin-4,6-diamine (86p, 0.85 g, 2.6 
mmol) in dry THF (35 mL) containing triethylamine (1.8 mL): Yield 0.30 g ( 33 %); 
mp 143–144 °C (dec); 1H NMR (DMSO-d6) δ 3.31–3.71 (8H, m, 4 × CH2), 6.72–6.74 
(2H, m, 2 × ArH), 7.01–7.07 (4H, m, 4 × ArH), 7.10–7.14 (1H, m, ArH), 7.32–7.41 
(4H, m, 4 × ArH), 7.71–7.73 (1H, m, ArH), 7.81–7.90 (3H, m, 3 × ArH), 8.41–8.42 
(1H, m, ArH), 8.46 (1H, s, ArH) 8.58, 8.80, 9.73 (each 1H, s, exchangeable, 3 × NH). 
Anal. (C31H28Cl2N6O2·H2O): C, H, N. 
1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-chloro-4-(pyridin-2-ylmethoxy) 
phenylamino)quinazolin-6-yl)urea(87q). Compound 87q was synthesized from 81 
(freshly prepared from 80, 2.00 g, 6.5 mmol) and N4-(3-chloro-4-(pyridin-2-
ylmethoxy)phenyl)quinazolin-4,6-diamine (86q, 0.98 g, 2.6 mmol) in dry THF (35 
mL) containing triethylamine (1.8 mL): Yield 0.90 g (56 %); mp 156–157 °C (dec); -
1H NMR (DMSO-d6) δ 3.68–3.74 (8H, m, 4 × CH2), 5.30 (2H, s, CH2), 6.74 (2H, d, J 
= 9.0 Hz, 2 × ArH), 7.25–7.27 (1H, m, ArH), 7.34 (2H, d, J = 9.0 Hz, 2 × ArH), 7.37–
7.39 (1H, m, ArH), 7.58–7.60 (1H, m, ArH), 7.69–7.74 (2H, m, 2 × ArH), 7.86–7.91 
(2H, m, 2 × ArH), 8.01–8.02 (1H, m, ArH), 8.42–8.42 (1H, m, ArH), 8.48 (1H, s, 
ArH), 8.60–8.61 (1H, m, ArH) 8.57, 8.80, 9.72 (each 1H, s, exchangeable, 3 × NH). 
Anal. (C31H28Cl3N7O2·1.5H2O): C, H, N. 
2.5 Conclusion 
In continuation of our research on the developing DNA-directed alkylating agents, we 
have synthesized a series of N-mustard-quinazoline conjugates, in which the N-
mustard pharmacophore was attached at the C-6 of the 4-anilinoquinazolines via a 
urea linker. A variety of substituent(s) were introduced to the C-4 anilino moiety for 
studying their structure-activity relationships. All newly synthesized compounds were 
tested against various human tumor cell lines In vitro and In vivo. Antitumor activities 
of these compounds are shown in Chapter 3. 
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2.6 Representative Spectra 
2.6.1 1H NMR Spectrum for compound 79. 
 
]2.6.2 1H NMR Spectrum for compound 80. 
 
 
 
 
 
 
2.4.1 1H NMR Spectrum for compound 78a. 
 
2.4.1 1H NMR Spectrum for compound 78a. 
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2.6.3 1H NMR Spectrum for compound 83. 
 
2.6.4 1H NMR Spectrum for compound 85h. 
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2.6.5 1H NMR Spectrum for compound 86h. 
 
2.6.6 1H NMR Spectrum for compound 87h. 
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2.6.7 1H NMR Spectrum for compound 85m. 
 
2.6.8 1H NMR Spectrum for compound 86m. 
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2.6.9 1H NMR Spectrum for compound 87m. 
 
2.6.10 1H NMR Spectrum for compound 87m (ARO). 
 
N
N
HN
H
N
H
N
N
Cl
Cl
O
O
N
N
HN
H
N
H
N
N
Cl
Cl
O
O
 Chapter 2                                          Synthesis of N-mustard-quinazoline conjugates… 
 52 
2.6.11 1H NMR Spectrum for compound 85q. 
 
2.6.12 1H NMR Spectrum for compound 86q. 
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2.6.13 1H NMR Spectrum for compound 87q. 
 
2.6.14 1H NMR Spectrum for compound 87q(ARO). 
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2.6.15 1H NMR Spectrum for compound 85l. 
 
2.6.16 1H NMR Spectrum for compound 86l. 
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2.6.17 1H NMR Spectrum for compound 87l. 
 
2.6.18 1H NMR Spectrum for compound 87l (ARO). 
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2.7 Elemental analysis 
Table 1. Elemental analysis of compounds 85a-q. 
 
 
 
 
 
 
Compound 
No. MF M.W. 
Elemental Analysis 
CHN Calculated (%) CHN Found (%) 
C H N C H N 
85a 
 C14H9FN4O2 284.25 59.16 3.19 19.71 59.00 3.21 19.70 
85b 
 C14H9ClN4O2 300.70 55.92 3.02 18.63 56.00  3.12 18.73 
85c 
 C14H9BrN4O2 345.15 48.72 2.63 16.23 48.60 2.68 16.43 
85d 
 C15H9F3N4O2 334.25 53.90 2.71 16.76 53.80 2.65 16.75 
85e 
 C14H9FN4O2 284.25 59.16 3.19 19.71 59.07 3.20 19.70 
85f 
 C14H9BrN4O2 345.15 48.72 2.63 16.23 48.68 2.63 16.23 
85g 
 C14H8ClFN4O2 318.69 52.76 2.53 17.58 52.69 2.60 17.45 
85h 
 C14H8ClFN4O2 318.69 52.76 2.53 17.58 52.67 2.57 17.50 
85i 
 C14H8Cl2N4O2 335.14 50.17 2.41 16.72 50.25 2.42 16.73 
85j 
 C14H8BrFN4O2 363.14 46.30 2.22 15.43 46.20 2.24 15.47 
85k 
 C15H8ClF3N4O2 368.70 48.86 2.19 15.20 48.67 2.26 15.38 
85l 
 C15H11ClN4O3 330.73 54.47 3.35 16.94 54.49 3.34 16.97 
85m 
 C15H12N4O3 296.28 60.81 4.08 18.91 60.75 4.05 18.88 
85n 
 C17H16N4O5 356.33 57.30 4.53 15.72 57.24 4.53 15.72 
85o 
 C16H10N4O2.0.5 299.28 64.21 3.70 18.72 64.71 3.60 18.50 
85p 
 C20H14N4O3 358.35 61.49 4.99 13.88 61.76 5.00 13.86 
85q C20H14ClN5O3.2H2O 443.84 54.12 4.09 15.78 54.47 4.17 15.79 
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Table 2. Elemental analysis of compounds 86a-q. 
 
 
 
 
 
 
 
 
Compound 
No. MF M.W. 
Elemental Analysis 
CHN Calculated (%) CHN Found (%) 
C H N C H N 
86a 
 C14H11FN4.0.8H2O 254.26 62.58 4.73 20.85 62.76 4.63 20.74 
86b 
 C14H11ClN4 270.72 62.11 4.10 20.70 62.22 4.05 20.60 
86c 
 C14H11BrN4 315.17 53.35 3.52 18.78 53.45 3.42 18.68 
86d 
 C15H11F3N4 304.27 59.21 3.64 18.41 59.30 3.48 18.28 
86e 
 C14H11FN4.1.3H2O 277.68 60.55 4.94 20.18 60.28 4.80 19.67 
86f 
 C14H11BrN4.0.2H2O 318.77 52.75 3.60 17.58 52.42 3.62 17.01 
86g 
 C14H10ClFN4 288.71 58.24 3.49 19.41 58.24 3.54 19.10 
86h 
 C14H10ClFN4 288.71 58.24 3.49 19.41 58.44 3.39 19.60 
86i 
 C14H10Cl2N4 305.16 55.10 3.30 18.36 54.72 3.29 18.04 
86j 
 C14H10BrFN4 333.16 50.47 3.03 16.82 50.60 3.09 17.00 
86k 
 C15H10ClF3N4 338.71 53.19 2.98 16.54 53.02 3.03 16.15 
86l 
 C15H13ClN4O 300.74 59.91 4.36 18.63 59.71 4.39 18.17 
86m 
 C15H14N4O.0.2H2O 269.90 66.75 5.38 20.76 66.75 5.18 20.76 
86n 
 C17H18N4O3 326.35 62.57 5.56 17.17 62.23 5.62 16.83 
86o 
 C16H12N4.1.2H2O 281.91 68.17 5.15 19.87 68.24 5.36 19.30 
86p 
 C20H16N4O 328.37 73.15 4.91 17.06 73.25 5.01 17.20 
86q 
 C20H16ClN5O 377.83 63.58 4.27 18.54 63.20 4.40 18.08 
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Table 3. Elemental analysis of compounds 87a-q. 
 
 
Compound 
No. MF M.W. 
Elemental Analysis 
CHN Calculated (%) CHN Found (%) 
C H N C H N 
87a 
 C25H23Cl2FN6O.H2O 531.41 56.50 4.74 15.81 56.60 4.63 15.65 
87b 
 C25H23Cl3N6O.H2O 547.86 54.81 4.60 15.34 54.86 4.54 15.22 
87c 
 C25H23BrCl2N6O.1.5H2O 601.32 49.93 4.36 13.98 50.09 4.21 13.95 
87d 
 C26H23Cl2F3N6O.0.5H2O 572.41 54.56 4.23 14.68 54.73 4.11 14.65 
87e 
 C25H23Cl2FN6O 513.39 58.49 4.52 16.37 58.33 4.56 16.19 
87f 
 C25H23BrCl2N6O.1.5H2O 601.32 49.93 4.36 13.98 49.68 4.15 13.71 
87g 
 C25H22Cl3FN6O.0.5H2O 556.85 53.92 4.16 15.09 53.83 3.97 15.00 
87h 
 C25H22Cl3FN6O 601.89 49.89 4.69 13.96 50.07 4.29 13.31 
87i 
 C25H22Cl4N6O 564.29 53.21 3.93 14.89 53.25 3.93 14.89 
87j 
 C25H22BrCl2FN6O.1.5H2O 619.31 48.48 4.07 13.57 48.51 3.88 13.45 
87k 
 C26H22Cl3F3N6O.0.5H2O 606.85 51.46 3.82 13.85 51.83 3.68 13.95 
87l 
 C26H25Cl3N6O2.H2O 577.89 54.04 4.71 14.54 54.17 4.68 14.62 
87m 
 C26H26Cl2N6O2.H2O 543.44 57.46 5.19 15.46 57.07 5.19 15.32 
87n 
 C28H30Cl2N6O4.H2O 603.50 55.73 5.34 13.93 55.41 5.34 13.79 
87o 
 C27H24Cl2N6O.H2O 537.44 60.34 4.88 15.64 59.93 4.86 15.45 
87p 
 C31H28Cl2N6O2.H2O 605.51 61.49 4.99 13.88 61.76 5.00 13.86 
87q 
 C31H28Cl3N7O2.1.5H2O 663.98 56.08 4.71 14.77 55.86 4.37 14.60 
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3.1 Biological results and discussion 
3.1.1 In vitro cytotoxicity 
To study the structure-activity relationships of the N-mustard-quinazoline conjugates, 
we have introduced electron-withdrawing halogen(s), electron-donating methoxy 
function(s), and other substituent to the 4-anilino ring. These derivatives were 
subjected to evaluating their cytotoxicities in inhibiting human lymphoblastic 
leukemia (CCRF-CEM) and its drug-resistant sublines resistant to Taxol (CCRF-
CEM/Taxol) and Vinblastine (CCRF-CEM/VBL) cell growth in vitro (Table 1). It 
demonstrated that the newly synthesized conjugates possess significant cytotoxicity 
with IC50 in micro molar range. The most cytotoxic compound of this series is the 
3',4',5'-trimethoxyphenyl derivative 87n with an IC50 value of 0.38 µM. However, the 
potency of the C-3'-OMe derivative (87m, IC50>1.32 μM) is much weaker than the 
corresponding trimethoxy derivative 87n. As for the halogen-substituted derivatives, 
it is clearly to see that order of the cytotoxicity of C-3'-halogen substituted 
compounds is C-3'-Br (87c)> C-3'-Cl (87b)> C-3'-F (87a). In contrast, the C-4'-F 
substituted derivatives 87e is apparently more potent than the corresponding C-4'-Br 
derivative 87f.  In the series of C-3'-C-4' dihalogens substituted conjugates, the order 
of the cytotoxicity is 87g > 87h > 87i  87j.  The SAR study shows that the position 
of the substitutions, numbers and types of halogen atom are critical for their activity. 
The cytotoxicity of compounds bearing other substituent, such as C-3' or C-4'-CF3 
(87d and 87k, respectively), C-3'-ethynyl (87o), C-4'-phenoxy (87p), and 3-chloro-4-
(pyridin-2-ylmethoxy) (87q), were also evaluated. It reveals that C-3'-ethynyl (87o) is 
most cytotoxic among these conjugates with a IC50 value of 0.50 μM. Compounds 
having a CF3 substituent (87d and 87k) are less cytotoxic than other compounds 
tested. 
The cytotoxicity of the newly synthesized compounds against human CCRF-CEM 
drug-resistant sublines (resistant to Vinblastine and Taxol, CCRF-CEM/VBL and 
CCRF-CEM/taxol, respectively) were also studied. The results revealed that they 
generally have no or little cross-resistance to these two natural products except 
compounds 87n, which has certain extent of cross-resistance (Table 1). It suggests 
that the N-mustard derivatives were neither a good substrate of p-glycoprotein nor 
mutated tubulin. 
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Table 1. The cytotoxicity of newly synthesized phenyl N-mustard-6-
aminoquinazoline conjugates against human lymphoblastic leukemia (CCRF-CEM) 
and its drug-resistant sublines (CCRF-CEM/Taxol and CCRF-CEM/VBL). [a] 
N
N
HN
H
N
R
H
N
N
OCl
Cl
87a-q
2'
3'
4'
5'
 
Compd. Substitute R Cell Growth inhibition (IC50 µM) 
 2' 3' 4' 5' CCRF-CEM 
CCRF-
CEM/ 
Taxol[b] 
CCRF-
CEM/ 
VBL[b] 
87a H F H H 2.51±0.11 
3.46±0.18 
[1.38][c] 
4.28±0.01 
[1.70] 
87b H Cl H H 1.66±0.14 
4.56±0.00
01 
[2.75] 
3.26±0.05 
[1.96] 
87c H Br H H 0.95±0.11 
4.58±0.05 
[4.82] 
2.62±0.01 
[2.76] 
87d H CF3 H H 3.97±0.22 
4.57±0.13 
[1.15] 
4.68±0.05 
[1.17] 
87e H H F H 0.74±0.02 
3.16±0.07 
[4.27] 
1.24±0.03 
[1.67] 
87f H H Br H 4.64±0.16 
8.79±0.16 
[1.89] 
7.88±0.36 
[1.70] 
87g F Cl H H 0.75±0.01 
1.55±0.02 
[2.07] 
1.04±0.03 
[1.39] 
87h H Cl F H 1.00±0.09 
1.16±0.14 
[1.16] 
1.14±0.03 
[1.14] 
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87i H Cl Cl H 2.60±0.02 
5.61±0.16 
[2.16] 
6.75±0.53 
[2.60] 
87j H Br F H 2.68±0.11 
4.40±0.30 
[1.64] 
4.74±0.15 
[1.77] 
87k H CF3 Cl H 4.77±0.22 
5.36±0.14 
[1.12] 
5.28±0.58 
[1.11] 
87l H Cl OMe H 0.80±0.01 
3.34±0.02 
[4.17] 
3.75±0.04 
[4.68] 
87m H OMe H H 1.32±0.02 
3.58±0.12 
[2.71] 
3.38±0.17 
[2.56] 
87n H OMe OMe OMe 0.38±0.02 
12.32±0.7
9 
[32.42] 
24.51±1.7
2 
[64.50] 
87o H 3-ethynyl H H 0.50±0.04 
2.29±0.02 
[4.58] 
2.33±0.34 
[4.66] 
87p H H OPh H 4.77±0.01 
7.99±0.18 
[1.67] 
10.88±0.0
2 
[2.28] 
87q H Cl 
OCH2(
2-
pyridin
yl) 
H 1.41±0.07 
4.58±0.08 
[3.24] 
2.65±0.13 
[1.88] 
Taxol     0.003 ±0.0003 
0.43±0.05 
[143] 
1.27±0.05 
[423] 
Vinblastine     0.0007±0.001 
0.08±0.01 
[106.2] 
0.50±0.12 
[679.5] 
Carboplatin     3.4±0.99  
2.45±0.65 
[0.7] 
[a]Cell growth inhibition was measured by the XTT assay101 for leukemic cells after 
72-h incubation using a microplate spectrophotometer as described previously.103 
Similar in vitro results were obtained by using the Cell Counting Kit-8 for the CCK-8 
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assays as described by technical manual of Dojindo Molecular Technologies, Inc. 
(Gaithersburg, MD; Website: www.dojindo.com). IC50 values were determined from 
dose-effect relationship at six or seven concentrations of each drug by using the 
CompuSyn software by Chou and Martin105 based on the median-effect principle and 
plot using the serial deletion analysis.106, 107 Ranges given for taxol and vinblastine 
were mean ± SE (n = 4). 
[b]CCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells 
that are 143-fold resistant to Taxol, and 423-fold resistant to vinblastine, respectively, 
when comparing with the IC50 of the parent cell line. 
[c]Numbers in the brackets are fold of cross-resistant determined by comparison with 
the corresponding IC50 of the parent cell line. 
 
The selected compounds were further evaluated for their cytotoxicity in inhibiting 
other human solid tumors such as human breast tumor (MX-1), colon cancer (HCT-
116), human non-small cell lung cancer (H1299), and prostate cancer (PC3) cell 
growth in vitro. As shown in Table 2, one can see that these conjugates possess good 
to moderate cytotoxic effects against the growth of these cell lines tested in vitro. In 
comparison with the cytotoxicities of the N-mustard-quinoline conjugates, previously 
synthesized in our laboratory,95 the N-mustard-quinazoline conjugates are less potent 
in inhibiting all tumor cell lines examined. 
 
Table 2.The cytotoxicity of phenyl N-mustard-6-aminoquinazoline conjugates (87a-
q) against human solid tumor (breast carcinoma MX-1, colon carcinoma HCT-116, 
lung carcinoma H1299 and prostate carcinoma PC3) cell growth in vitro.[a] 
Compd. 
Cell Growth inhibition (IC50 µM) 
MX-1[a] HCT-116[a] H1299[b] PC3[b] 
87a 10.11±0.09 9.62±0.12 ND ND 
87b 7.84±0.03 7.46±0.02 10.49±2.04 10.37±0.32 
87c 6.92±0.05 2.17±0.03 8.04±1.26 10.13±0.13 
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87d 5.30±0.63 5.97±0.24 ND ND 
87e 3.43±0.003 3.18±0.03 11.60±1.54 8.24±1.76 
87f 6.71±0.03 7.79±0.36 ND ND 
87g 4.55±0.02 3.84±0.0005 5.52±1.59 6.29±1.12 
87h 5.38±0.05 3.36±0.05 ND[c] ND 
87i 6.45±0.50 2.79±0.14 ND ND 
87j 7.10±0.14 5.99±0.63 ND ND 
87k 7.44±0.58 5.34±0.06 ND ND 
87l 5.51±0.09 5.27±0.18 6.94±1.71 8.02±2.08 
87m 2.59±0.13 2.44±0.03 8.79±1.32 9.44±0.87 
87n 4.02±0.03 2.24±0.01 10.28±1.25 10.98±1.89 
87o 6.27±0.24 3.47±0.13 ND ND 
87p 8.47±0.15 12.41±0.04 ND ND 
87q 4.62±0.20 2.22±0.54 ND ND 
Cisplatin 4.95±0.60 26.65±4.19 ND ND 
 
[a]Cell growth inhibition was measured by the SRB assay102 for solid tumor cells 
after 72-h incubation using a microplate spectrophotometer as described previously.103 
[b]Cell growth inhibition was determined by the Alamar blue assay104 in a 72 h 
incubation using a microplate spectrophotometer as described previously. 
[c]Not determined. 
 
3.1.2 In vivo therapeutic activity 
The in vitro cytotoxicity of the tested compound may not always directly reflex to its 
therapeutic efficacy in tumor xenograft model. In the present studies, we selected 
compounds 87b, 87g, and 87h for evaluating their therapeutic efficacy in nude mice 
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bearing human mammary carcinoma (MX-1) xenografts (fig. 1, 2). To find a maximal 
tolerable dose of compound tested, we administrated various doses to view its 
therapeutic effects via intravenous injection (iv inj.). The preliminary results show 
that compound 87h possessed significant tumor growth inhibition (72 %) in 
comparison with the untreated control when mice were treated successfully with the 
dose of 50 mg/kg, every two days for three times (Q2D×3), 60 mg/kg (Q2D×3), and 
then 70 mg/kg, every two days for two times (Q2D×2). With the same drug 
administration route (iv inj.), compound 87b showed a moderate tumor inhibition (62 
%), at the doses of 30 mg/kg (Q2D×3) and 35 mg/kg, every two days for five times 
(Q2D×5). Compound 87g also showed to have moderate tumor suppression (52 %) at 
the dose of 30 mg/kg (Q2D×3) and then 40 mg/kg (Q2D×5). Although all the tested 
compounds induced a 5-7% body-weight change during the treatment (Table 3), the 
body-weight of mice readily recovered after cessation of the treatment, suggesting 
that these agents have relatively low toxicity to the host. 
Conjugates 87b and 87g were also selected for evaluating their therapeutic efficacy 
against human prostate PC-3 xenograft in nude mice. Figure 3 shows that there were 
27 % and 69 % tumor suppression by 87b and 87g, respectively, at the maximal 
tolerable dose of 55 mg/kg, every two days for six times (Q2D×6) with acceptable 
toxicity (about 10-11 % body weight loss). Similar observations were found that N-
mustard-quinazoline conjugates are much less potent against human breast MX-1 
xenograft in mice than that of the N-mustard-quinoline conjugates.95 
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Figure 1. Therapeutic effect of 87b (50 mg/kg, i.v. infusion, Q2Dx3, 60 mg/kg, i.v. 
infusion, Q2Dx3, 70 mg/kg, i.v. infusion, Q2Dx2 ), and 87h (30 mg/kg, i.v. infusion, 
Q2Dx3, 35 mg/kg, i.v. infusion, Q2Dx5,  n=4), in nude mice bearing human 
mammary carcinoma MX-1 xenograft; average tumor size changes (Figure 1A) and 
average body weight changes (Figure 1B). 
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Figure 2. Therapeutic effect of 87g (30 mg/kg, i.v. infusion, Q2Dx3, 40 mg/kg, i.v. 
infusion, Q2Dx5), in nude mice bearing human mammary carcinoma MX-1 
xenograft; average tumor size changes (Figure 2A) and average body weight changes 
(Figure 2B). 
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Figure 3. Therapeutic effect of 87b (55 mg/kg, i.v. infusion, Q2Dx6, n=5 ), and 87g 
(55 mg/kg, i.v. infusion, Q2Dx6, n=5), in nude mice bearing 
prostate  PC-3 xenograft; average tumor size changes (Figure 3A) and average body 
weight changes (Figure 3B). 
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3.1.3 DNA cross-linking study by alkaline agarose gel shift assay 
The alkaline gel shift assay was performed to assess DNA cross-linking activity of 
compounds 87g, 87l, 87b, and 87e (Fig. 4). The pEGFP-N1 plasmid DNA was treated 
with compounds, 87g, 87l, 87b, and 87e at various concentrations as indicated (1, 10 
and 20 µM). Melphalan was used as a positive control. The tested compounds show 
moderate cross-linking behavior at lower concentrations; however, at high 
concentrations, the cross-linking behavior was similar to melphalan. These results 
revealed that the newly synthesized N-mustard-quinazoline conjugates are capable to 
induce DNA cross-linking. 
 
Figure 4. Representative DNA cross-linking gel shift assay for 87g, 87l, 87b, and 87e 
at various concentrations as indicated. Control lane shows single-stranded DNA (SS), 
while cross-linking (CL) shown in all tested lanes is DNA double-stranded cross-
linking. Melphalan (1 and 5 µM) was used as a positive control. 
3.1.4 Cell cycle inhibition 
It was reported that DNA damage induced by DNA alkylating agents is known to 
cause cell cycle delay and arrest the cell cycle progression predominantly at the G2/M 
boundary.99 We therefore studied the inhibitory effect of 87b on cell cycle distribution 
(Table 3). The human non small lung carcinoma H1299 cells were treated with 87b at 
the concentrations of 5, 10, and 20 µM for 24 h. The cells were harvested, stained 
with propidium iodide (PI) and analyzed with a flow cytometer. It clearly shows that 
5 µM of 87b significantly accumulated the cells at G2/M phase, while 10 and 20 µM 
of 87b prevented the cell cycle progression, which may be due to high level of DNA 
cross-linking. Similar G2/M arrest was previously observed in SW626 cells treated 
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with melphalan.100 Furthermore, increased sub-G1 populations were noticed in cells 
treated with 87b at 20 µM. 
Table 3. Cell cycle inhibition in human non-small cell lung adenocarcinoma H1299 
by treating with compound  87b. 
Concentra
tion 
(µM) 
0 5 10 20 
 
sub G1 8.8±6.9 8.9±0.03 7.5±0.2 35.3±2.2 
G1 44.8±3.0 30.5±0.4 34.8±0.4 28.3±1.0 
S 24.9±3.3 20.6±4.0 28.5±0.2 23.5±3.5 
G2/M 21.5±0.6 40.0±3.5 29.3±0.01 12.9±0.2 
 
3.2 Biological experiments 
3.2.1 Cytotoxicity Assays 
The effects of the newly synthesized compounds on cell growth were determined in 
T-cell acute lymphocytic leukemia CCRF-CEM) and their resistant subcell lines 
(CCRF-CEM/Taxol and CCRF-CEM/VBL) by the XTT assay104 and human solid 
tumor cells (i.e. breast carcinoma MX-1 and colon carcinoma HCT-116) the SRB 
assay105 in a 72 h incubation using a microplate spectrophotometer as described 
previously.106 After the addition of phenazine methosulfate-XTT solution at 37 oC for 
6 h, absorbance at 450 and 630 nm was detected on a microplate reader (EL 340; Bio-
Tek Instruments Inc., Winooski, VT). The cytotoxicity of the newly synthesized 
compounds against non-small cell lung cancer H1299, human prostate cancer PC3, 
were determined by the Alamar blue assay107 in a 72 h incubation using a microplate 
spectrophotometer as described previously. After the addition of Alamar blue 
solution, it was incubated at 37 oC for 6 h. Absorbance at 570 and 600 nm was 
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detected on a microplate reader. IC50 values were determined from dose-effect 
relationship at six or seven concentrations of each drug by using the CompuSyn 
software by Chou and Martin108 based on the median-effect principle and plot.109, 110 
Ranges given for taxol and vinblastine were mean ± SE (n = 4). 
3.2.2 In vivo studies 
Athymic nude mice bearing the nu/nu gene were used for human breast tumor MX-1 
and prostate PC-3 xenograft. Outbred Swiss-background mice were obtained from the 
National Cancer Institute (Frederick, MD). Male mice 8 weeks old or older weighing 
about 22 g were used for the experiments. Drug was administrated via the tail vein by 
i.v. injection.103 Tumor volumes were assessed by measuring length × width × height 
(or width) by using caliper.  Vehicle used was DMSO (50 L) and Tween 80 (40 L) 
in saline (160 L). The maximal tolerable dose of the tested compound was 
determined and applied for the in vivo antitumor activity assay. All animal studies 
were conducted in accordance with the guidelines of the National Institutes of Health 
Guide for the Care and Use of Animals and the protocol approved by the Memorial 
Sloan-Kettering Cancer Center’s Institutional Animal Care and Use Committee.  
3.2.3 Alkaline agarose gel shift assay 
Formation of DNA cross-linking was analyzed by alkaline agarose gel 
electrophoresis. In brief, purified pEGFP-N1 plasmid DNA (1500 ng) was mixed with 
various concentrations (1–20 µM) of 21g, 21l, 21b and 21e in 40 µL binding buffer (3 
mM sodium chloride/1mM sodium phosphate, pH 7.4, and 1 mM EDTA). The 
reaction mixture was incubated at 37oC for 2 h. At the end of reaction, the plasmid 
DNA was linearized by digestion with BamHI and followed by precipitation with 
ethanol. The DNA pellets were dissolved and denatured in alkaline buffer (0.5 N 
NaOH–10mM EDTA). An aliquot of 20 µL of DNA solution (1000 ng) was mixed 
with a 4 µL of 6 X alkaline loading dye and then electrophoretically resolved on a 0.8 
% alkaline agarose gel with NaOH–EDTA buffer at 4oC. The electrophoresis was 
carried out at 18 V for 22 h. After staining the gels with an ethidium bromide solution, 
and the DNA was then visualized under UV light. 
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3.2.4 Flow cytometric analysis 
The effects of 21b on cell cycle distribution were analyzed with a flow cytometer as 
described previously.111 Briefly, human non-small cell lung carcinoma H1299 cells 
were treated with 21b at 5, 10, and 20 µM for 24 h. The attached cells were then 
trypsinized, washed with phosphate buffer saline (PBS), and fixed with ice-cold 70% 
ethanol for 30 min. The cells were stained with 4 µg/ml propidium iodide (PI) in PBS 
containing 1% Triton X-100 and 0.1 mg/ml RNase A. The stained cells were then 
analyzed using the FACS SCAN flow cytometer (Becton Dickinson, San Joes, CA, 
USA). The percentage of the cells in each cell cycle phase was determined using the 
ModFit LT 2.0 software based on the DNA histograms. 
3.3 Conclusion 
To continue our research on the developing DNA-directed alkylating agents, we have 
synthesized a series of N-mustard-quinazoline conjugates, in which the N-mustard 
pharmacophore was attached at the C-6 of the 4-anilinoquinazolines via a urea linker. 
The preliminary antitumor studies revealed that these agents exhibited significant 
antitumor activity in inhibiting various human tumor cell growths in vitro. Among 
compounds selected for evaluating their antitumor activity against human breast 
tumor (MX-1) xenograft in nude mice, 4-[3’-Cl,4’-F-phenylamino]quinazoline 
derivative (87h) is the most potent. Studies on the therapeutic efficacy against MX-1 
xenograft in nude mice revealed that the tested compounds have moderate antitumor 
activity, but they are less toxic to the host based on the observation of the average 
body-weight changes. In the present studies we also show that the newly synthesized 
compounds are able to induce DNA cross-linking through alkaline agarose gel shift 
assay and inhibited cell cycle arrest at G2/M phase. 
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4.1 Chemistry 
The general synthetic route of the newly N-mustard-6-hydroxyquinoline conjugates is 
shown in Schemes 1. The N-mustard-6-hydroxyquinoline conjugates (95aa’-95bg’) 
was prepared starting from the commercially available 4-nitroaniline 88 was reacted 
with the commercially available substituted ethyl 3-oxobutanoate 89a-b to give 
corresponding (E)-ethyl 3-((4-methoxyphenyl)amino)but-2-enoate 90a and (E)-ethyl 
3-((4-methoxyphenyl)amino)-3-phenylacrylate 90b in ethanol at 50°C, and this 
products was cyclized by using diphenylether at 250°C to give 6-methoxy-2-
subsitutedquinolin-4(1H)-one 91a-b with good yield110-112. Compounds (91a-b), was 
treated with POCl3 to produce substituted 4-chloro-6-methoxyquinoline (92a-b)113. 
Compound 92a was then treated with boron tribromide at -50 oC by following 
literature procedure114 gave 4-chloro-2-methylquinoline-6-ol (93a). Compound 92b 
was treated with sulfuric acid at 100 oC to give 4-chloro-2-phenylquinolin-6-ol (93b). 
The other compounds 94aa’-bg’ were obtained by the treatment of Substituted aniline 
in Isopropanol (IPA) in the presence of concentrated HCl115. Reaction of 94aa’-bg’ 
with the known 4-[N,N-bis(2-chloroethyl)-amino]phenylisocyanate 81 (chapter 2) 
[freshly prepared from N,N-bis(2-chloroethyl)benzene-1,4-diamine hydrochloride 
(80)] in the presence of triethylamine afforded N-mustard-6-hydroxyquinoline 
c.onjugate 95aa’-bg’ bearing a carbamate linker. 
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4.2 Reaction Scheme 
Scheme 1. Synthetic route for N-mustard-4-anilinoquinazoline conjugates 
bearing a carbamate linker  
NH2
H3CO O
R
O
N
H
R
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h
 
Reagent and condition: (a) con. HCl/room temperature, (b) EtOH/AcOH/50°C, (c) 
Diphenylether/250°C, (d) POCl3/reflux, (e) BBr3/MDC/-50°C, (f) H2SO4/100°C, (g) 
IPA/con.HCl/reflux (h) Et3N/DMF/room temperature.   
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4.3 Physical Data 
Table 1. Analytical data and yields of Substituted 6-hydroxy-4-anilinoquinolines 
(94aa’-bg’) 
 
Sr. 
 No. 
Substitute  
R 
Substitute 
R1 MF MW 
Yield 
% 
MP °C 
94aa’ 
 Me C6H5 C16H14N2O 250.30 91 >300 
94ab’  Me 3'-F-C6H4 C16H13FN2O 268.29 80 >300 
94ac’  Me 3'-Cl-C6H4 C16H13ClN2O 284.74 81 >300 
94ad’  Me 3'-Br-C6H4 C16H13BrN2O 329.19 82 >300 
94ae’  Me 4'-F-C6H4 C16H13FN2O 268.29 95 >300 
94af’  Me 4'-Cl-C6H4 C16H13ClN2O 284.74 95 228–229 
94ag’  Me 4'-Br-C6H4 C16H13BrN2O 329.19 94 >300 
94ba’ 
 Ph C6H5 C21H16N2O 312.36 52 >300 
94bb’ 
 Ph 3'-F-C6H4 C21H15FN2O 330.36 79 193-194 
94bc’ 
 Ph 3'-Cl-C6H4 C21H15ClN2O 346.81 58 >300 
94bd’ 
 Ph 3'-Br-C6H4 C21H15BrN2O 391.26 82 >300 
94be’ 
 Ph 4'-F-C6H4 C21H15FN2O 330.36 61 249-250 
94bf’ 
 Ph 4'-Cl-C6H4 C21H15ClN2O 346.81 70 293-294 
94bg’ 
 Ph 4'-Br-C6H4 C21H15BrN2O 391.26 72 >300 
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Table 2. Analytical data and yields of Substituted N-mustard quinoline 
carbamate conjugates (95aa’-bg’) 
N
HN
R1
O
R
H
N
N
Cl
Cl
O
95aa'-95bg'  
 
Sr. 
No. 
Substitute  
R 
Substitute R1 MF MW 
Yield 
% 
MP °C 
95aa’ 
 Me C6H5 C27H26Cl2N4O2 509.43 40 202-203 
95ab’  Me 3'-F-C6H4 C27H25Cl2FN4O2 527.42 38 207-208 
95ac’  Me 3'-Cl-C6H4 C27H25Cl3N4O2 543.87 51 224-225 
95ad’  Me 3'-Br-C6H4 C27H25BrCl2N4O2 588.32 34 201-202 
95ae’  Me 4'-F-C6H4 C27H25Cl2FN4O2 527.42 36 223-224 
95af’  Me 4'-Cl-C6H4 C27H25Cl3N4O2 543.87 31 189-191 
95ag’  Me 4'-Br-C6H4 C27H25BrCl2N4O2 588.32 30 229-231 
95ba’ 
 Ph C6H5 C32H28Cl2N4O2 571.50 42 209-210 
95bb’  Ph 3'-F-C6H4 C32H27Cl2FN4O2 589.49 45 210-211 
95bc’  Ph 3'-Cl-C6H4 C32H27Cl3N4O2 605.94 37 197-198 
95bd’  Ph 3'-Br-C6H4 C32H27BrCl2N4O2 650.39 37 186-187 
95be’  Ph 4'-F-C6H4 C32H27Cl2FN4O2 589.49 50 186-187 
95bf’  Ph 4'-Cl-C6H4 C32H27Cl3N4O2 605.94 38 204-205 
95bg’  Ph 4'-Br-C6H4 C32H27BrCl2N4O2 650.39 40 213-214 
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4.4 Experimental Section 
General methods and materials 
Compound solvents and reagents were reagent grade and used without purification 
unless otherwise noted. The melting points were recorded on a Fargo melting point 
apparatus and are uncorrected. Column chromatography was carried out on silica gel 
G60 (70-230mesh, ASTM; Merck and 230-400 mesh, silicycle inc.). Reaction 
progress was monitored using analytical thin-layer chromatography (TLC) on 
0.25mmMerck F-254 silica gel glass plates. Visualization was achieved by UV light 
(254 nm). 1H NMR spectra were recorded with a Bruker AVANCE 600 DRX and 400 
MHz spectrometer; Chemical shifts are reported in parts per million (δ) using 
tetramethylsilane as the internal standard with coupling constants (J) reported in hertz 
(Hz). The peak shapes are denoted as follows: s, singlet; d, doublet; t, triplet; q, 
quartet; m, multiplet; dd, double doublet; brs, broad singlet. Elemental analyses were 
performed on a Heraeus CHN-O Rapid analyzer. High performance liquid 
chromatography analysis for checking purity of synthesized compounds were 
recorded on a Hitachi D-2000 Elite instrument: column, Mightysil RP-18 GP 250-4.6 
(5µL) mobile phase, MeCN/THF (70:30 v/v); flow rate, 1 mL/min; injected sample 
10µL, column temp, 27°C; wavelength, 254nm. The purity of all compounds was > 
95 % based on analytical HPLC. 
(E)-Ethyl-3-(4-methoxyphenylamino)but-2-enoate (90a). P-anisidine (88, 50.00gm, 
0.40mol) and Ethylaetoacetate (89a, 52.84 g, 0.40mol) was mixes well and sonicated 
for 30 min. In that, solution was added con. HCl (3 mL) at room temperature, over 5 
min. the mixture was then stirred for 12 h at room temperature. After completion of 
the reaction, the mixture was diluted with water, and aqueous layer extracted three 
times with ethyl acetate. The organic layer was washed two times with water and 
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dried over Na2SO4. After evaporation, the solid product was washed with hexane to 
give 90a, 35.0 g (63 %); 1H NMR (DMSO-d6) δ 1.18 (3H, t, J = 7.0 Hz, Me), 1.88 
(3H, s, Me), 3.75 (3H, s, Me), 4.05 (2H, q, J = 7.0 Hz, CH2), 4.62 (1H, s, CH), 6.91–
6.94 (2H, m, 2 × ArH), 7.11–7.13 (2H, m, 2 × ArH), 10.14 (1H, s, exchangeable, 
NH). Anal. (C13H17NO3): C, H, N. 
(E)-Ethyl -3-(4-methoxyphenylamino)-3-phenylacrylate (90b). To a solution of 4-
methoxyaniline (88, 12.3 g, 100 mmol) and ethanol (600 mL) was added ethyl 
benzoylacetate (89b, 19.2 g, 100 mmol) at room temperature. The reaction mixture 
was heated up to 50°C. The acetic acid (2 mL) was added into the reaction mixture at 
50°C. The reaction mixture was heated up to reflux temperature for 24 hrs. After 
completion of the reaction, it was cooled to room temperature. The solid was 
collected by filtration, washed with ethanol and dried to give 90b, 10.9 g, (42 %); mp 
112–113°C (111–113°C lit); 1H NMR (DMSO-d6) δ 1.23 (3H, t, J = 7.2 Hz, Me), 
3.64 (3H, s, Me), 4.11 (2H, q, J = 7.2 Hz, CH2), 4.85 (1H, s, CH), 6.70 (4H, s, 4 × 
ArH), 7.31–7.36 (5H, m, 5 × ArH), 10.11 (1H, s, exchangeable, NH). Anal. 
(C18H19NO3): C, H, N. 
6-Methoxy-2-methylquinoline-4(1H)-one (91a). To a magnetically stirred solution 
of diphenylether(552 mL) was added portion wise (E)-Ethyl-3-(4-
methoxyphenylamino)but-2-enoat (90a, 69.0 g, 293 mmol) at 240° C over 30min. 
After that, the mixture was then stirred for 1h at 250°C. After completion of the 
reaction, the precipitated product was separated from the reaction mixture by filtration 
and was washed with hexane. The desired product was obtained as a yellowish 
powder. Then crud product was slurred with chloroform and filter it washed with little 
amount of solvent to give 91a, 35.0 g (63 %); 1H NMR (DMSO-d6) δ 2.34 (3H, s, 
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Me), 3.82 (3H, s, Me), 5.90 (1H, s, ArH), 7.24–7.27 (1H, m, ArH), 7.46–7.49 (2H, m, 
2 × ArH), 11.66 (1H, s, exchangeable, NH). Anal. (C11H11NO2): C, H, N. 
6-Methoxy-2-phenylquinoline-4(1H)-one (91b). The diphenylether (350 mL) was 
heated up to 240°C. The (E)-ethyl 3-(4-methoxyphenylamino)-3-phenylacrylate (90b, 
44.6 g, 150 mmol) was added portionwise into the diphenylether at 240°C. After 
completion of the addition, the temperature was raised to 250°C. After 20 min, the 
mixture was cooled to room temperature. The solid was come out from reaction mass. 
The solid was collected by filtration and washed with hexane to give 91b, 34.0 g, (92 
%); mp 309–310°C (302–304°C lit.); 1H NMR (DMSO-d6) δ 3.85 (3H, s, Me), 6.34 
(1H, brs, ArH), 7.33 (1H, dd, J = 2.8 Hz, J = 9.1 Hz, ArH), 7.51 (1H, d, J = 2.8 Hz, 
ArH), 7.57–7.59 (3H, m, 3 × ArH), 7.53 (1H, d, J = 9.1 Hz, ArH ), 7.83–7.89 (2H, m, 
2 × ArH), 11.70 (1H, brs, exchangeable, NH). Anal. (C16H13NO2): C, H, N.  
4-Chloro-6-methoxy-2-methylquinoline (92a). To a magnetically stirred solution of 
POCl3 (161 mL) at 0°C was added portion wise 6-methoxy-2-methylqunolin-4(1H)-
one (91a, 35 g, 185 mmol) over 30min. The temperature was raised to 110°C and the 
mixture was stirred for 2h. After completion of reaction, the excess POCl3 was 
removed by vacuo. The mixture was poured into ice water. The reaction mass was 
neutralized by Sodium bicarbonate and last ammonia solution. After neutralize, the 
precipitated product was separated from the reaction mixture. It was filtered and 
washed with water, finally with hexane and dried to give 92a, 33.0 g (86 %); 1H NMR 
(DMSO-d6) δ 2.61 (3H, s, Me), 3.93 (3H, s, Me), 7.38 (1H, d, J = 3.0 Hz, ArH), 7.46 
(1H, dd, J = 3.0 Hz, J = 9.2 Hz, ArH), 7.64 (1H, s, ArH), 7.91 (1H, d, J = 9.2 Hz, ArH 
). Anal. (C11H10ClNO): C, H, N. 
4-Chloro-6-methoxy-2-phenylquinoline (92b). The 6-methoxy-2-phenylquinoline-
4(1H)-one (91b, 5.02 g, 20 mmol) was added portionwise into the solution of POCl3 
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(20 mL) at room temperature. After that, the reaction mixture was heated up to reflux 
temperature for 1 hour. After completion of the reaction, it was cooled up to room 
temperature. The excess POCl3 was removed by vacuum distillation. The residue was 
poured into ice water and neutralized by ammonia solution. The solid was collected 
by filtration, washed with water and dried, to give 92b, 4.0 g, (74 %); mp 106–107°C 
(102–103°C lit.); 1H NMR (DMSO-d6) δ 3.97 (3H, s, Me), 7.43–7.44 (1H, m, ArH), 
7.48–7.57 (4H, m, 4 × ArH), 8.04–8.06 (1H, m, ArH), 8.25–8.27 (2H, m, 2 × ArH), 
8.33 (1H, s, ArH). Anal. (C16H12ClNO): C, H, N. 
4-Chloro-2-methylquinoline-6-ol (93a). The boron tribromide (1.9 ml, 20 mmol) 
was added in the MDC (20 ml) at -50°C. After being stirred 10 min, the 4-chloro-6-
methoxy-2-methylquinoline (92a, 1.28 g, 6.0 mmol) was added over the top at -50°C. 
The reaction mixture was stirred at room temperature for 2 hours. After completion of 
the reaction, the solvent was evaporated under reduce pressure. The residue was 
poured into saturated sodium bicarbonate solution. The solid was separated out. It was 
filtered and washed with water. To give 93a, 1.0 g (84.03 %); mp 224–225°C (223–
224°C lit.);  1H NMR (DMSO-d6) δ 2.57 (3H, s, Me), 7.32–7.35 (2H, m, 2 × ArH), 
7.54 (1H, s, ArH), 7.82–7.84 (1H, m, ArH), 10.24 (1H, s, exchangeable, OH). Anal. 
(C10H8ClNO): C, H, N. 
4-Chloro-2-phenylquinolin-6-ol (93b). The 4-chloro-6-methoxy-2-phenylquinoline 
(92b, 6.0 g, 22 mmol) was added into the solution of sulfuric acid (60 mL) at room 
temperature. The reaction mixture was heated up to 100°C for 2 hrs. The reaction 
mass was poured into ice. The solid was collected by filtration and washed with 
water. To give 93b, 5.0 g, (88 %); mp 194–196°C; 1H NMR (DMSO-d6) δ  7.39–7.43 
(2H, m, 2 × ArH), 7.47–7.54 (3H, m, 3 × ArH), 7.98–8.01 (1H, m, ArH), 8.22–8.25 
(3H, m, 3 × ArH), 10.44 (1H, s, exchangeable, OH). Anal. (C15H10ClNO): C, H, N. 
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4-(Phenylamino)-2-methylquinolin-6-ol (94aa’). To a solution of 4-chloro-2-
methyl-6-hydroxyquinoline (93a, 1.35 g, 7.0 mmol), aniline (0.78 g, 8.4 mmol) and 
IPA (30 mL) was added HCl two drops at room temperature. The reaction mixture 
was heated up to reflux temperature for 6 hours. After completion of the reaction, it 
was cooled to room temperature. The solid was filtered off and washed with IPA to 
give 94aa’, yield 1.6 g (91 %); mp > 300°C; 1H NMR (DMSO-d6) δ 2.57 (3H, s, Me), 
6.63 (1H, s, ArH), 7.38–7.41 (1H, m, ArH), 7.44–7.46 (2H, m, 2 × ArH), 7.58–7.61 
(3H, m, 3 × ArH), 7.89–7.90 (1H, m, ArH), 7.93–7.95 (1H, m, ArH), 10.28 (1H, s, 
exchangeable, OH), 10.57 (1H, s, exchangeable, NH). Anal. (C16H14N2O): C, H, N. 
4-(3-Fluorophenylamino)-2-methylquinolin-6-ol (94ab’). Compound 94ab’ was 
synthesized from 4-chloro-2-methyl-6-hydroxyquinoline (93a, 1.5 g, 7.7 mmol), 3-
fluoroaniline (0.90 g, 8.2 mmol) and IPA (35 mL) containing HCl 1-2 drops: yield 1.6 
g (80 %); mp > 300°C; 1H NMR (DMSO-d6) δ 2.61 (3H, s, Me), 6.79 (1H, s, ArH), 
7.19–7.24 (1H, m, ArH), 7.32–7.37 (2H, m, 2 × ArH), 7.55–7.62 (2H, m, 2 × ArH), 
7.88–7.89 (1H, m, ArH), 7.97–7.99 (1H, m, ArH ), 10.33 (1H, s, exchangeable, OH), 
10.63 (1H, s, exchangeable, NH). Anal. (C16H13FN2O): C, H, N. 
4-(3-Chlorophenylamino)-2-methylquinolin-6-ol (94ac’). Compound 94ab’ was 
synthesized from 4-chloro-2-methyl-6-hydroxyquinoline (93a, 0.5 g, 2.5 mmol), 3-
chloroaniline (0.32 g, 2.5 mmol) and IPA (30 mL) containing HCl 1-2 drops: yield 0.6 
g (81 %); mp > 300°C; 1H NMR (DMSO-d6) δ 2.60 (3H, s, Me), 6.75 (1H, s, ArH), 
7.43–7.47 (2H, m, 2 × ArH), 7.54–7.56 (2H, m, 2 × ArH), 7.59-7.62 (1H, dd, J = 2.4 
Hz, J = 9.2 Hz, ArH), 7.88 (1H, d, J = 2.4 Hz, ArH), 7.99 (1H, d, J = 9.2 Hz, ArH ), 
10.34 (1H, s, exchangeable, OH), 10.64 (1H, s, exchangeable, NH). Anal. 
(C16H13ClN2O): C, H, N. 
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4-(3-Bromophenylamino)-2-methylquinolin-6-ol (94ad’). Compound 94ad’ was 
synthesized from 4-chloro-2-methyl-6-hydroxyquinoline (93a, 1.0 g, 5.0 mmol), 3-
bromoaniline (0.91 g, 5.3 mmol) and IPA (30 mL) containing HCl 1-2 drops: yield 
1.4 g (82 %); mp > 300°C; 1H NMR (DMSO-d6) δ 2.60 (3H, s, Me), 6.74 (1H, s, 
ArH), 7.49–7.51 (2H, m, 2 × ArH), 7.57–7.61 (2H, m, 2 × ArH), 7.68 (1H, s, ArH), 
7.86–7.87 (1H, m, ArH), 7.94–7.96 (1H, m, ArH ), 10.30 (1H, s, exchangeable, OH), 
10.61 (1H, s, exchangeable, NH). Anal. (C16H13BrN2O): C, H, N. 
4-(4-Fluorophenylamino)-2-methylquinolin-6-ol (94ae’). Compound 94ae’ was 
synthesized from 4-chloro-2-methyl-6-hydroxyquinoline (93a, 1.5 g, 7.7 mmol), 4-
fluoroaniline (0.90 g, 8.2 mmol) and IPA (35 mL) containing HCl 1-2 drops: yield 1.9 
g (95 %); mp > 300°C; 1H NMR (DMSO-d6) δ 2.56 (3H, s, Me), 6.54 (1H, s, ArH), 
7.36–7.41 (2H, m, 2 × ArH), 7.47–7.50 (2H, m, 2 × ArH), 7.59 (1H, dd, J = 2.4 Hz, J 
= 8.8 Hz, ArH), 7.88 (1H, d, J = 2.4 Hz, ArH), 7.96 (1H, d, J = 8.8 Hz, ArH ), 10.28 
(1H, s, exchangeable, OH), 10.60 (1H, s, exchangeable, NH). Anal. (C16H13FN2O): C, 
H, N. 
4-(4-Chlorophenylamino)-2-methylquinolin-6-ol (94af’). Compound 94af’ was 
synthesized from 4-chloro-2-methyl-6-hydroxyquinoline (93a, 1.0 g, 5.0 mmol), 4-
chloroaniline (0.68 g, 5.3 mmol) and IPA (30 mL) containing HCl 1-2 drops: yield 1.4 
g (95 %); mp 228–229°C; 1H NMR (DMSO-d6) δ 2.58 (3H, s, Me), 6.69 (1H, s, ArH), 
7.48–7.50 (2H, m, 2 × ArH), 7.58–7.62 (3H, m, 3 × ArH), 7.88– 7.89 (1H, m, ArH), 
7.97–7.99 (1H, m, ArH ), 10.31 (1H, s, exchangeable, OH), 10.61 (1H, s, 
exchangeable, NH). Anal. (C16H13ClN2O): C, H, N. 
4-(4-Bromophenylamino)-2-methylquinolin-6-ol (94ag’). Compound 94ag’ was 
synthesized from 4-chloro-2-methyl-6-hydroxyquinoline (93a, 1.0 g, 5.0 mmo), 4-
bromoaniline (0.91 g, 5.3 mmol) and IPA (30 mL) containing HCl 1-2 drops: yield 
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1.6 g (94 %); mp > 300°C; 1H NMR (DMSO-d6) δ 2.58 (3H, s, Me), 6.72 (1H, s, 
ArH), 7.42–7.44 (2H, m, 2 × ArH), 7.59 (1H, dd, J = 2.4 Hz, J = 8.8 Hz, ArH), 7.71–
7.73 (2H, m, 2 × ArH), 7.87 (1H, d, J = 2.4 Hz, ArH), 7.96 (1H, d, J = 8.8 Hz, ArH ), 
10.28 (1H, s, exchangeable, OH), 10.60 (1H, s, exchangeable, NH). Anal. 
(C16H13BrN2O): C, H, N. 
4-(Phenylamino)-2-phenylquinolin-6-ol (94ba’). To a solution of 4-chloro-2-
phenylquinolin-6-ol (93b, 1.28 g, 5 mmol), aniline (0.56 g, 6 mmol) and IPA (30 mL) 
was added HCl two drops at room temperature. The reaction mixture was heated up to 
reflux temperature for 6 hours. After completion of the reaction, it was cooled to room 
temperature. The solid was collected by filtration and washed with IPA. To give 
94ba’, yield 0.8 g (52 %); mp > 300°C; 1H NMR (DMSO-d6) δ 6.90 (1H, s, ArH), 
7.38–7.42 (1H, m, ArH), 7.55–7.59 (4H, m, 4 × ArH), 7.60–7.64 (3H, m, 3 × ArH), 
7.70 (1H, dd, J = 2.4 Hz, J = 9.2 Hz, ArH), 7.85–7.87 (2H, m, 2 × ArH), 8.01 (1H, d, 
J = 2.4 Hz, ArH), 8.28 (1H, d, J = 9.2 Hz, ArH ), 10.61 (1H, s, exchangeable, OH), 
10.81 (1H, s, exchangeable, NH). Anal. (C21H16N2O): C, H, N. 
4-(3-Fluorophenylamino)-2-phenylquinolin-6-ol (94bb’). Compound 94bb’ was 
synthesized from 4-chloro-2-phenylquinolin-6-ol (93b, 1.28 g, 5 mmol), 3-
flouroaniline (0.7 g, 6 mmol) and IPA (30 mL) containing HCl 1-2 drops: yield 1.3 g 
(79 %); mp 193–194°C; 1H NMR (DMSO-d6) δ 7.05 (1H, s, ArH), 7.20–7.24 (1H, m, 
ArH), 7.42–7.48 (2H, m, 2 × ArH), 7.56–7.66 (4H, m, 4 × ArH), 7.69 (1H, dd, J = 2.4 
Hz, J = 9.1 Hz, ArH), 7.88–7.90 (2H, m, 2 × ArH), 7.96 (1H, d, J = 2.4 Hz, ArH), 
8.24 (1H, d, J = 9.1 Hz, ArH ), 10.57 (1H, s, exchangeable, OH), 10.78 (1H, s, 
exchangeable, NH). Anal. (C21H15FN2O): C, H, N.    
4-(3-Chlorophenylamino)-2-phenylquinolin-6-ol (94bc’). Compound 94bc’ was 
synthesized from 4-chloro-2-phenylquinolin-6-ol (93b, 1.28 g, 5 mmol), 3-
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chloroaniline (0.77 g, 6 mmol) and IPA (30 ml) containing HCl 1-2 drops: 1.0 g (58 
%); mp > 300°C; 1H NMR (DMSO-d6) δ 7.03 (1H, s, ArH), 7.43–7.45 (1H, m, ArH), 
7.55–7.60 (2H, m, 2 × ArH), 7.62–7.65 (4H, m, 4 × ArH), 7.69 (1H, dd, J = 2.0 Hz, J 
= 9.2 Hz, ArH), 7.89–7.91 (2H, m, 2 × ArH), 7.96 (1H, d, J = 2.0 Hz, ArH), 8.27 (1H, 
d, J = 9.2 Hz, ArH ), 10.60 (1H, s, exchangeable, OH), 10.80 (1H, s, exchangeable, 
NH). Anal. (C21H15ClN2O): C, H, N. 
4-(3-Bromophenylamino)-2-phenylquinolin-6-ol (94bd’). Compound 94bd’ was 
synthesized from 4-chloro-2-phenylquinolin-6-ol (93b, 1.28 g, 5 mmol), 3-
bromoaniline (1.03 g, 6 mmole) and IPA (30 mL) containing HCl 1-2 drops: yield 1.6 
g (82 %); mp >300°C; 1H NMR (DMSO-d6) δ 7.03 (1H, s, ArH), 7.48–7.52 (1H, m, 
ArH), 7.56–7.58 (1H, m, ArH), 7.61–7.68 (5H, m, 5 × ArH), 7.76–7.77 (1H, m, ArH), 
7.87–7.89 (2H, m, 2 × ArH), 7.93–7.94 (1H, m, ArH), 8.19–8.21 (1H, m, ArH ), 
10.53 (1H, s, exchangeable, OH), 10.76 (1H, s, exchangeable, NH). Anal. 
(C21H15BrN2O): C, H, N. 
4-(4-Fluorophenylamino)-2-phenylquinolin-6-ol (94be’). Compound 94be’ was 
synthesized from 4-chloro-2-phenylquinolin-6-ol (93b, 1.28 g, 5 mmol), 4-
fluoroaniline (0.70 g, 6 mmol) and IPA (30 mL) containing HCl 1-2 drops: yield 1.0 g 
(61 %); mp 293–294°C; 1H NMR (DMSO-d6) δ 6.83 (1H, s, ArH), 7.38–7.42 (2H, m, 
2 × ArH), 7.57–7.61 (2H, m, 2 × ArH), 7.62–7.66 (4H, m, 4 × ArH), 7.82–7.85 (2H, 
m, 2 × ArH), 7.39–8.11 (1H, m, ArH ), 8.12–8.13 (1H, m, ArH ), 10.47 (1H, s, 
exchangeable, OH), 10.68 (1H, s, exchangeable, NH). Anal. (C21H15FN2O): C, H, N. 
4-(4-Chlorophenylamino)-2-phenylquinolin-6-ol (94bf’). Compound 94bf’ was 
synthesized from 4-chloro-2-phenylquinolin-6-ol (93b, 1.28 g, 5 mmol), 4-
chloroaniline (0.77 g, 6 mmol) and IPA (30 mL) containing HCl 1-2 drops: yield 1.2 
g( 70 %); mp 293–294°C; 1H NMR (DMSO-d6) δ 6.98 (1H, s, ArH), 7.57–7.65 (4H, 
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m, 4 × ArH), 7.66–7.69 (4H, m, 4 × ArH), 7.87–7.90 (2H, m, 2 × ArH), 7.95–7.96 
(1H, m, ArH), 8.20–8.22 (1H, m, ArH ), 10.54 (1H, s, exchangeable, OH), 10.75 (1H, 
s, exchangeable, NH). Anal. (C21H15ClN2O): C, H, N. 
4-(4-Bromophenylamino)-2-phenylquinolin-6-ol (94bg’). Compound 94bg’ was 
synthesized from 4-chloro-2-phenylquinolin-6-ol (93b, 1.28 g, 5 mmole), 4-
bromoaniline (1.03 g, 6 mmole) and IPA (30 mL) containing HCl 1-2 drops: yield 1.4 
g (72 %); mp >300°C; 1H NMR (DMSO-d6) δ 7.00 (1H, s, ArH), 7.52–7.55 (2H, m, 2 
× ArH), 7.59–7.65 (3H, m, 3 × ArH), 7.69 (1H, dd, J = 2.4 Hz, J = 9.1 Hz, ArH), 
7.72–7.74 (2H, m, 2 × ArH), 7.89–7.91 (2H, m, 2 × ArH), 7.97 (1H, d, J = 2.4 Hz, 
ArH), 8.26 (1H, d, J = 9.1 Hz, ArH ), 10.57 (1H, s, exchangeable, OH), 10.79 (1H, s, 
exchangeable, NH). Anal. (C21H15BrN2O): C, H, N. 
4-(Phenylamino)-2-methylquinolin-6-yl 4-(bis(2-chloroethyl)amino)phenyl 
carbamate (95aa’). To a solution of 4-(phenylamino)-2-methylquinolin-6-ol (94aa’, 
0.50 g, 2.0 mmol) in dry DMF (25 mL) containing triethylamine (1.4 mL) was added 
a solution of isocynate 81 (freshly prepared from 80, 1.53 g, 5.0 mmol) in dry DMF (5 
mL) at room temperature. After being stirred for 2 h at room temperature, the solid 
was filtered and washed with dry DMF. The filtrate was evaporated to dryness in 
vacuo. The residue was purified by column chromatography using CHCl3/MeOH 
(100:2 v/v) as an eluent. The fractions containing the main product were combined 
and evaporated to dryness and the residue was recrystallized from CHCl3 to give 
95aa’, 0.40 g (40 %); mp 202–203 °C; 1H NMR (Acetic acid-d4) δ 2.65 (3H, s, Me), 
3.67–3.75 (8H, m, 4 × CH2), 6.76–6.80 (3H, m, 3 × ArH), 7.40–7.44 (3H, m, 3 × 
ArH), 7.49–7.61 (4H, m, 4 × ArH), ), 7.81 (1H, dd, J = 2.1 Hz, J = 9.2 Hz, ArH), 8.05 
(1H, d, J = 9.2 Hz, ArH), 8.34 (1H, d, J = 2.1 Hz, ArH). Anal. 
(C27H26Cl2N4O2·1.7H2O): C, H, N. 
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4-(3-Fluorophenylamino)-2-methylquinolin-6-yl 4-(bis(2-chloroethyl)amino) 
phenylcarbamate (95ab’). Compound 95ab’ was synthesized from isocynate 81 
(freshly prepared from 80, 1.53 g, 5.0 mmol) and 4-(3-fluorophenylamino)-2-
methylquinolin-6-ol (94ab’, 0.54, 2.0 mmol) in dry DMF(20 mL) containing 
triethylamine (1.4 mL): Yield 0.40 (38 %); mp 207–208 °C; 1H NMR (Acetic acid-d4) 
δ 2.69 (3H, s, Me), 3.69–3.76 (8H, m, 4 × CH2), 6.78 (2H, d, J = 8.8 Hz, 2 × ArH), 
6.93 (1H, s, ArH), 7.12–7.17 (1H, m, ArH), 7.29–7.32 (1H, m, ArH), 7.34–7.36 (1H, 
m, ArH), 7.44 (2H, d, J = 8.8 Hz, 2 × ArH), 7.52–7.54 (1H, m, ArH), 7.81–7.84 (1H, 
m, ArH), 8.07–8.09 (1H, m, ArH), 8.34–8.35 (1H, m, ArH). Anal. (C27H25Cl2FN4O2): 
C, H, N. 
4-(3-chlorophenylamino)-2-methylquinolin-6-yl 4-(bis(2-chloroethyl)amino) 
phenyl carbamate (95ac’). Compound 95ac’ was synthesized from isocynate 81 
(freshly prepared from 80, 1.53 g, 5.0 mmole) and 4-(3-chlorophenylamino)-2-
methylquinolin-6-ol (94ac’, 0.57, 2.0 mmole) in dry DMF(30 mL) containing 
triethylamine (1.4 mL): Yield 0.33 (51 %) ; mp 224–225 °C; 1H NMR (Acetic acid-
d4) δ 2.68 (3H, s, Me), 3.67–3.76 (8H, m, 4 × CH2), 6.77–6.79 (2H, m, 2 × ArH), 6.88 
(1H, s, ArH), 7.40–7.47 (3H, m, 3 × ArH), 7.48–7.55 (3H, m, 3 × ArH), 7.81–7.84 
(1H, m, ArH), 8.07–8.09 (1H, m, ArH), 8.34–8.35 (1H, m, ArH). Anal. 
(C27H25Cl3N4O2): C, H, N. 
4-(3-bromophenylamino)-2-methylquinolin-6-yl 4-(bis(2-chloroethyl)amino) 
phenyl carbamate (95ad’). Compound 95ad’ was synthesized from isocynate 81 
(freshly prepared from 80, 1.53 g, 5.0 mmol) and 4-(3-bromophenylamino)-2-
methylquinolin-6-ol (94ad’, 0.66 g, 2.0 mmol) in dry DMF (25 mL) containing 
triethylamine (1.4 mL): Yield 0.40 g (34 %); mp 201–202 °C; 1H NMR (Acetic acid-
d4) δ 2.67 (3H, s, Me), 3.68–3.77 (8H, m, 4 × CH2), 6.75–6.77 (2H, m, 2 × ArH), 6.86 
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(1H, s, ArH), 7.41–7.47 (3H, m, 3 × ArH), 7.50–7.55 (3H, m, 3 × ArH), 7.80–7.84 
(1H, m, ArH), 8.07–8.09 (1H, m, ArH), 8.33–8.34 (1H, m, ArH). Anal. 
(C27H25BrCl2N4O2·2.2H2O): C, H, N. 
4-(4-fluorophenylamino)-2-methylquinolin-6-yl 4-(bis(2-chloroethyl)amino) 
phenyl carbamate (95ae’). Compound 95ae’ was synthesized from isocynate 81 
(freshly prepared from 80, 1.53 g, 5.0 mmole) and 4-(4-fluorophenylamino)-2-
methylquinolin-6-ol (94ae’, 0.54, 2.0 mmole) in dry DMF (20 mL) containing 
triethylamine (1.4 mL): Yield 0.39 (36 %) ; mp 223–224 °C; 1H NMR (Acetic acid-
d4) δ 2.65 (3H, s, Me), 3.69–3.75 (8H, m, 4 × CH2), 6.71 (1H, s, ArH), 6.78 (2H, d, J 
= 8.9 Hz, 2 × ArH), 7.26–7.30 (2H, m, 2 × ArH), 7.43 (2H, d, J = 8.9 Hz, 2 × ArH), 
7.50–7.54 (2H, m, 2 × ArH), 7.82 (1H, dd, J = 1.9 Hz, J = 9.2 Hz, ArH), 8.05 (1H, d, 
J = 9.2 Hz, ArH), 8.33 (1H, d, J = 1.9 Hz, ArH). Anal. (C27H25Cl2FN4O2): C, H, N. 
4-(4-chlorophenylamino)-2-methylquinolin-6-yl 4-(bis(2-chloroethyl)amino) 
phenyl carbamate(95af’). Compound 95af’ was synthesized from isocynate 81 
(freshly prepared from 80, 1.53 g, 5.0 mmole) and 4-(4-chlorophenylamino)-2-
methylquinolin-6-ol (94af’, 0.57, 2.0 mmole) in dry DMF(20 mL) containing 
triethylamine (1.4 mL): Yield 0.55 (31 %) ; mp 189–191 °C; 1H NMR (Acetic acid-
d4) δ 2.68 (3H, s, Me), 3.69–3.77 (8H, m, 4 × CH2), 6.79 (2H, d, J = 9.0 Hz, 2 × ArH), 
6.84 (1H, s, ArH), 7.45 (2H, d, J = 9.0 Hz, 2 × ArH), 7.50–7.57 (4H, m, 4 × ArH), 
7.63–7.86 (1H, m, ArH), 8.06–8.08 (1H, m, ArH), 8.35–8.36 (1H, m, ArH). Anal. 
(C27H25Cl3N4O2): C, H, N. 
4-(4-bromophenylamino)-2-methylquinolin-6-yl 4-(bis(2-chloroethyl)amino) 
phenyl carbamate(95ag’). Compound 95ag’ was synthesized from isocynate 81 
(freshly prepared from 80, 1.53 g, 5.0 mmole) and 4-(4-bromophenylamino)-2-
methylquinolin-6-ol (94ag’, 0.67, 2.0 mmole) in dry DMF(30 mL) containing 
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triethylamine (1.4 mL): Yield 0.38 (30 %) ; mp 229–230 °C; 1H NMR (Acetic acid-
d4) δ 2.69 (3H, s, Me), 3.69–3.77 (8H, m, 4 × CH2), 6.79 (2H, d, J = 9.0 Hz, 2 × ArH), 
6.87 (1H, s, ArH), 7.43–7.46 (4H, m, 4 × ArH), 7.71 (2H, d, J = 9.0 Hz, 2 × ArH), 
7.83–7.86 (1H, m, ArH), 8.07–8.08 (1H, m, ArH), 8.36–8.37 (1H, m, ArH). Anal. 
(C27H25BrCl2N4O2·H2O): C, H, N. 
4-(Phenylamino)-2-phenylquinolin-6-yl (4-(bis(2-chloroethyl)amino)phenyl 
carbamate (95ba’). To a solution of 4-(Phenylamino)-2-phenylquinolin-6-ol (94ba’, 
0.31, 1.0 mmol) in dry DMF (30 mL) containing triethylamine (0.7 mL) was added a 
solution of isocynate 81 (freashly prepared from 80, 0.77 g, 2.5 mmol) in dry DMF (5 
mL) at room temperature. After being stirred for 2 h at room temperature, the solid 
was filtered and washed with dry DMF. The filtrate was evaporated to dryness in 
vacuo. The residue was purified by column chromatography using CHCl3/hexane 
(100:10 v/v) as an eluent. The fractions containing the main product were combined 
and evaporated to dryness and the residue was recrystallized from CHCl3 to give 
95ba’, 0.24 g (42 %); mp 209–210 °C; 1H NMR (Acetic acid-d4) δ 3.68–3.71 (4H, m, 
2 ×  CH2), 3.75–3.76 (4H, m, 2 ×  CH2), 6.78–6.80 (2H, m, 2 × ArH), 7.17 (1H, s, 
ArH), 7.44–7.46 (3H, m, 3 × ArH), 7.58–7.63 (5H, m, 5 × ArH), 7.65–7.67 (1H, m, 
ArH), 7.86–7.88 (2H, m, 2 × ArH), 7.89–7.92 (1H, m, ArH), 8.26–8.28 (1H, m, ArH), 
8.46–8.47 (1H, m, ArH). Anal. (C32H28Cl2N4O2): C, H, N. 
4-(3-Fluorophenylamino)-2-phenylquinolin-6-yl (4-(bis(2-chloroethyl)amino) 
phenyl carbamate(95bb’). Compound 95bb’ was synthesized from isocynate 81 
(freashly prepared from 80, 1.13 g, 3.7 mmol) and 4-(3-fluorophenylamino)-2-
phenylquinolin-6-ol (94bb’, 0.50, 1.5 mmol) in dry DMF(30 mL) containing 
triethylamine (1.0 mL): Yield 0.40 g (45 %); mp 210–221 °C; 1H NMR (Acetic acid-
d4) δ 3.67–3.77 (8H, m, 4 × CH2), 6.76–6.79 (2H, m, 2 × ArH), 7.12–7.17 (1H, m, 
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ArH), 7.26 (1H, s, ArH), 7.35–7.38 (1H, m, ArH), 7.43–7.45 (3H, m, 3 × ArH), 7.53–
7.66 (4H, m, 4 × ArH), 7.87–7.91 (3H, m, 3 × ArH), 8.25–8.27 (1H, m, ArH), 8.43–
8.44 (1H, m, ArH). Anal. (C32H27Cl2FN4O2): C, H, N. 
4-(3-Chlorophenylamino)-2-phenylquinolin-6-yl (4-(bis(2-chloroethyl)amino) 
phenyl carbamate (95bc’). Compound 95bc’ was synthesized from isocynate 81 
(freshly prepared from 80, 0.76 g, 2.5 mmol) and 4-(3-chlorophenylamino)-2-
phenylquinolin-6-ol (94bc’, 0.35 g, 1.0 mmol) in dry DMF(25 mL) containing 
triethylamine (0.7 mL): Yield 0.22 g (37 %); mp 197–198 °C; 1H NMR (Acetic acid-
d4) δ 3.69–3.79 (8H, m, 4 × CH2), 6.78–6.80 (2H, m, 2 × ArH), 7.24 (1H, s, ArH), 
7.42–7.45 (3H, m, 3 × ArH), 7.53–7.69 (6H, m, 6 × ArH), 7.89–7.93 (3H, m, 3 × 
ArH), 8.27–8.29 (1H, m, ArH), 8.45–8.46 (1H, m, ArH). Anal. (C32H27Cl3N4O2): C, 
H, N. 
4-(3-bromophenylamino)-2-phenylquinolin-6-yl (4-(bis(2-chloroethyl)amino) 
phenyl carbamate (95bd’). Compound 95bd’ was synthesized from isocynate 81 
(freashly prepared from 80, 1.13 g, 3.7 mmole) and 4-(3-bromophenylamino)-2-
phenylquinolin-6-ol (94bd’, 0.58, 1.5 mmole) in dry DMF(30 mL) containing 
triethylamine (1.0 mL): Yield 0.36 g (37 %); mp 186–187 °C; 1H NMR (Acetic acid-
d4) δ 3.69–3.78 (8H, m, 4 × CH2), 6.78–6.80 (2H, m, 2 × ArH), 7.23 (1H, s, ArH), 
7.44–7.51 (3H, m, 3 × ArH), 7.57–7.69 (5H, m, 5 × ArH), 7.77–7.78 (1H, m, ArH), 
7.89–7.92 (3H, m, 3 × ArH), 8.26–8.29 (1H, m, ArH), 8.44–8.45 (1H, m, ArH). Anal. 
(C32H27BrCl2N4O2): C, H, N. 
4-(4-fluorophenylamino)-2-phenylquinolin-6-yl (4-(bis(2-chloroethyl)amino) 
phenyl carbamate (95be’). Compound 95be’ was synthesized from isocynate 81 
(freashly prepared from 80, 0.77 g, 2.5 mmole) and 4-(4-fluorophenylamino)-2-
phenylquinolin-6-ol (94be’, 0.33, 1.0 mmole) in dry DMF(30 mL) containing 
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triethylamine (0.7 mL): Yield 0.29 g (50 %); mp 186–187 °C; 1H NMR (Acetic acid-
d4) δ 3.68–3.71 (4H, m, 2 ×  CH2), 3.75–3.76 (4H, m, 2 ×  CH2), 6.79 (2H, d, J = 8.9 
Hz, 2 × ArH), 7.09 (1H, s, ArH), 7.29–7.33 (2H, m, 2 × ArH), 7.45 (2H, d, J = 8.9 
Hz, 2 × ArH), 7.58–7.65 (5H, m, 5 × ArH), 7.86–7.92 (3H, m, 3 × ArH), 8.25–8.28 
(1H, m, ArH), 8.44–8.45 (1H, m, ArH). Anal. (C32H27Cl2FN4O2): C, H, N. 
4-(4-chlorophenylamino)-2-phenylquinolin-6-yl (4-(bis(2-chloroethyl)amino) 
phenyl carbamate (95bf’). Compound 95bf’ was synthesized from isocynate 81 
(freashly prepared from 80, 0.77 g, 2.5 mmole) and 4-(4-chlorophenylamino)-2-
phenylquinolin-6-ol (94bf’, 0.35, 1.0 mmole) in dry DMF(30 mL) containing 
triethylamine (0.7 mL): Yield 0.23 g (38 %); mp 204–205 °C; 1H NMR (Acetic acid-
d4) δ 3.67–3.70 (4H, m, 2 ×  CH2), 3.74–3.76 (4H, m, 2 ×  CH2), 6.78 (2H, d, J = 8.9 
Hz, 2 × ArH), 7.18 (1H, s, ArH), 7.44 (2H, d, J = 8.9 Hz, 2 × ArH), 7.54–7.61 (6H, 
m, 6 × ArH), 7.63–7.67 (1H, m, ArH), 7.88–7.90 (3H, m, 3 × ArH), 8.24–8.27 (1H, 
m, ArH), 8.43–8.44 (1H, m, ArH). Anal. (C32H27Cl3N4O2): C, H, N.   
4-(4-bromophenylamino)-2-phenylquinolin-6-yl (4-(bis(2-chloroethyl)amino) 
phenyl carbamate (95bg’). Compound 95bg’ was synthesized from isocynate 81 
(freashly prepared from 80, 1.13 g, 3.7 mmole) and 4-(4-bromophenylamino)-2-
phenylquinolin-6-ol (94bg’, 0.58, 1.5 mmole) in dry DMF(30 mL) containing 
triethylamine (1.0 mL): Yield 0.38 g (40 %); mp 213–214 °C; 1H NMR (Acetic acid-
d4) δ 3.68–3.71 (4H, m, 2 ×  CH2), 3.75–3.76 (4H, m, 2 ×  CH2), 6.79 (2H, d, J = 8.9 
Hz, 2 × ArH), 7.21 (1H, s, ArH), 7.45 (2H, d, J = 8.9 Hz, 2 × ArH), 7.53 (2H, d, J = 
8.7 Hz, 2 × ArH), 7.58–7.66 (3H, m, 3 × ArH), 7.72 (2H, d, J = 8.7 Hz, 2 × ArH), 
7.89–7.92 (3H, m, 3 × ArH), 8.26–8.28 (1H, m, ArH), 8.44–8.45 (1H, m, ArH). Anal. 
(C32H27BrCl2N4O2): C, H, N.  
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4.5 Conclusion 
Designing DNA-directed alkylating agents by linking the alkylating warhead to the 
DNA-affinic carrier is one of the promising strategies to overcome the drawbacks of 
alkylating agents. In the current studies, we have designed and synthesized a series of 
DNA-directed alkylating agents by linking the phenyl N-mustard pharmacophore with 
the 6-hydroxy function of 4-anilinoquinoline derivatives via a carbamate linker. All 
the compounds were characterized by 1H NMR and elemental analysis. The antitumor 
activity of all newly synthesized derivatives is under investigation.   
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4.6 Representative Spectra 
4.6.1 1H NMR Spectrum for compound 90b. 
 
4.6.2 1H NMR Spectrum for compound 90b. 
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4.6.3 1H NMR Spectrum for compound 90b. 
 
 4.6.4 1H NMR Spectrum for compound 93a. 
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4.6.5 1H NMR Spectrum for compound 90b. 
4.6.6 1H NMR Spectrum for compound 91b. 
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 4.6.7 1H NMR Spectrum for compound 92b. 
 
 4.6.8 1H NMR Spectrum for compound 93b. 
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4.6.9 1H NMR Spectrum for compound 94bc’. 
 
4.6.10 1H NMR Spectrum for compound 95bc’. 
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4.6.11 1H NMR Spectrum for compound 95bc’(Aro). 
 
4.6.12 1H NMR Spectrum for compound 94ab’. 
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4.6.13 1H NMR Spectrum for compound 95ab’. 
 
4.6.14 1H NMR Spectrum for compound 95ab’(Aro). 
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4.6.15 1H NMR Spectrum for compound 94ae’. 
 
4.6.16 1H NMR Spectrum for compound 95ae’. 
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4.6.17 1H NMR Spectrum for compound 95ae’(Aro). 
 
4.6.18 1H NMR Spectrum for compound 94bb’. 
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4.6.19 1H NMR Spectrum for compound 94bb’(D2O). 
 
4.6.20 1H NMR Spectrum for compound 94bb’(Aro). 
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4.6.21 1H NMR Spectrum for compound 95bb’. 
 
4.6.22 1H NMR Spectrum for compound 95bb’(Aro). 
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4.6.23 1H NMR Spectrum for compound 94bg’. 
 
4.6.24 1H NMR Spectrum for compound 94bg’(D2O). 
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4.6.25 1H NMR Spectrum for compound 94bg’(Aro). 
 
4.6.26 1H NMR Spectrum for compound 95bg’. 
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4.6.27 1H NMR Spectrum for compound 95bg’(Aro). 
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4.7 Elemental analysis 
Table 2. Elemental analysis of compounds 94aa’-bg’. 
 
 
 
 
  
 
 
Sr. 
No. 
BO No. MF MW 
Elemental Analysis 
CHN Calculated % CHN Found % 
C H N C H N 
94aa’ 
 BO-1911 C16H14N2O 250.30 76.78 5.64 11.19 76.58 5.70 11.10 
94ab’  BO-1760 C16H13FN2O 268.29 71.63 4.88 10.44 71.87 4.71 10.28 
94ac’  BO-1756 C16H13ClN2O 284.74 67.49 4.60 9.84 67.58 4.82 9.68 
94ad’  BO-1758 C16H13BrN2O 329.19 58.38 3.98 8.15 58.52 4.14 8.33 
94ae’  BO-1763 C16H13FN2O 268.29 71.63 4.88 10.44 71.77 4.99 10.57 
94af’  BO-1766 C16H13ClN2O 284.74 67.49 4.60 9.84 67.66 4.87 9.71 
94ag’  BO-1759 C16H13BrN2O 329.19 58.38 3.98 8.15 58.44 4.13 8.32 
94ba’ 
 BO-1904 C21H16N2O 312.36 80.75 5.16 8.97 80.91 5.44 9.29 
94bb’ 
 BO-1895 C21H15FN2O 330.36 76.35 4.58 8.48 76.14 4.17 8.24 
94bc’ 
 BO-1893 C21H15ClN2O 346.81 72.73 4.63 8.08 72.58 4.87 8.29 
94bd’ 
 BO-1894 C21H15BrN2O 391.26 64.46 3.86 7.16 64.59 3.99 7.31 
94be’ 
 BO-1905 C21H15FN2O 330.36 76.35 4.85 8.48 76.57 4.67 8.31 
94bf’ 
 BO-1900 C21H15ClN2O 346.81 72.73 4.63 8.08 72.59 4.48 8.29 
94bg’ 
 BO-1899 C21H15BrN2O 391.26 64.46 3.86 7.16 64.21 3.67 7.35 
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Table 2.3 Elemental analysis of compounds 95aa’-bg’. 
 
Sr. 
No. 
BO No. MF MW 
Elemental Analysis 
CHN Calculated % CHN Found % 
C H N C H N 
95aa’ 
 BO-1912 C27H26Cl2N4O2·1.7H2O 540.05 60.05 5.49 10.37 59.91 4.92 10.14 
95ab’  BO-1897 C27H25Cl2FN4O2 527.42 61.49 4.78 10.62 61.09 4.79 10.58 
95ac’  BO-1770 C27H25Cl3N4O2 543.87 59.63 4.63 10.30 59.33 4.59 9.97 
95ad’  BO-1771 C27H25BrCl2N4O2·2.2H2O 627.96 51.64 4.72 8.92 51.34 4.40 8.89 
95ae’  BO-1909 C27H25Cl2FN4O2 527.42 61.49 4.78 10.62 61.12 4.82 10.38 
95af’  BO-1910 C27H25Cl3N4O2 543.87 59.63 4.63 10.30 59.23 4.69 10.14 
95ag’  BO-1896 C27H25BrCl2N4O2·H2O 606.34 53.48 4.49 9.24 53.81 4.29 9.18 
95ba’ 
 BO-1906 C32H28Cl2N4O2 571.50 67.25 4.94 9.80 66.85 4.97 9.82 
95bb’  BO-1908 C32H27Cl2FN4O2 589.49 65.20 4.62 9.50 65.20 4.62 9.50 
95bc’  BO-1898 C32H27Cl3N4O2 605.94 63.43 4.49 9.25 63.26 4.53 9.25 
95bd’  BO-1901 C32H27BrCl2N4O2 650.39 59.09 4.18 8.61 59.04 4.18 8.61 
95be’  BO-1907 C32H27Cl2FN4O2 589.49 65.20 4.62 9.50 64.85 5.10 9.18 
95bf’  BO-1903 C32H27Cl3N4O2 605.94 63.43 4.49 9.25 63.33 4.78 9.10 
95bg’  BO-1902 C32H27BrCl2N4O2 650.39 59.09 4.18 8.61 59.07 4.24 8.59 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                              Chapter -5 
Synthesis and characterization of : 
1-(4-(bis(2-chloroethyl)amino)phenyl)-
3-(2-phenylquinazolin-4-yl)urea 
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5.1 Chemistry 
The synthesis of the N-mustard-quinazoline conjugates is shown in Schemes 1. The 
N-mustard-4-aminoquinazoline conjugate 99 was prepared starting from the known 
compound 2-phenylquinazolin-4(3H)-one (96, Scheme 1).116, 117 Compound 96 was 
treated with POCl3 to produce 4-chloro-2-phenyl quinazoline113 (97), which was then 
reacted with ammonia in phenol at 170 oC to give 2-phenylquinazolin-4-amine 
(98)118. Reaction of 98 with the known 4-[N,N-bis(2-chloroethyl)-
amino]phenylisocyanate 81 [freshly prepared from N,N-bis(2-chloroethyl)benzene-
1,4-diamine hydrochloride (80)] in the presence of triethylamine afforded N-mustard-
4-aminoquinazoline conjugate 99 in low yield. 
5.2 Reaction Scheme 
Scheme 1. 
N
NH
O
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N
Cl
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N
HN N
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Scheme 1. Reagents and conditions: (a) POCl3/reflux, (b) Phenol/NH3(g)/140 °C; (c) 
triphosgene/Et3N/CHCl3/THF, room temperature; (d) Et3N/CHCl3, room temperature. 
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5.3 Experimental 
General methods and materials 
Solvents and reagents used were of reagent grade and used without purification unless 
otherwise noted. The melting points were recorded on a Fargo melting point apparatus 
and are uncorrected. Column chromatography was carried out on silica gel G60 (70-
230mesh, ASTM; Merck and 230-400 mesh, silicycle inc.). Reaction progress was 
monitored using analytical thin-layer chromatography (TLC) on 0.25mmMerck F-254 
silica gel glass plates. Visualization was achieved by UV light (254 nm). 1H NMR 
spectra were recorded with a Bruker AVANCE 600 DRX and 400 MHz spectrometer; 
Chemical shifts are reported in parts per million (δ) using tetramethylsilane as the 
internal standard with coupling constants (J ) reported in hertz (Hz). The peak shapes 
are denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, 
double doublet; brs, broad singlet. Elemental analyses were performed on a Heraeus 
CHN-O Rapid analyzer. High performance liquid chromatography analysis for 
checking purity of synthesized compounds were recorded on a Hitachi D-2000 Elite 
instrument: column, Mightysil RP-18 GP 250-4.6 (5µL) mobile phase, MeCN/THF 
(70:30 v/v); flow rate, 1 mL/min; injected sample 10µL, column temp, 27°C; 
wavelength, 254nm. The purity of all compounds was > 95 % based on analytical 
HPLC. 
 
4-Chloro-2-phenylquinazoline (97). To a magnetically stirred solution of POCl3 (25 
mL) at 0°C was added portion wise 2-phenylquinazolin-4(3H)-one 96 (5.0 g). The 
reaction mixture was refluxed for 2 hrs. After completion of the reaction, the excess 
POCl3 was removed by vacuo. The residue was poured into a mixture of chloroform 
(50 mL) + ice cold water (80 mL) + ammonia solution (20 mL). The chloroform layer 
was separated and the aqueous layer was extracted with an additional 20 ml of 
chloroform. The united chloroform extracts were dried over Na2SO4 and filtered, and 
the solvent was removed by distillation to give 97, 4.5 g (87 %); mp 125–127 °C 
(lit.24 124–125 °C); 1H NMR (DMSO-d6) δ 7.58–7.69 (4H, m, 4 × ArH), 7.91–7.92 
(2H, m, 2 × ArH), 8.16–8.21 (3H, m, 3 × ArH). Anal. Calcd. for (C14H9ClN2): C, 
69.86; H, 3.77; N, 11.64. Found: C, 70.08; H, 3.97; N, 11.50. 
 
2-Phenylquinazolin-4-amine (98). A mixture of 4-chloro-2-phenylquinazolin 97 (3.0 
g, 12.0 mmol) and excess phenol was heated at 170 oC for 2 h. After completion of 
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the reaction, the ammonia gas was passed into the reaction mass at 150 °C for 1 h. 
After that the reaction mixture was cooled to room temperature and poured into 5% 
sodium hydroxide solution. The solid was filtered and washed with water and dried to 
give 98, 2.0 g (74 %); mp 140–141 °C (lit.25 146–147 °C); 1H NMR (DMSO-d6) δ 
7.45–7.53 (4H, m, 4 × ArH), 7.75–7.79 (2H, m, 2 × ArH), 7.83 (2H, brs, 
exchangeable, NH2), 8.23–8.25 (1H, m, ArH), 8.45–8.48 (2H, m, 2 × ArH). Anal. 
Calcd. for (C14H11N3): C, 76.00; H, 5.01; N, 18.99. Found: C, 76.28; H, 5.10; N, 
18.73. 
   
1-(4-Bis(2-chloroethyl)phenyl)-3-(2-phenylquinazolin-4-yl)urea (99). A solution of 
isocyanate 14 (freshly prepared from 13, 1.5 g 4.9 mmol) in chloroform (10 mL) was 
added dropwise to a solution of 2-phenyl quinazolin-4-amine 98 (0.63 g, 2.8 mmol) in 
chloroform (30 mL) containing triethylamine (1 mL) at room temperature. The 
reaction mixture was stirred at room temperature for 1 h. The solid material was 
fallout from reaction mass. It was filtered and washed with chloroform to give 1-(4-
bis(2-chloroethyl)phenyl)-3-(2-phenylquinazolin-4-yl)urea 99, 0.2 g (17 %); mp 263–
264 °C; 1H NMR (DMSO-d6) δ 3.68–3.71 (8H, m, 4 × CH2), 6.81 (2H, d, J = 8.6 Hz, 
2 × ArH), 7.48 (2H, d, J =8.6 Hz, 2 × ArH), 7.58–7.56 (4H, m, 4 × ArH), 7.94–7.95 
(2H, m, 2 × ArH), 8.35–8.37 (2H, m, 2 × ArH), 8.72–8.74 (1H, m, ArH), 10.47, 12.02 
(each 1H, s, 2 × NH). Anal. Calcd. for (C25H23Cl2N5O): C, 62.51; H, 4.83; N, 14.58. 
Found: C, 62.60; H, 5.01; N,14.38. 
 
5.4 Conclusion  
In order to discover new chemically stable DNA-directed alkylating agents, we  
connected the phenyl N-mustard pharmacophore to the 4-amino function of 
quinazolines using a urea moiety as the linker; however, the product 1-(4-(bis(2-
chloroethyl)amino)phenyl)-3-(2-phenylquinazolin-4-yl)urea 99 has very poor 
solubility, which does not show solubility even in DMSO. Thus, due to solubility 
issues, the synthesis of above mentioned series was discontinued. 
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5.5 Representative Spectra 
5.5.1 1H NMR Spectrum for compound 98. 
 
5.5.2 1H NMR Spectrum for compound 98 (ARO). 
 
 
Chapter 5                                          Synthesis of N-mustard-quinazoline conjugates… 
  111 
 
5.5.3 1H NMR Spectrum for compound 99. 
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6.1 INTRODUCTION 
In the past years, our laboratory have synthesized a series of DNA-directed alkylating 
agents in which N-mustard derivatives linked to the DNA-affinic molecules such as  
acridine, 9-anilinoacridines, quinoline, 4-anilinoquinazoline and 4-anilinoquinoline 
chromophore via various alkyl spacers, urea and carbamates linker1-4.  These studies 
demonstrated that the strategy to design DNA-directed alkylating agents has high 
possibility in finding new potential anticancer agents. To find a new DNA-directed 
alkylating agent with potential antitumor activity, we then proposed to replace N-
mustard pharmacophore with N-nitrosourea or N-nitrosocarbamate residue. 
Nitrosoureas and nitrosocarbamate derivatives which are extremely active class of 
antitumor agents that is effective against solid tumors, as well as leukemia. In 
particular, 2-chloro ethyl derivatives and some of their metabolites show great 
promises as effective anti tumor agents5,6. For the treatment of number of 
experimental and clinical tumors, several N-(2-chloroethyl)-N-nitrosoureas have 
successfully been applied as chemotherapeutics agents. Not only do this drug show 
the ability to inhibit the growth and spread of many form of solid tumors in man and 
animals, but some of them, such as N,N-bis(2-chloroethyl)-N-nitrosourea 5 (BCNU) 
and N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea 3 (CCNU), also have been found 
to rapidly enter the cerebrospinal fluid and control meningeal tumor implants. As a 
result they have been used in the treatment of brain tumors and menigeal leukemia. 
The drug decomposes spontaneously in the body to form two active compounds and 
alkylaing agents and a carbamolyting agent. The organic isocyanate which is formed 
carbamoylates lysine residue in proteins and may inactive DNA repair enzymes. The 
alkylating agent reacts initially with the O-6 position of a guanine moiety in one 
strand of DNA, then with the N-3 position of cytosine in the other strand to produce 
interstrand cross linking. Nitrosourea or nitrosocarbamates which utilized either a 
quinoline or quianazoline ring as a carrier group were synthesized and evaluated for 
anticancer activity. 
During a random screening program of anticancer agents conducted at the 
Chemotherapy National Service Center (CCNSC) compound 1-methyl-3-nitro-1-
nitrosoguanidine7 1 showed very weak antileukemic activity8, 9. Assay of analogs of 
this compound led to the discovery of the antitumor activity of 1-methyl-1-
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nitrosourea10 2, was tested and shown8 to be more effective than 1 in increasing the 
life span of mice with ip-inoculated leukemia. It was soon discovered that 
introduction of a 2-chloroethyl chain on the nitrogen atom bearing the nitroso group 
(CNUs) led to much increased activity11. These chloroethyl derivatives were 
lipophilic enough to cross the blood–brain barrier and therefore were useful in the 
treatment of brain tumors, which led to the synthesis of a large number of 
nitrosoureas, including lomustine 3 (CCNU) and its methyl derivative semustine 4, 
carmustine 5 (BCNU), nimustine 6 (ACNU), the water-soluble tauromustine 7 and 
fotemustine 8, but toxicity problems have prevented their widespread use. In 1967, 
streptozotocin (streptozocin) 9, a hydrophilic natural nitrosourea, was isolated from a 
strain of S. achromogenes. This compound was chosen as a lead because initial SAR 
studies suggested that hydrophilic nitrosoureas were more potent and less toxic, and a 
number of analogs, like chlorozotocin 10, were prepared. Currently, the most 
clinically important nitrosoureas are CCNU, BCNU, ACNU, and streptozotocin. 
Nitrosoureas have been widely studied from a mechanistic point of view.  
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Figure 1. Chemical structures of some Nitrosourea derrivatives.
 
The presence of the nitroso group labilizes the nitrogen-carbon bond, leading to two 
electrophiles, an isocyanate 12 and a diazene hydroxide 14, which has been detected 
in some cases by electrospray ionization mass spectroscopy.12 This intermediate in 
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turn generates a diazonium salt 1513 (Fig. 2). Alkylation seems to be the main reaction 
responsible for antitumor activity, while carbamoylation takes place primarily on 
amino groups in proteins, leading to inhibition of several DNA repair mechanisms. N-
Nitrosoamides and N-nitrosocarbamates, which can behave as alkylating (but not 
carbamoylating) agents have also antitumor activity, which supports the above 
statement.14 The above mechanism was based mainly on studies of the thermal 
decomposition of nitrosoureas under anhydrous conditions,13 but in water solution the 
reaction is much more complex and has been explained by the mechanism shown in 
Fig. 3. Addition of a molecule of water to the nitrosourea, in its tautomeric form,15 
gives the tetrahedral intermediate 19, which is decomposed into a primary amine, 
carbon dioxide, and 14. This elimination requires an antiperiplanar  conformation for 
25. Addition of a nucleophile other than water to the nitrosourea tautomer explains the 
isolation of carbamoylated products, formed by elimination of 14. 
 
Most nitrosoureas contain one chloroethyl chain on the nitrosated nitrogen, which 
allows them to act as DNA cross-linking agents. Reaction of electrophilic diazonium 
species 25 with guanine is assumed to take place on O-6 to give 27. In fact, addition 
of O6-alkylguanine-DNA alkyltransferase, an enzyme that breaks O-6 guanine 
adducts, prevents cross-linking. This monoalkylated product reacts subsequently with 
the N-3 atom of the cytosine unit in the complementary DNA strand, by anchimeric 
assistance of the guanine N-1 atom through intermediate 28, giving the cross-linked 
product 30 (Fig. 4). 
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In an alternative mechanism, intact nitrosourea molecules rather than diazonium 
species can directly alkylate DNA. Thus, nucleophilic attack of guanine O-6 to the 
nitrosourea tautomer 31 gives intermediate 33. Although alternative mechanisms have 
been proposed, according to labeling experiments it is probable that 33 cyclizes to the 
nitrosoisoxazolidine 34, which is attacked by another O-6 atom of a guanine unit 
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neighboring in the DNA sequence to give 35. In this adduct, the O-6 of the first 
guanine is carbamoylated and the O-6 of the second guanine is alkylated with a 2-
hydoxydiazoethyl group (Fig. 5). Diazonium generation and attack of N-3 from a 
cytosine of the opposite DNA strand, with anchimeric assistance from guanine N-1, 
finally gives the carbamoylated cross-linked product 36. 
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Figure 5. Alternative mechanisam for DNA cross-linking by nitrosoureas.
 
Streptozotocin differs from other nitrosoureas in that it does not cross the blood–brain 
barrier because of its high hydrophilicity, and it also shows a relatively low 
myelosuppression because of decreased entry into bone marrow cells. Its main 
cytotoxicity is exerted on the pancreas b cells because their glucose carrier facilitates 
drug uptake to the islets. Therefore, the main applications of streptozotocin are the 
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induction of diabetes mellitus in experimental animals and treatment of islet cell 
pancreatic tumors, normally in association with nicotinamide for reasons that will be 
explained below. As expected from its nitrosourea structure, streptozotocin 
methylates DNA, specially at the guanine N-7 and O-6 positions,16 but there is also 
much evidence that shows that free radicals play an essential role in its cytotoxicity.17 
It has been shown that streptozotocin induces the generation of nitric oxide,18 
superoxide and hydroxyl radicals, and also that association with oxygen radical 
scavengers, such as nicotinamide, prevents streptozotocin induced cleavage of is let 
DNA.19 
6.2 Aliphatic analogs 
Johnston et. Al. have synthesized a group of monosubstituted N-nitrosoureas, the 
substitution with either the methyl or 2-chloroethyl group, i.e. compounds 2 and 36, 
resulted20,21 in higher anticancer activity than either a substitution with longer carbon 
chains or an unsaturated group. Substitution at both nitrogen of the urea with the 2-
chloroethyl moiety resulted in the bis(N-2-chloroethyl)-N-nitrosourea (BCNU, 
carmustine, 5) which was found20 to be the most active agent of a large series of such 
analogs and more active than the N1 methyl analogs 37. Compounds 36 and 5 were 
clearly superior to 2 against both the ip and ic-implanted L1210 leukemia.21  
Same group have synthesized 1,3-bis(2-haloethyl)-1-nitrosoureas 38-42 for their 
anticancer activity, the bis-fluoroethyl (BFNU, 38) and 39 were active22 against both 
ip- and ic-implanted L1210 leukemia, whereas the bis-bromoethyl compound (BBNU, 
40) and the bromo-chloro compound 41 were only active against ip-implanted L1210 
and the bis-iodoethyl compound (BINU, 42) was inactive against both ip- and ic 
implanted L1210. The order of reactivity of the 2-haloethyl compound F, Cl > Br > I 
is reversed in the C-X bond strengths, i.e. I < Br < Cl < F. Thus, the iodo and bromo 
analogs 42 and 40 should be more susceptible to nucleophilic attack and, hence, could 
undergo decomposition in the plasma before reaching the interior of the cells. 
Much attention has been devoted to the synthesis and biological testing of 
bisnitrosoureas. The first reported21 bis-N-methylnitrosoamides 43-45 were somewhat 
more active than the simple analog 37. 
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Similarly, the biological evaluation23,24,25 of the bis-N-(2-chloroethyl)- N-nitrosoureas 
46-50 against the rat leukemia L5222 revealed little change from that of the parent 
compound BCNU (5), and no relationship could be found23,24 between the 
polymethylene chain length linking the CENU moieties and their anticancer activities. 
Tauromustine (TCNU, 51), a analog of the amino acid taurine, as well as its two 
probable metabolites 52 and 53 were synthesized. The anticancer activity of 
compounds 51-53 against L1210 leukemia, Walker mammary carcinoma, Lewis lung 
carcinoma, Harding-Passey melanoma, and colon carcinoma C was equal to or better 
than that of BCNU (5), and several other N-nitrosoureas. Several nitroso-carbamate 
derivatives were synthesized and tested for anticancer activity26. Compound 54, 55 
were found to be highly active against both the ip- and ic-inoculated L1210 
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6.3 Alicyclic Analogs 
Early in the history of nitrosourea research it was discovered22 that the N-cyclohexyl-
N’-(2-haloethyl)- N’-nitrosoureas (FCNU, 56) and CCNU (lomustine, 3) had excellent 
activities against both the ip- and ic-implanted L1210 leukemia, as was demonstrated 
by the number of survivors on day 27. As a result of this work a large number of alkyl-
substituted cyclohexyl analogs 57-64 were synthesized and screened22,28 against the 
L1210 cell line by means of the log kill and therapeutic ratio ED50/ LD10 criteria. A 
number of analogs which included substituted cyclohexyl 57-60, cyclopentyl 61, 
methylcyclopentyl 62, and 2-indanyl 63, bornyl 64, were found22,28 to be highly active 
against both the ip- and ic-inoculated L1210, with their therapeutic ratios ranging 
from 0.28 to 0.77. 
 
6.4 Aromatic analogs 
Kim and co-worker have synthesized a large series of ortho-, meta-, and para-
substituted phenyl analogs of N-methyl-N-nitrosourea and N-(2-chloroethyl)-N-
nitrosourea and tested in vitro29,30 for inhibitory activity against the L1210 leukemia. 
However, the in vivo testing of various ortho-, meta-, para-substituted aryl 
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nitrosourea analogs and aryl bis-nitrosoureas  revealed22,21,28,31,32 that only a few 
compounds such as 65-70 possessed activities against the ip-inoculated L1210, albeit 
all were found to be inactive against the ic-inoculated L1210. The conclusion drawn22 
from these results was that an aromatic ring prevents the passage of these drugs across 
the blood-brain barrier. 
Bigler et. al. have synthesized33 Several nitrosourea analogs of CCNU, 71-74 and 
tested for anticancer activity. The congeners 71, 72, and 74 had moderate and 
compound 73 high activity against the ipinoculated P388 and L1210 leukemias over a 
wide dose range. The 4-phenyl-4’-fluorophenyl analog 73 also exhibited high activity 
against solid cancers, including the B16 melanoma, colon adenocarcinoma, and Lewis 
lung carcinoma, but either low or no activity against the Harding-Passey melanoma 
and the ependymoblastoma brain tumor.33 the (2-chloroethyl)nitrosocarbamate have 
been synthesized and tested for anticancer activity. Compound 75 and 76 were 
showed very good in vitro activity against NCI-H23 (lung) and SNB-7 (CNS).   
6.5 Heterocyclic analogs 
Several para substituted derivatives of phensuximide (77) were known to be good 
anticonvulsant agents,34 and a relationship was established35 between  anticonvulsant 
activity and the ability to penetrate the central nervous system (CNS). On the basis of 
these results, several N-nitrosourea analogs 78-82 of phensuximide were synthesized 
and tested36 as potential CNS anticancer agents. The 2-chloroethyl derivative 82 was 
the only analog with a significant activity of 96% ILS against ip-L1210 in mice.36 The 
compound was found to have a moderate activity against the CNS cancer 
ependymoblastoma with a 140% ILS, but the clinical drugs BCNU (5) and MeCCNU 
(58) were much more effective against both cancer lines. By contrast, the glutarimide 
analog 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1- nitrosourea (PCNU, 83) had a 
high activity against both the ip- and ic-inoculated L1210 in mice.37,38 
Substitution of the cyclohexyl ring of CCNU (3) with either piperidine, morpholine, 
or 2,6-dimethylmorpholine rings yielded the corresponding CENU semicarbazides 84, 
85, and 86, respectively.39,40 The water-insoluble piperidine analog 84 was very active 
against the rat leukemia L5222 and Yoshida sarcoma in the rat similarly to the water-
soluble morpholino congeners 85 and 86.39-41 The unsubstituted morpholine CENU 85 
was more active than 86 against two neurogenic cancers but both were less active than 
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the clinical drug cyclophosphamide.41 A pyridine analogs 87 were synthesized and 
tested39 for anticancer activity. The 3-picolyl analog 87 was very active against P388 
leukemia in vivo. 
 
Substitution of the cyclohexyl ring of CCNU (3) with either piperidine, morpholine, 
or 2,6-dimethylmorpholine rings yielded the corresponding CENU semicarbazides 84, 
85, and 86, respectively.39,40 The water-insoluble piperidine analog 84 was very active 
against the rat leukemia L5222 and Yoshida sarcoma in the rat similarly to the water-
soluble morpholino congeners 85 and 86.39-41 The unsubstituted morpholine CENU 85 
was more active than 86 against two neurogenic cancers but both were less active than 
the clinical drug cyclophosphamide.41 A pyridine analogs 87 were synthesized and 
tested39 for anticancer activity. The 3-picolyl analog 87 was very active against P388 
leukemia in vivo.  
Chapter 6                                                                                                Introduction….. 
  130 
Filippatos and co-workers have synthesized 8-quinolylnitrosourea 88 and various 
tricyclic xanthen-9-yl- and thioxanthen- 9-ylnitrosoureas 89 and 90.42 The compound 
89 and 90 was only weakly active against the P388 leukemia in vivo. Recently, 
Domarkas et. al. have synthesized several nitroso urea using 4-anilinoquinazoline5. 
Compound 91 shown good EGFR TK inhibitor and presented an anomalously long 
half-life in serum-containing media (t1/2 = 41 h). Reynolds et. al. have synthesized43 
some (2-chloroethyl)nitrosocarbamate as potential anticancer alkylating agents. 
Compound 92a,b were found very good active against DLD-1 (colon) cancer cell 
lines.      
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6.6 Hydroxyalkyl Analogs 
Eisenbrand and co-workers have synthesized water-soluble analogs 93-95 possessed 
dramatically different anticancer activities.23,24 Thus, the anticancer evaluation of 3-
(2-hydroxyethyl)- 1-(2- chloroethyl)-1-nitrosourea (HECNU, 93) resulted in 90% 
cures against the ip-inoculated rat L5222 leukemia and an 85% cancer weight 
reduction against sc-implanted Walker carcinoma. However, the corresponding 
figures for 94 and 95 were 10.5% and 5.0%, respectively. Further studies revealed24,25 
that HECNU (93) was more active than BCNU (5) against both the ip- and ic-
implanted L5222 leukemia. A number of esters 96 and ethers 97 and 98 of HECNU 
have been found44 to have high activity against the rat L5222 leukemia and rat glioma 
G616. In particular, the methanesulfonate analog HECNU-MS (96) possessed 
excellent antileukemic activity. 
On the basis of this, Heal and co-worker have synthesized several polyhydroxy-
CENU analogs 99-102 and displayed as high activity as that of BCNU (5) against the 
L1210 leukemia. The water-soluble polyhydroxy analogs were strongly 
myelosuppressive, as measured by the depression of peripheral blood neutrophil count 
on day three, the nadir of white blood cell suppression.45 
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6.7 Carbohydrate Analogs 
Several CENU analogs of 1-deoxyaldopentose, namely the ribofuranosyl-CENU 
(RFCNU, 103), ribopyranosyl-CENU (RPCNU, 104), and xylopyranosyl-CENU 
(XPCNU, 105) were synthesized46,47 and shown47-49 to have some activity in vivo 
against the L1210. In these studies the prolongation of survival (PS) values are given 
as ∞ when more than 50% of the animals are cured. These compounds were less toxic 
and had greater therapeutic indices than CCNU (3) or MeCCNU (58). Of all 
compounds tested, only RFCNU (103) was not immunosuppressive in the hemolytic 
plaqueforming cell (PFC) test, either before or after the addition of the antigen in the 
form of fresh sheep red blood cells administered ip to mice.49 The other compounds 
104 and 105 were immunosuppressive whether given before or after the antigen. 
Compound 106 had the highest %ILS and greatest reduction of the tumor volume of 
any member of this series as well as CCNU (3) and RFCNU (103). The percentage of 
mice developing the melanoma after 39 days was 42% for 106 and 65% for CCNU, 
but at 90 days the values were approximately 65% for both compounds.50 
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6.8 Amino acid and peptide analogs 
The structure-activity studies of N-2-(chloroethyl)- N-nitrosourea (CENU) analogs of 
hydroxyalkyl compounds, such as HECNU 93, and of carbohydrates indicated that 
such water-soluble analogs possessed greatly reduced bone marrow toxicity and 
improved therapeutic indices. The attachment of L-amino acids to the CENU moiety 
could add desirable hydrophilic properties. 
Suami and other group have synthesized CENU amino acid primary amides 108-
11351,52 and tested anticancer activity in vivo against the rat L5222 and murine L1210 
leukemias. Among the primary amides the CENU sarcosinamide 112 was particularly 
attractive because of a combination of high anticancer activity of 711% ILS, very high 
chemical stability with a half-life of 330 min, and low toxicity with a LD50 of 392 
mg/kg.458 The L-proline analog 113 also had high chemical stability and low toxicity 
but also a greatly reduced anticancer activity, so there was no obvious correlation 
between the % ILS and the chemical half-life values. The CENU L-serinamide (111) 
had excellent therapeutic indices equal to 40.51 
A large number of CENU analogs of carboxylic acids and amides of amino acids 114, 
115, dipeptides 116, 117, 118, and tripeptides 119, 120 were screened for in vivo 
activity against three transplantable mouse adenosarcomas of the colon (MAC)53-55 
and MNU induced mammary carcinoma56. The amide derivatives 114, 115, and 117 
had higher activity against the sc-administered solid tumors MAC 13 and MAC 26 
than the acid analogs 115. The free acid dipeptide analog CENU-Ala-Ala (115) was 
highly active against the ascitic MAC 15A tumor line but was either weakly active or 
inactive against the sc-administered MAC 13 and MAC 26 tumor lines.53,54 
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6.9 Steroid Analogs 
The discovery of estrogen receptors (ER) in human breast cancer has led to significant 
progress in the management of the disease. A series of androgen-linked 
nitrosocarbamates which are related to the estrogen analog estramustine (121) were 
synthesized.57 From this series the N-(2-chloroethyl)-N-nitrosocarbamate of 19-
nortestosterone (122) was studied in detail.58 Compound 122 exhibited excellent in 
vitro activity against the L1210 leukemia but it had only a low in vivo activity against 
the L1210, Ehrlich ascites, and Walker  carcinoma. Compound 122 possessed 
alkylating but no carbamoylating properties.58 The administration of 122 caused a 
dose-dependent reduction of the growth of dimethylbenz(a)anthracene (DMBA)-
induced mammary tumors in rats,58 and a greater reduction of tumor growth and 
tumor DNA synthesis than either administration of 19-nortestosterone or CCNU (3).  
Carroll et. al. have synthesized59 steroid-linked N-nitrosourea 123 caused, at a daily 
dose of 40 mg/kg, an 80-100% inhibition of a rat mammary tumor. The first estrogen-
linked N-nitrosoureas 124, 125 were synthesized and tested anticancer activity. The 
CENU analogs 124 at a daily dose of 40 mg/kg, were found60 to inhibit the growth of 
DMBA-induced rat transplantable mammary cancer by factors of 85% and 100%, 
respectively whereas the corresponding N-methyl-N-nitrosoureas 125 at the same 
daily doses inhibited the cancer growth by only 23% and 15%, respectively. 
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6.10 Nucleoside Analogs 
Most of the reported work on the nucleoside compounds has focused on the 
attachment of the N-nitrosourea group to the 3’- and 5’-positions of the carbohydrate 
portion of the molecules. The C3’ N-methyl- and N-chloroethyl-N-nitrosourea 
containing compounds 126 and 127 had approximately an equal growth inhibitory 
effect on the H.Ep-2 cells while the C5’ N-chloroethyl analog 129, but not the N-
methyl analog 128, was shown61 to have good in vitro activity. No clear correlation 
was found61 between the cytotoxicity of compounds 126-129 and their 
carbamoylating and alkylating activities relative to BCNU (33). Thus, the C3’ 
compounds 126 and 127 had widely differing alkylating activities but nearly equal 
growth inhibitory properties.61 The C5’ analogs 128 and 129 had low alkylating 
activities but only 129 was cytotoxic. 
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6.11 Aim of the current work 
The goals of the current study are finding new anticancer agents with high therapeutic 
efficacy, low toxicity, good bioavailability, and effective against various multi-drug 
resistant tumor cells. In the past years, we have focused on the research and 
development of DNA-alkylating agents as anticancer agents. The following class of 
DNA-alkylating have been designed and synthesized for antitumor evaluation: 
I. Synthesis and characterization of several new (2-chloroethyl) 
nitrosocarbamates derivatives 
N
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The chemical synthesis and characterization of Nitrosocarbamate derivatives are 
described in the Chapter 7. 
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7.1 Chemistry  
The (2-Chloroethyl)nitrosocarbamates conjugates were prepared via reaction of 
Anthranilamide 131 and substituted benzaldehyde (132a-d) in the presence of 
FeCl3.6H2O to produce substituted 4-hydroxyquinazoline(133a-e)62, followed by 
treatment of 133a-e with POCl3 to give substituted 4-chloroquinazoline(134a-e)63. 
Reaction of 134a with resorsinol in xylene containing DMAP to give 3-(2-
phenylquinazolin-4-yloxy) phenol(135a). The other compounds 135b-f was obtained 
by the treatment of Substituted aniline in isopropanol (IPA) in the presence of 
concentrated HCl as previously described64. Condensation of 135a-f with the 
commercially available 2-chloroethylisocynate in anhydrous chloroform in the 
presence of triethylamine (TEA) at room temperature to furnish the carbamate 
derivatives (136a-f)5, which were subsequently nitrosated with NOBF4 in acetonitrile 
to give nitrosocarbamates 137a-f5. The latter compounds were purified by column 
chromatography on silica gel with a mixture of ethylacetate/hexane as eluent.     
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7.2 Reaction Scheme 
Scheme 1: Synthetic route of N-nitrosocarbamate derrivatives  
 
Scheme 1: (a) FeCl3.6H2O/water/reflux; (b) POCl3/reflux; (c) DMAP/xylene/140°C; (d) 
HCl/IPA/reflux; (e) Triethylamine/Chloroform, room temprature; (f)   Nitrosonium 
tetrafluoroborate/acetonitrile/room temprature. 
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7.3 Physical data 
Table 1. Analytical data and yields of compounds (5a-f). 
 
Sr. No. 
Substitute 
MF MW Yield % 
MP °C 
R X Y 
135a C6H5 O OH C20H14N2O2 314.34 34 194-195 
135b C6H5 NH OH C20H15N3O 313.35 64 239-241 
135c 2-Furyl NH OH C18H13N3O2 303.31 80 297-298 
135d 2-Thiophen NH OH C18H13N3O2S 319.38 77 280-281 
135e 
3'-MeO-
C6H4 
NH OH C21H17N3O2 343.38 79 270-272 
135f H NH OH C14H11N3O 237.36 87 231-233 
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Table 2. Analytical data and yields of Carbamate derivatives (6a-f). 
 
Sr. 
No. 
Substitute 
MF MW 
Yield 
% 
MP °C 
R X Y 
136a C6H5 O OH C23H18ClN3O3 419.86 64 140-142 
136b C6H5 NH OH C23H19ClN4O2 418.88 75 230-231 
136c 2-Furyl NH OH C21H17ClN4O3 408.84 74 247-249 
136d 2-Thiophen NH OH C21H17ClN4O2S 424.90 70 236-237 
136e 3'-MeO-C6H4 NH OH C24H21ClN4O3 448.90 82 170-171 
136f H NH OH C17H15ClN4O2 342.78 69 165-167 
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Table 3. Analytical data and yields of Nitrosocarbamate derivatives (7a-f). 
 
Sr. 
No. 
Substitute 
MF MW 
Yield 
% 
MP °C 
R X Y 
137a C6H5 O OH C23H17ClN4O4 448.86 37 98-99 
137b C6H5 NH OH C23H18ClN5O3 447.87 38 133-135 
137c 2-Furyl NH OH C21H16ClN5O4 437.84 34 109-110 
137d 
2-
Thiophen 
NH OH C21H16ClN5O3S 453.90 47 107-108 
137e 
3'-MeO-
C6H4 
NH OH C24H20ClN5O4 477.90 56 140-141 
137f H NH OH C17H14ClN5O3 371.78 45 101-102 
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7.4 Experimental 
Chemistry: general methods 
All commercial chemicals and solvents were reagent grade and were used without 
further purification unless otherwise specified. Melting points were determined on a 
Fargo melting point apparatus and are uncorrected. Column chromatography was 
carried out on Silica Gel G60 (70–230 mesh, ASTM; Merck and 230–400 mesh, 
Silicycle Inc.). Thin-layer chromatography was performed on Silica Gel G60 F254 
(Merck) with short-wavelength UV light for visualization. All reported yields are 
isolated yields after chromatography or crystallization. Elemental analyses were done 
on a Heraeus CHN–O Rapid instrument. 1H NMR spectra were recorded on a 
Brucker AVANCE 600 DRX and 400 MHz, Brucker Top-Spin spectrometers in the 
indicated solvent. The chemical shifts were reported in ppm (d) relative to TMS.  
 
Procedure: 
2-Phenylquinazolin-4(3H)-one (133a). A mixture of an anthranilamide 131 (10.0 g, 
73.5 mmole), benzaldehyde (132a, 7.8 g, 73.5 mmole) and FeCl3.6H2O (39.1 g, 147.0 
mmole) in refluxing water (700 mL) was stirred for 1 h. After completion of the 
reaction, the reaction mixture was cooled to room temperature and filtered to give the 
crude product. The crude product was purified by recrystallization from DMF and 
water, to give 133a, 14 g (86 %); mp 235–237 °C; 1H NMR (DMSO-d6) δ 7.48–7.59 
(4H, m, 4 × ArH), 7.71–7.73 (1H, m, ArH), 7.79–8.13 (1H, m, ArH), 8.16–8.18 (3H, 
m, 3 × ArH), 12.51 (1H, s, exchangeable, NH). 
2-(Furan-2-yl)-quinazolin-4(3H)-one (133b). Compound 133b was synthesized 
from anthranilamide 1 (10.0 g, 73.5 mmole), furan-2-carbaldehyde (132b, 7.0 g, 73.5 
mmole) and FeCl3.6H2O (39.1 g, 147.0 mmole) in water (700 mL): Yield 11.0 g (73 
%); mp 217–219 °C; 1H NMR (DMSO-d6) δ 6.75–6.76 (1H, m, ArH), 7.50 (1H, t, J = 
7.0 Hz, ArH), 7.63–8.64 (1H, m, ArH), 7.69 (1H, d, J = 8.0 Hz, ArH), 7.80–7.84 (1H, 
m, ArH), 8.00 (1H, d, J = 1.2 Hz, ArH), 8.12 (1H, d, J = 8.0 Hz, ArH), 12.50 (1H, s, 
exchangeable, NH). 
2-(Thiophen-2-yl)-quinazolin-4(3H)-one (133c). Compound 133c was synthesized 
from anthranilamide 131 (10.0 g, 73.5 mmole), thophen-2-carbaldehyde (132c, 8.2 g, 
73.5 mmole) and FeCl3.6H2O (39.1 g, 147.0 mmole) in water (700 mL): Yield 17.0 g 
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(80 %); mp 280–281 °C; 1H NMR (DMSO-d6) δ 7.23–7.24 (1H, m, ArH), 7.25–7.51 
(2H, m, 2 × ArH), 7.79–7.88 (2H, m, 2 × ArH), 8.11–8.13 (1H, m, ArH), 8.23–8.24 
(1H, m, ArH), 12.66 (1H, s, exchangeable, NH). 
 2-(3-Methoxyphenyl)-quinazolin-4(3H)-one (133d). Compound 133c was 
synthesized from anthranilamide 131 (10.0 g, 73.5 mmole), 3-methoxybenzaldehyde 
(132c, 10.0 g, 73.5 mmole) and FeCl3.6H2O (39.1 g, 147.0 mmole) in water (700 
mL): Yield 16.0 g (88 %); mp 208–209 °C; 1H NMR (DMSO-d6) δ 3.88 (3H, s, Me), 
7.10–7.13 (1H, m, ArH), 7.20–7.22 (1H, m, ArH), 7.53–7.58 (2H, m, 2 × ArH), 7.72–
7.75 (2H, m, 2 × ArH), 7.83–7.87 (1H, m, ArH), 8.16–8.18 (1H, m, ArH), 12.12 (1H, 
s, exchangeable, NH). 
 
4-Chloro-2-phenylquinazoline (134a). To a magnetically stirred solution of POCl3 
(25 mL) at 0°C was added portion wise 2-phenylquinazolin-4(3H)-one 133a (5.0 g, 
22.4 mmole). The reaction mixture was refluxed for 2 hrs. After completion of the 
reaction, the excess POCl3 was removed by vacuo. The residue was poured into a 
mixture of chloroform (50 mL) + ice cold water (80 mL) + ammonia solution (20 
mL). The chloroform layer was separated and the aqueous layer was extracted with an 
additional 20 ml of chloroform. The united chloroform extracts were dried over 
Na2SO4 and filtered, and the solvent was removed by distillation to give 134a, 4.5 g 
(87 %); mp 125–127 °C (lit.21 124–125 °C); 1H NMR (DMSO-d6) δ 7.58–7.69 (4H, 
m, 4 × ArH), 7.91–7.92 (2H, m, 2 × ArH), 8.16–8.21 (3H, m, 3 × ArH). Anal. 
(C14H9ClN2): C, H, N. 
4-Chloro-2-(furan-2-yl)-quinazoline (134b). Compound 134b was synthesized from 
2-(furan-2-yl)-quinazolin-4(3H)-one 133b (5.0 g, 23.5 mmole) in POCl3 (25 mL): 
Yield 5.0 g (92 %); mp 115–116 °C; 1H NMR (DMSO-d6) δ 6.74–6.76 (1H, m, ArH), 
7.44–7.53 (1H, m, ArH), 7.76–7.80 (2H, m, 2 × ArH), 7.81–7.85 (1H, m, ArH), 8.00–
8.13 (2H, m, 2 × ArH). 
4-Chloro-2-(thiophen-2-yl)-quinazoline(134c). Compound 134c was synthesized 
from 2-(thiophen-2-yl)-quinazolin-4(3H)-one 133c (5.0 g, 21.9 mmole) in POCl3 (25 
mL): Yield 4.5 g (83 %); mp 121–123 °C; 1H NMR (DMSO-d6) δ 6.72–6.76 (1H, m, 
ArH), 7.43–7.53 (1H, m, ArH), 7.76–7.80 (2H, m, 2 × ArH), 7.81–7.88 (2H, m, 2 × 
ArH), 8.12–8.13 (1H, m, ArH). 
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4-Chloro-2-(3-methoxyphenyl)-quinazoline(134d). Compound 134d was 
synthesized from 2-(3-methoxyphenyl)-quinazolin-4(3H)-one 133d (5.0 g, 19.8 
mmole) in POCl3 (25 mL): Yield 5.0 g (94 %); mp 110–111 °C; 1H NMR (DMSO-d6) 
δ 3.84 (3H, s, Me), 7.02–7.05 (1H, m, ArH), 7.36–7.38 (2H, m, 2 × ArH), 7.50–7.52 
(1H, m, ArH), 7.83–7.87 (3H, m, 3 × ArH), 8.16–8.18 (1H, m, ArH). 
4-Chloroquinazoline (134e). Compound 134e was synthesized from quinazolin-
4(3H)-one 133e (5.0 g, 34.2 mmole) in POCl3 (25 mL): Yield 5.2 g (89 %); mp 98–99 
°C; 1H NMR (DMSO-d6) δ 7.61–7.69 (1H, m, ArH), 7.79–7.83 (1H, m, ArH), 7.90–
7.99 (1H, m, ArH), 8.16–8.18 (1H, m, ArH), 8.79 (1H, s, ArH). 
3-(2-Phenylquinazolin-4-yloxy)phenol (135a). To a solution of 4-chloro-2-
phenylquinazoline 134a (3 g, 12.5 mmole), resorcinol (2.1 g, 18.7 mmole) and xylene 
(30 mL), was added DMAP at room temperature. The reaction mixture was stirred at 
140°C for 24 hours. After completion of the reaction, the reaction mixture was cooled 
up to 0-5 °C. The product was collected by filtration and washed with 10% NaOH and 
finally with water, to give 135a, 1.3 g (34 %); mp 194–195 °C; 1H NMR (DMSO-d6) 
δ 6.78–6.80 (1H, m, ArH), 6.83–6.88 (2H, m, 2 × ArH), 7.32–7.36 (1H, m, ArH), 
7.46–7.50 (3H, m, 3 × ArH), 7.72–7.76 (1H, m, ArH), 8.01–8.05 (2H, m, 2 × ArH), 
8.06–8.26 (2H, m, 2 × ArH), 8.35–8.37 (1H, m, ArH), 9.79 (1H, s, exchangeable, 
OH). Anal. (C20H14N2O2): C, H, N. 
3-((2-Phenylquinazolin-4-yl)amino)phenol (135b). To a solution of 4-chloro-2-
phenylquinazoline 134a (3.0 g, 12.5 mmole) and m-aminophenol (1.36 g, 12.5 
mmole) in 40 mL of isopropanol (IPA) was added HCl two drops at room 
temperature. The reaction mixture was heated up to reflux temperature for 3 h and 
then was cooled to room temperature. The solid was collected by filtration and 
washed with IPA, and dried to give 135b, 2.5 g (64 %); mp 239–241 °C; 1H NMR 
(DMSO-d6) δ 6.77–6.82 (1H, m, ArH), 6.83–6.90 (2H, m, 2 × ArH), 7.23–7.28 (1H, 
m, ArH), 7.34–7.40 (3H, m, 3 × ArH), 7.79–8.05 (3H, m, 3 × ArH), 8.08–8.26 (2H, 
m, 2 × ArH), 8.28–8.32 (1H, m, ArH), 9.70 (1H, brs, exchangeable, OH), 11.30 (1H, 
brs, exchangeable, NH). Anal. (C20H15N3O): C, H, N.  
3-((2-(Furan-2-yl)quinazolin-4-yl)amino)phenol (135c). Compound 135c was 
synthesized from 4-chloro-2-(furan-2-yl)-quinazoline 134b (2.0 g, 8.6 mmole), m-
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aminophenol (1.0 g, 8.7 mmole) and IPA (30 mL) containing HCl 1-2 drops: yield 2.1 
g (80 %); mp 297–298 °C; 1H NMR (DMSO-d6) δ 6.75–6.77 (1H, m, ArH), 6.91–6.93 
(1H, m, ArH), 7.27–7.36 (2H, m, 2 × ArH), 7.40–7.41 (1H, m, ArH), 7.75–7.81 (2H, 
m, 2 × ArH), 8.03–8.07 (1H, m, ArH), 8.19–8.26 (2H, m, 2 × ArH), 8.91–8.93 (1H, 
m, ArH), 9.75 (1H, brs, exchangeable, OH), 11.35 (1H, brs, exchangeable, NH). Anal. 
(C18H13N3O2): C, H, N. 
3-((2-(Thiophen-2-yl)quinazolin-4-yl)amino)phenol (135d). Compound 135d was 
synthesized from 4-chloro-2-(thiophen-2-yl)-quinazoline 134b (2.0 g, 8.1 mmole), m-
aminophenol (0.88 g, 8.1 mmole) and IPA (30 mL) containing HCl 1-2 drops: yield 
2.0 g (77 %); mp 280–281 °C; 1H NMR (DMSO-d6) δ 6.76–6.77 (1H, m, ArH), 7.28–
7.39 (4H, m, 4 × ArH), 7.74–7.78 (1H, m, ArH), 8.03–8.33 (2H, m, 2 × ArH), 8.34–
8.35 (1H, m, ArH), 8.82–8.84 (2H, m, 2 × ArH), 9.25 (1H, brs, exchangeable, OH), 
11.26 (1H, brs, exchangeable, NH). Anal. (C18H13N3O2S): C, H, N. 
3-((2-(3-Methoxyphenyl)quinazolin-4-yl)amino)phenol (135e). Compound 135e 
was synthesized from 4-chloro-2-(3-methoxyphenyl)-quinazoline 134d (1.0 g, 3.7 
mmole), m-aminophenol (0.40 g, 3.7 mmole) and IPA (30 mL) containing HCl 1-2 
drops: yield 1.0 g (79 %); mp 270–272 °C; 1H NMR (DMSO-d6) δ 3.57 (3H, s, Me), 
6.77–6.79 (1H, m, ArH), 7.25–7.34 (4H, m, 4 × ArH), 7.54–7.57 (1H, m, ArH), 7.81–
7.85 (1H, m, ArH), 7.90–7.96 (2H, m, 2 × ArH), 8.07–8.11 (1H, m, ArH), 8.23–8.26 
(1H, m, ArH), 8.79–8.81 (1H, m, ArH), 8.90 (1H, brs, exchangeable, OH), 11.46 (1H, 
brs, exchangeable, NH). Anal. (C21H17N3O2): C, H, N. 
3-(Quinazolin-4-ylamino)phenol (135f). Compound 135f was synthesized from 4-
chloroquinazoline 134e (2.0 g, 12.1 mmole), m-aminophenol (1.3 g, 12.1 mmole) and 
IPA (30 mL) containing HCl 1-2 drops: yield 2.5 g (87 %); mp 231–232 °C; 1H NMR 
(DMSO-d6) δ 6.76–6.78 (1H, m, ArH), 7.13–7.18 (2H, m, 2 × ArH), 7.25–7.29 (1H, 
m, ArH), 7.84–7.88 (1H, m, ArH), 7.97–7.99 (1H, m, ArH), 8.09–8.13 (1H, m, ArH), 
8.87–8.93 (2H, m, 2 × ArH), 9.80 (1H, brs, exchangeable, OH), 11.56 (1H, brs, 
exchangeable, NH). Anal. (C14H11N3O): C, H, N. 
3-((2-Phenylquinazolin-4-yl)oxy)phenyl (2-chloroethyl)carbamate (136a). To a 
solution of 3-(2-phenylquinazolin-4-yloxy)phenol 135a (1.2 g, 3.8 mmole) and  
chloroform (15 mL) containing triethylamine (0.6 mL) was added 2-
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chloroethylisocynate (0.45 g, 4.0 mmole) at 0 °C over 20 min. The reaction mixture 
was stirred at room temperature for 1 hour. After that, the reaction mixture was 
poured into ice cold water and separated organic layer. The aqueous layer was 
extracted two times by chloroform and combined all organic layers. The organic layer 
was washed with 10% K2CO3 solution and water, which was dried over Na2SO4 and 
evaporated by vacuo. The solid was collected and purified by Colum chromatography 
using dichloromethane as an eluent, to give 136a, 0.9 g (64 %); mp 140–142 °C; 1H 
NMR (DMSO-d6) δ 3.40 (2H, q, J = 6.0 Hz, CH2), 3.68 (2H, t, J = 6.0 Hz, CH2), 
7.14–7.16 (1H, m, ArH), 7.16–7.35 (2H, m, 2 × ArH), 7.44–7.48 (3H, m, 3 × ArH), 
7.54–7.58 (1H, m, ArH), 7.74–7.78 (1H, m, ArH), 8.04–8.11 (2H, m, 2 × ArH), 8.12 
(1H, t, J = 5.6 Hz, exchangeable, NH), 8.27–8.29 (2H, m, 2 × ArH), 8.37–8.39 (1H, 
m, ArH). Anal. (C23H18ClN3O3): C, H, N. 
3-((2-Phenylquinazolin-4-yl)amino)phenyl (2-chloroethyl)carbamate (136b). 
Compound 136b was synthesized from 3-((2-Phenylquinazolin-4-yl)amino)phenol 
135b (2.0 g, 6.3 mmole) and 2-chloroethylisocynate (0.72 g, 6.9 mmole) in 
chloroform (30 mL) containing triethylamine (1.1 mL): Yield 2.0 (75 %); mp 230–
231 °C; 1H NMR (DMSO-d6) δ 3.44 (2H, q, J = 6.0 Hz, CH2), 3.72 (2H, t, J = 6.0 Hz, 
CH2), 6.81–6.83 (1H, m, ArH), 6.91–7.02 (1H, m, ArH), 7.40–7.48 (3H, m, 3 × ArH), 
7.52–7.55 (1H, m, ArH), 7.75–7.82 (2H, m, 2 × ArH), 8.04–8.09 (2H, m, 2 × ArH), 
8.06–8.07 (1H, m, ArH), 8.08–8.09 (1H, m, ArH ), 8.11 (1H, t, J = 5.6 Hz, 
exchangeable, NH), 8.49–8.50 (1H, m, ArH), 9.75 (1H, s, exchangeable, NH). Anal. 
(C23H19ClN4O2): C, H, N. 
3-((2-(Furan-2-yl)quinazolin-4-yl)amino)phenyl (2-chloroethyl)carbamate (136c). 
Compound 136c was synthesized from 3-((2-(furan-2-yl)quinazolin-4-
yl)amino)phenol 135c (1.0 g, 3.3 mmole) and 2-chloroethylisocynate (0.52 g, 4.9 
mmole) in chloroform (20 mL) containing triethylamine (0.5 mL): Yield 1.0 (74 %); 
mp 247–249 °C; 1H NMR (DMSO-d6) δ 3.45 (2H, q, J = 6.0 Hz, CH2), 3.71 (2H, t, J 
= 6.0 Hz, CH2), 6.67–6.69 (1H, m, ArH), 6.87–6.90 (1H, m, ArH), 7.02–7.28 (1H, m, 
ArH), 7.41–7.45 (1H, m, ArH), 7.57–7.62 (1H, m, ArH), 7.82–7.89 (4H, m, 4 × ArH), 
8.04–8.06 (1H, m, ArH), 8.12 (1H, t, J = 5.6 Hz, exchangeable, NH), 8.56–8.58 (1H, 
m, ArH), 9.88 (1H, s, exchangeable, NH). Anal. (C21H17ClN4O3·H2O): C, H, N. 
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3-((2-(Thiophen-2-yl)quinazolin-4-yl)amino)phenyl (2-chloroethyl)carbamate 
(136d). Compound 136d was synthesized from 3-((2-(thiophen-2-yl)quinazolin-4-
yl)amino)phenol 135d (1.5 g, 4.7 mmole) and 2-chloroethylisocynate (0.74 g, 7.0 
mmole) in chloroform (25 mL) containing triethylamine (0.8 mL): Yield 1.4 (70 %); 
mp 236–237 °C; 1H NMR (DMSO-d6) δ 3.44 (2H, q, J = 6.0 Hz, CH2), 3.72 (2H, t, J 
= 6.0 Hz, CH2), 6.90–6.92 (1H, m, ArH), 7.20–7.22 (1H, m, ArH), 7.43–7.47 (1H, m, 
ArH), 7.58–7.62 (1H, m, ArH), 7.72–7.73 (1H, m, ArH), 7.80–7.88 (3H, m, 3 × ArH), 
7.96–7.97 (1H, m, ArH), 8.04–8.05 (1H, m, ArH), 8.13 (1H, t, J = 5.6 Hz, 
exchangeable, NH), 8.57–8.59 (1H, m, ArH), 9.99 (1H, s, exchangeable, NH). Anal. 
(C21H17ClN4O2S): C, H, N. 
3-((2-(3-Methoxyphenyl)quinazolin-4-yl)amino)phenyl (2-chloroethyl)carbamate 
(136e). Compound 136e was synthesized from 3-((2-(3-methoxyphenyl)quinazolin-4-
yl)amino)phenol 135e (0.7 g, 2.0 mmole) and 2-chloroethylisocynate (0.32 g, 3.1 
mmole) in chloroform (10 mL) containing triethylamine (0.4 mL): Yield 0.75 (82 %); 
mp 170–171 °C; 1H NMR (DMSO-d6) δ 3.45 (2H, q, J = 6.0 Hz, CH2), 3.70 (2H, t, J 
= 6.0 Hz, CH2),  3.85 (3H, s, Me), 6.91–6.93 (1H, m, ArH), 7.07–7.09 (1H, m, ArH), 
7.41–7.48 (2H, m, 2 × ArH), 7.62–7.66 (1H, m, ArH), 7.85–7.93 (3H, m, 3 × ArH), 
8.03–8.04 (1H, m, ArH), 8.05–8.06 (1H, m, ArH), 8.07–8.09 (2H, m, 2 × ArH ), 
8.59–8.61 (1H, m, ArH), 9.94 (1H, s, exchangeable, NH). Anal. (C24H21ClN4O3): C, H, 
N. 
3-(Quinazolin-4-ylamino)phenyl (2-chloroethyl)carbamate (136f). Compound 
136f was synthesized from 3-(quinazolin-4-ylamino)phenol 135f (0.5 g, 2.1 mmole) 
and 2-chloroethylisocynate (0.33 g, 3.2 mmole) in chloroform (10 mL) containing 
triethylamine (0.3 mL): Yield 0.51 (69 %); mp 165–167 °C; 1H NMR (DMSO-d6) δ 
3.41 (2H, q, J = 6.0 Hz, CH2), 3.70 (2H, t, J = 6.0 Hz, CH2), 6.88–6.91 (1H, m, ArH), 
7.37–7.41 (1H, m, ArH), 7.76–7.68 (1H, m, ArH), 7.77–7.82 (3H, m, 3 × ArH), 7.86–
7.88 (1H, m, ArH), 8.09 (1H, t, J = 5.6 Hz, exchangeable, NH), 8.58–8.59 (1H, m, 
ArH), 8.65 (1H, s, ArH), 9.85 (1H, s, exchangeable, NH). Anal. (C17H15ClN4O2): C, H, 
N. 
3-((2-Phenylquinazolin-4-yl)oxy)phenyl (2-chloroethyl)(nitroso)carbamate 
(137a). 3-((2-phenylquinazolin-4-yl)oxy)phenyl (2-chloroethyl)carbamate 136a (0.5 
g, 1.1 mmole) were suspended in anhydrous acetonitrile (15 mL) containing acetic 
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acid (0.2 mL). Nitrosoniumtetrafluoroborate (0.21 g, 1.7 mmole) was added, and the 
reaction mixture was stirred at room temperature until disappearance of starting 
material as monitored by TLC. The reaction mixture was poured into 100 mL of ice-
cooled water/ethyl acetate (50 % v/v) solution, and the pH was adjusted to 5-6 by 
careful addition of 5 % sodium bicarbonate solution. The water phase was extracted 
twice with ethyl acetate, and the organic extracts were washed with brine, dried over 
sodium sulphate, and concentrated under reduced pressure. The crud product was 
purified by using Colum Chromatography on silica gel eluting with a mixture of ethyl 
acetate/hexane, to give 137a, 0.2 g (37 %); mp 98–99 °C; 1H NMR (DMSO-d6) δ 4.01 
(2H, t, J = 6.0 Hz, CH2), 4.60 (2H, t, J = 6.0 Hz, CH2), 7.36–7.38 (1H, m, ArH), 7.39–
7.40 (3H, m, 3 × ArH), 7.61–7.62 (1H, m, ArH), 7.66–7.70 (1H, m, ArH), 7.75–7.79 
(1H, m, ArH), 8.04–8.07 (2H, m, 2 × ArH), 8.27–8.31 (3H, m, 3 × ArH), 8.39–8.40 
(1H, m, ArH). Anal. (C23H17ClN4O4): C, H, N. 
3-((2-Phenylquinazolin-4-yl)amino)phenyl (2-chloroethyl)(nitroso)carbamate 
(137b). Compound 7b was synthesized from 3-((2-phenylquinazolin-4-
yl)amino)phenyl (2-chloroethyl)carbamate 136b (0.5 g, 1.2 mmole), 
Nitrosoniumtetrafluoroborate (0.21 g, 1.7 mmole) in acetonitrile (10 mL) containing 
acetic acid (0.5 mL): Yield 0.21 (38 %); mp 133–135 °C; 1H NMR (DMSO-d6) δ 3.74 
(2H, t, J = 6.0 Hz, CH2), 4.27 (2H, t, J = 6.0 Hz, CH2), 7.21–7.24 (1H, m, ArH), 7.46–
7.49 (3H, m, 3 × ArH), 7.58–7.67 (2H, m, 2 × ArH), 7.89–7.92 (3H, m, 3 × ArH), 
8.27–8.28 (1H, m, ArH), 8.47–8.49 (2H, m, 2 × ArH), 8.59–8.61 (1H, m, ArH), 10.00 
(1H, s, exchangeable, NH). Anal. (C23H18ClN5O3·0.5H2O): C, H, N.   
3-((2-(Furan-2-yl)quinazolin-4-yl)amino)phenyl(2-chloroethyl)(nitroso) 
carbamate (137c). Compound 137c was synthesized from 3-((2-(furan-2-
yl)quinazolin-4-yl)amino)phenyl (2-chloroethyl)carbamate 136c (0.5 g, 1.2 mmole), 
Nitrosoniumtetrafluoroborate (0.21 g, 1.7 mmole) in acetonitrile (10 mL) containing 
acetic acid (0.5 mL): Yield 0.18 (34 %); mp 109–110 °C; 1H NMR (DMSO-d6) δ 3.75 
(2H, t, J = 6.0 Hz, CH2), 4.21 (2H, t, J = 6.0 Hz, CH2), 6.64–6.65 (1H, m, ArH), 7.19–
7.21 (2H, m, 2 × ArH), 7.56–7.64 (2H, m, 2 × ArH), 7.82–7.99 (4H, m, 4 × ArH), 
8.28–8.29 (1H, m, ArH), 8.57–8.59 (1H, m, ArH), 10.02 (1H, s, exchangeable, NH). 
Anal. (C21H16ClN5O4): C, H, N. 
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3-((2-(Thiophen-2-yl)quinazolin-4-yl)amino)phenyl(2-chloroethyl)(nitroso) 
carbamate (137d). Compound 137c was synthesized from 3-((2-(thiophen-2-
yl)quinazolin-4-yl)amino)phenyl (2-chloroethyl)carbamate 136d (1.0 g, 2.4 mmole), 
Nitrosoniumtetrafluoroborate (0.39 g, 3.4 mmole) in acetonitrile (20 mL) containing 
acetic acid (0.5 mL): Yield 0.5 (47 %); mp 107–108 °C; 1H NMR (DMSO-d6) δ 3.72 
(2H, t, J = 6.0 Hz, CH2), 4.31 (2H, t, J = 6.0 Hz, CH2), 6.66–6.67 (1H, m, ArH), 7.20–
7.31 (3H, m, 3 × ArH), 7.56–7.64 (1H, m, ArH), 7.81–7.99 (4H, m, 4 × ArH), 8.30–
8.32 (1H, m, ArH), 8.58–8.59 (1H, m, ArH), 10.12 (1H, s, exchangeable, NH). Anal. 
(C21H16ClN5O3S): C, H, N. 
3-((2-(3-Methoxyphenyl)quinazolin-4-yl)amino)phenyl (2-chloroethyl)(nitroso) 
carbamate (137e). Compound 137e was synthesized from 3-((2-(3-
methoxyphenyl)quinazolin-4-yl)amino)phenyl (2-chloroethyl)carbamate 136e (0.5 g, 
1.1 mmole), Nitrosoniumtetrafluoroborate (0.21 g, 1.7 mmole) in acetonitrile (10 mL) 
containing acetic acid (0.5 mL): Yield 0.30 (56 %); mp 140–141 °C; 1H NMR 
(DMSO-d6) δ 3.58 (3H, s, Me), 3.72 (2H, t, J = 6.0 Hz, CH2), 4.30 (2H, t, J = 6.0 Hz, 
CH2), 7.22–7.26 (1H, m, ArH), 7.44–7.46 (2H, m, 2 × ArH), 7.59–7.67 (2H, m, 2 × 
ArH), 7.90–7.91 (3H, m, 3 × ArH), 8.27–8.28 (1H, m, ArH), 8.49–8.51 (2H, m, 2 × 
ArH), 8.60–8.61 (1H, m, ArH), 10.12 (1H, s, exchangeable, NH). Anal. 
(C24H20ClN5O4): C, H, N. 
3-(Quinazolin-4-ylamino)phenyl (2-chloroethyl)(nitroso)carbamate (137f). 
Compound 137f was synthesized from 3-(quinazolin-4-ylamino)phenyl (2-
chloroethyl)carbamate 136f (0.5 g, 1.5 mmole), Nitrosoniumtetrafluoroborate (0.25 g, 
2.1 mmole) in acetonitrile (15 mL) containing acetic acid (0.5 mL): Yield 0.25 (45 
%); mp 101–102 °C; 1H NMR (DMSO-d6) δ 3.72 (2H, t, J = 6.0 Hz, CH2), 4.25 (2H, 
t, J = 6.0 Hz, CH2), 7.46–7.49 (2H, m, 2 × ArH), 7.58–7.60 (1H, m, ArH), 7.89–7.92 
(2H, m, 2 × ArH), 8.27–8.28 (1H, m, ArH), 8.44–8.49 (2H, m, 2 × ArH), 8.66 (1H, s, 
ArH), 10.05 (1H, s, exchangeable, NH). Anal. (C17H14ClN5O3): C, H, N. 
7.5 Conclusion 
In this study, we have designed and synthesized a series DNA-alkylating agents, in 
which the N-(2-chloroethyl)-N-nitrosocarbamate residue is linked to DNA-binding 4-
anilinoquinazoline via a carbamate spacer. All the compounds were characterized by 
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1H NMR and elemental analysis. The antitumor activity of all newly synthesized 
derivatives is under investigation. 
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7.6   1HNMR spectra 
7.6.1 1H NMR Spectrum for compound 135a. 
 
7.6.2 1H NMR Spectrum for compound 135a (D2O). 
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7.6.3 1H NMR Spectrum for compound 135a (ARO). 
 
7.6.4 1H NMR Spectrum for compound 136a. 
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7.6.5 1H NMR Spectrum for compound 136a (D2O). 
7.6.6 1H NMR Spectrum for compound 136a (ARO). 
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7.6.7 1H NMR Spectrum for compound 137a. 
7.6.8 1H NMR Spectrum for compound 137a (ARO). 
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7.6.9 1H NMR Spectrum for compound 133b. 
 
7.6.10 1H NMR Spectrum for compound 133b (ARO). 
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7.6.11 1H NMR Spectrum for compound 134b. 
 
7.6.12 1H NMR Spectrum for compound 134b (ARO). 
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7.6.13 1H NMR Spectrum for compound 135c. 
 
7.6.14 1H NMR Spectrum for compound 135c (D2O). 
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7.6.15 1H NMR Spectrum for compound 135c (ARO). 
 
7.6.16 1H NMR Spectrum for compound 136c. 
 
N
N
HN OH
O
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7.6.17 1H NMR Spectrum for compound 136c (ARO). 
 
7.6.18 1H NMR Spectrum for compound 137c. 
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7.6.19 1H NMR Spectrum for compound 136c (ARO). 
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7.7 Elemental analysis 
Table 2.3  Elemental analysis of compounds 135a-f. 
Sr. No. MF MW 
Elemental Analysis 
CHN Calculated % CHN Found % 
C H N C H N 
135a C20H14N2O2 314.34 76.42 4.49 8.91 76.28 4.58 8.79 
135b C20H15N3O 313.35 76.66 4.82 13.41 76.43 4.66 13.62 
135c C18H13N3O2 303.31 71.28 4.32 13.85 71.41 4.21 13.59 
135d C18H13N3O2S 319.38 67.69 4.10 13.16 67.54 4.39 13.28 
135e C21H17N3O2 343.38 73.45 4.99 12.24 73.57 5.12 12.37 
135f C14H11N3O 237.36 70.87 4.67 17.71 70.75 4.82 17.89 
 
 
Table 2.3  Elemental analysis of compounds 136a-f. 
Sr. 
No. MF MW 
Elemental Analysis 
CHN Calculated % CHN Found % 
C H N C H N 
136a C23H18ClN3O3 419.86 65.79 4.32 10.01 65.87 4.49 10.22 
136b C23H19ClN4O2 418.88 65.95 4.57 13.38 65.77 4.43 13.51 
136c C21H17ClN4O3.H2O 408.84 59.09 4.49 13.13 59.20 4.50 12.90 
136d C21H17ClN4O2S 424.90 59.36 4.03 13.19 59.51 4.37 13.12 
136e C24H21ClN4O3 448.90 64.21 4.72 12.48 64.39 4.91 12.63 
136f C17H15ClN4O2 342.78 59.57 4.41 16.34 59.41 4.28 16.18 
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Table 2.3  Elemental analysis of compounds 137a-f. 
Sr. 
No. MF MW 
Elemental Analysis 
CHN Calculated % CHN Found % 
C H N C H N 
137a C23H17ClN4O4 448.86 61.54 3.82 12.48 61.31 3.97 12.57 
137b C23H18ClN5O3.0.5H2O 447.87 6O.46 4.19 15.33 60.66 4.20 15.21 
137c C21H16ClN5O4 437.84 57.48 3.45 12.77 57.61 3.59 12.93 
137d C21H16ClN5O3S 453.90 55.45 3.32 12.32 55.59 3.49 12.46 
137e C24H20ClN5O4 477.90 60.32 4.22 14.65 60.21 4.36 14.61 
137f C17H14ClN5O3 371.78 54.78 3.52 15.03 54.89 3.78 15.34 
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Summary of the work 
The work that is to be presented in the thesis entitled “Studies on Synthesis of New 
Heterocyclic Skeletons and Related Compounds” has been divided into seven 
chapters which can be summarized as under. 
SECTION A 
Chapter-1 covers basic introduction to cancer and DNA-directed alkylating agents. 
Cancer is still the most lethal illnesses known worldwide after heart disease. Although 
significant research has done to date to cancer diseases, there is still a lack of effective 
chemotherapeutic treatment to cure it completely. DNA alkylating agents have played 
an important part in cancer chemotherapy. Alkylating agents, the oldest and most 
useful among the antineoplastic agents, can be defined as compounds capable of 
covalently binding an alkyl group to a biomolecule under physiological conditions 
(aqueous solution, 37°C, pH 7.4). Some of them especially nitrogen mustard (N-
mustard), are used clinically for the treatment of cancer.  
Chapter-2 deals with the synthesis of chemically stable DNA-directed alkylating 
agents, in which the phenyl N-mustard residue was linked to DNA binder 
quinazolines via a urea spacer for antitumor evaluation. N-mustard-quinazoline 
conjugates having a urea linker are synthesized from Substituted 6-amino-4-
anilinoquinazolines and N,N-bis(2-chloroethyl)-4-isocyanatoaniline  in the presence 
of triethylamine. 
Chapter-3 entitled “Antitumor evaluation of phenyl N-mustard-quinazoline 
conjugates bearing a urea linker.” In this chapter, a series of N-mustard-quinazoline 
conjugates via urea linker was tested for the anticancer activity. All of the new N-
mustards conjugates found to have potent antiproliferative activity against human 
leukemia (CCRF-CEM) and its drug resistant sublines (CCRF-CEM/Taxol and 
CCRF-CEM/VBL) and various solid tumors (breast carcinoma MX-1, colon 
carcinoma HCT-116, lung carcinoma H1299 and prostate carcinoma PC3) cell 
growths in vitro. Among these derivatives, compound 87h possessed significant 
tumor growth inhibition (72 %) in comparison with the untreated control. We also 
demonstrate that the newly synthesized compounds are able to induce DNA cross-
linking through alkaline agarose gel shift assay and inhibited cell cycle arrest at G2/M 
phase. 
Chapter-4 In this chapter, the efforts have been made for the synthesis of potent 
DNA-directed alkylating agents by linking the phenyl N-mustard pharmacophore with 
quinoline via a carbamate linker. N-mustard-6-hydroxyquinoline conjugates are 
synthesized from substituted 6-hydroxy-4-anilinoquinolines and N,N-bis(2-
chloroethyl)-4-isocyanatoaniline  in the presence of triethylamine. 
 
Chapter-5 entitled “Synthesis and yield optimization efforts for a novel compound: 
1-(4-(bis(2-chloroethyl)amino)phenyl)-3-(2-phenylquinazolin-4-yl)urea” deals with 
the discover new chemically stable DNA-directed alkylating agents, we therefore 
connected the phenyl N-mustard pharmacophore to the 4-amino function of 
quinazolines using a urea moiety as the linker. 1-(4-(bis(2-chloroethyl)amino)phenyl)-
3-(2-phenylquinazolin-4-yl)urea are synthesized from 4-amino-2-phenylquinazoline 
and N,N-bis(2-chloroethyl)-4-isocyanatoaniline  in the presence of triethylamine. 
SECTION B 
Chapter-6 deals with the general introduction about nitrosourea and carbamate 
derivatives. Among significant compounds, nitrosoureas and carbamate are an 
extremely active class of antitumor agents that are effective against solid tumors, as 
well as leukemias. In particular, 2-haloethyl derivatives and some of their metabolites 
show great promise as effective antitumor agent. For the treatment of a number of 
experimental and clinical tumors, several N-(2-chloroethyl)-N-nitrosourea have 
successfully been applied as chemotherapeutic agents. 
Chapter-7 entitled “Synthesis and characterization of several new (2-
Chloroethyl)nitrosocarbamates derivatives” Current chapter represents synthesis of 
(2-Chloroethyl)nitrosocarbamates derivatives using quinazoline as a moiety. 
Substituted quinazoline (2-Chloroethyl)nitrosocarbamates conjugates are synthesized 
from quinazoline (2-Chloroethyl)carbamates using Nitrosoniumtetrafluoroborate as a 
catalyst. 
In all 98 compounds were synthesized, characterized and evaluated for anti cancer 
activities.  
Bioorganic & Medicinal Chemistry 19 (2011) 1987–1998Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier .com/locate /bmcDesign, synthesis and antitumor evaluation of phenyl
N-mustard-quinazoline conjugates
Bhavin Marvania a,d, Pei-Chih Lee a, Ravi Chaniyara a,d, Huajin Dong b, Sharda Suman a, Rajesh Kakadiya a,
Ting-Chao Chou b, Te-Chang Lee a, Anamik Shah d, Tsann-Long Su a,c,⇑
a Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan
b Preclinical Pharmacology Core Laboratory, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
cGraduate Institute of Pharmaceutical Chemistry, China Medical University, Taichung, Taiwan
dDepartment of Chemistry, Saurashtra University, Rajkot, Gujarat, India
a r t i c l e i n f o a b s t r a c tArticle history:
Received 13 December 2010
Revised 25 January 2011
Accepted 26 January 2011
Available online 2 February 2011
Keywords:
Anticancer agents
Cell cycle
DNA-directed alkylating agents
DNA interstrand cross-linking agents
Nitrogen mustards0968-0896/$ - see front matter  2011 Elsevier Ltd. A
doi:10.1016/j.bmc.2011.01.055
⇑ Corresponding author. Tel.: +886 2 2789 9045; fa
E-mail address: tlsu@ibms.sinica.edu.tw (T.-L. Su).A series of N-mustard-quinazoline conjugates was synthesized and subjected to antitumor studies. The
N-mustard pharmacophore was attached at the C-6 of the 4-anilinoquinazolines via a urea linker. To
study the structure–activity relationships of these conjugates, various substituents were introduced to
the C-4 anilino moiety. The preliminary antitumor studies revealed that these agents exhibited signiﬁ-
cant antitumor activity in inhibiting various human tumor cell growths in vitro. Compounds 21b, 21g,
and 21h were selected for further antitumor activity evaluation against human breast carcinoma MX-1
and prostate PC-3 xenograft in animal model. These agents showed 54–75% tumor suppression with
low toxicity (5–7% body-weight changes). We also demonstrate that the newly synthesized compounds
are able to induce DNA cross-linking through alkaline agarose gel shift assay and inhibited cell cycle
arrest at G2/M phase.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Designing DNA-directed alkylating agents is one of the most
effective strategies to overcome the general drawbacks of DNA
alkylating agents. The common drawbacks of these agents include
high reactivity and the lack of DNA sequence-speciﬁc binding,
resulting in side effects and carcinogenicity.1,2 DNA-directed alkyl-
ating agents are synthesized by linking DNA-afﬁnic molecules
(carrier) to a N-mustard pharmacopore (warhead, such as alkyl
N-mustard or phenyl N-mustard). The generally useful DNA-afﬁnic
molecules are DNA-intercalating agents (e.g., 9-anilinoacridines
and acridines), binding agents (quinolines or quinazolines), and
DNA minor groove binding agents (e.g., distamycin A and netrop-
sin). Most of these carriers also exhibit anticancer activity by inhib-
iting Topoisomerases I and II.3 Emerging evidence shows that
DNA-directed alkylating agents are more cytotoxic than the used
carrier itself. Consequently, connecting DNA-afﬁnic molecules to
alkylating agents usually results in improved therapeutic efﬁcacy
than the corresponding untargeted alkylating agents.4–8
We have previously synthesized a series of alkyl N-mustard-9-
anilinoacridine conjugates having methylene (CH2) or alkoxy
[O(CH2)n] spacer to the aniline, and/or acridine ring(s).7–10
Although these conjugates (e.g., 1, Fig. 1) exhibited signiﬁcantll rights reserved.
x: +886 2 2782 5573.cytotoxicity against various human tumor cell growth in vitro
and potent antitumor activity in human tumor xenografted model,
they have a narrow therapeutic window and low bioavailability
(chemical instability with a short half-life) in mice, probably due
to the inductive effect of the alkoxy linker, increasing the reactivity
of the N-mustard moiety. To improve the poor bioavailability of
these derivatives, we have synthesized a series of phenyl N-mus-
tard-9-anilinoacridine conjugates bearing a urea, carbamate or car-
bonate linker.11,12 We revealed that these derivatives (e.g., 2) have
more chemical stability with potent anticancer activity. The linkers
used for the synthesis of phenyl N-mustard-9-anilinoacridine con-
jugates were previously applied in antibody-directed enzyme pro-
drug therapy (ADEPT) and melanocyte directed enzyme prodrug
therapy (MDEPT) of N-mustard derivatives.
More recently, we utilized quinolines as carriers to prepare a
series of N-mustard-quinoline conjugates having a urea or hydra-
zinecarboxamide linker (e.g., 3 and 4).13 Similarly, these conjugates
possess potent antitumor activity against a variety of human tu-
mor xenografts. Both linkers are also able to lower the reactivity
of the N-mustard moiety, resulting in a longer half-life in rat plas-
ma. The linkers in these derivatives are attached to the C-4 position
of the 4-aminoquinolines, demonstrating that quinolines are also
valuable carriers for building DNA-directed alkylating agents.
Aside from quinolines, 4-anilinoquinazoline derivatives [e.g.,
PD153035 (5) and EBEA22 (6)] were also reported to have high
DNA binding afﬁnity.14 Particularly, compound 6 possesses higher
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Figure 1. Chemical structures of N-mustard and quinazoline derivatives.
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both 5 and 6 have high afﬁnities and selectivity toward the epider-
mal growth factor receptor tyrosine kinase (EGF-R TK) and exhibited
potent cytotoxicity against several types of tumor cell growth in
vitro.15 Although compound 5 possessed potent cytotoxicity, this
agent has low therapeutic efﬁcacy in vivo because of its poor water
solubility. Quinazolines have also been applied for synthesizing
DNA-directed alkylating agents (e.g., 7, Fig. 1). It was demonstrated
that compound 7 is not a strong intercalator, but it may bindweakly
at the major groove side.16 These studies suggest that quinazolines
can be applied for designing DNA-directed alkylating agents.
In order to discover new chemically stable DNA-directed alkylat-
ing agents, we therefore connected the phenyl N-mustard pharma-
cophore to quinazolines using a urea moiety as the linker. Initially,
we attempted to attach the N-mustard to the 4-amino function of
quinazolines bearing a urea linker; however, the product, N-mus-
tard-4-aminoquinazoline 15 (Scheme 1) has very poor solubility,
even does not dissolve in DMSO. Consequently, we prepared 6-ami-
no-4-anilinoquinazolines for constructing new phenyl N-mustard-
6-aminoquinazoline conjugates, in which the N-mustard moiety is
linked to the 6-amino function via a urea linker. The studies will al-
low us to understand whether these conjugates have improved
water-solubility and cytotoxicity. The results show that the new
conjugates have better solubility in an intravenous injection
(iv injection) vehicle and possess potent cytotoxicity in inhibiting
various human lymphoblastic leukemia and solid tumor cell growth
in vitro. It should be noted that some of the 4-anilinoquinazolines
have already been used by the group of Jean-Claude to prepare
degradable conjugates with various alkylating moieties such as
N-nitroso ureas and triazenes (e.g., 8 and 9).17 We report herein
the chemical synthesis, antitumor activity, and DNA cross-linking
study of phenyl N-mustard-4-anilinoquinazoline conjugates.
2. Chemistry
The synthesis of the N-mustard-quinazoline conjugates is
shown in Schemes 1 and 2. The N-mustard-4-aminoquinazolineconjugate 15 was prepared starting from the known compound
2-phenylquinazolin-4(3H)-one (10, Scheme 1).18,19 Compound 10
was treated with POCl3 to produce 4-chloro-2-phenyl quinazoline
(11), which was then reacted with ammonia in phenol at 170 C to
give 2-phenylquinazolin-4-amine (12). Reaction of 12 with the
known 4-[N,N-bis(2-chloroethyl)-amino]phenylisocyanate 1420
[freshly prepared from N,N-bis(2-chloroethyl)benzene-1,4-dia-
mine hydrochloride (13)21] in the presence of triethylamine affor-
ded N-mustard-4-aminoquinazoline conjugate 15 in low yield.
Scheme 2 shows the synthesis of the N-mustard-6-aminoqui-
nazoline conjugates (21a–q). The key starting materials, 6-ami-
no-4-anilinoquinazolines (20a–q), were prepared by following
the literature methods.17 Among these derivatives, compounds
20b,c,d,f,h,j,o,p,q are known, while all other compounds are new
derivatives. Brieﬂy, the commercially available 5-nitroanthranilo-
nitrile 16 was treated with dimethylformamide dimethylacetal
(DMF–DMA) in acetic acid to give (E)-N-(2-cyano-4-nitrophenyl)-
N,N-dimethylformimidamide (17), which was then reacted with
substituted anilines (18a–q) in acetic acid to afford 6-nitroquinaz-
oline derivatives (19a–q). The nitro function in 19a–q was con-
verted into the corresponding 6-aminoquinazoline derivatives
(20a–q) by treating with Fe/acetic acid. Reaction of 20a–q with
the freshly prepared 14 in the presence of triethylamine gave the
desired N-mustard-6-aminoquinazoline conjugates (21a–q) bear-
ing a urea linker.
3. Biological result and discussion
3.1. In vitro cytotoxicity
To study the structure-activity relationships of the N-mustard-
quinazoline conjugates, we have introduced electron-withdrawing
halogen(s), electron-donating methoxy function(s), and other sub-
stituent to the 4-anilino ring. These derivatives were subjected to
evaluating their cytotoxicities in inhibiting human lymphoblastic
leukemia (CCRF-CEM) and its drug-resistant sublines resistant to
Taxol (CCRF-CEM/Taxol) and Vinblastine (CCRF-CEM/VBL) cell
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sized conjugates possess signiﬁcant cytotoxicity with IC50 in micro
molar range. The most cytotoxic compound of this series is the
30,40,50-trimethoxyphenyl derivative 21n with an IC50 value of
0.38 lM. However, the potency of the C-30-OMe derivative (21m,
IC50 >1.32 lM) is much weaker than the corresponding trimethoxy
derivative 21n. As for the halogen-substituted derivatives, it is
clearly to see that order of the cytotoxicity of C-30-halogen substi-
tuted compounds is C-30–Br (21c) > C-30–Cl (21b) > C-30–F (21a). In
contrast, the C-40–F substituted derivative 21e is apparently more
potent than the corresponding C-40–Br derivative 21f. In the series
of C-30–C-40 dihalogens substituted conjugates, the order of the
cytotoxicity is 21g > 21h > 21i ﬃ 21j. The SAR study shows that
the position of the substitutions, numbers and types of halogenatom are critical for their activity. The cytotoxicity of compounds
bearing other substituent, such as C-30 or C-40–CF3 (21d and 21k,
respectively), C-30-ethynyl (21o), C-40-phenoxy (21p), and
3-chloro-4-(pyridin-2-ylmethoxy) (21q), were also evaluated. It
reveals that C-30-ethynyl (21o) is most cytotoxic among these con-
jugates with a IC50 value of 0.50 lM. Compounds having a CF3 sub-
stituent (21d and 21k) are less cytotoxic than other compounds
tested.
The cytotoxicity of the newly synthesized compounds against
human CCRF-CEM drug-resistant sublines (resistant to Vinblastine
and Taxol, CCRF-CEM/VBL and CCRF-CEM/Taxol, respectively) were
also studied. The results revealed that they generally have no or lit-
tle cross-resistance to these two natural products except
compounds 21n, which has certain extent of cross-resistance
Table 1
The cytotoxicity of newly synthesized phenyl N-mustard-6-aminoquinazoline conjugates against human lymphoblastic leukemia (CCRF-CEM) and its drug-resistant sublines
(CCRF-CEM/Taxol and CCRF-CEM/VBL)a
N
N
HNH
N
R
H
N
N
OCl
Cl
21a-q
2'
3'
4'
5'
Compd Substitute R Cell growth inhibition (IC50 lM)
20 30 40 50 CCRF-CEM CCRF-CEM/Taxolb CCRF-CEM/VBLb
21a H F H H 2.51 ± 0.11 3.46 ± 0.18 [1.38]c 4.28 ± 0.01 [1.70]
21b H Cl H H 1.66 ± 0.14 4.56 ± 0.0001 [2.75] 3.26 ± 0.05 [1.96]
21c H Br H H 0.95 ± 0.11 4.58 ± 0.05 [4.82] 2.62 ± 0.01 [2.76]
21d H CF3 H H 3.97 ± 0.22 4.57 ± 0.13 [1.15] 4.68 ± 0.05 [1.17]
21e H H F H 0.74 ± 0.02 3.16 ± 0.07 [4.27] 1.24 ± 0.03 [1.67]
21f H H Br H 4.64 ± 0.16 8.79 ± 0.16 [1.89] 7.88 ± 0.36 [1.70]
21g F Cl H H 0.75 ± 0.01 1.55 ± 0.02 [2.07] 1.04 ± 0.03 [1.39]
21h H Cl F H 1.00 ± 0.09 1.16 ± 0.14 [1.16] 1.14 ± 0.03 [1.14]
21i H Cl Cl H 2.60 ± 0.02 5.61 ± 0.16 [2.16] 6.75 ± 0.53 [2.60]
21j H Br F H 2.68 ± 0.11 4.40 ± 0.30 [1.64] 4.74 ± 0.15 [1.77]
21k H CF3 Cl H 4.77 ± 0.22 5.36 ± 0.14 [1.12] 5.28 ± 0.58 [1.11]
21l H Cl OMe H 0.80 ± 0.01 3.34 ± 0.02 [4.17] 3.75 ± 0.04 [4.68]
21m H OMe H H 1.32 ± 0.02 3.58 ± 0.12 [2.71] 3.38 ± 0.17 [2.56]
21n H OMe OMe OMe 0.38 ± 0.02 12.32 ± 0.79 [32.42] 24.51 ± 1.72 [64.50]
21o H 3-ethynyl H H 0.50 ± 0.04 2.29 ± 0.02 [4.58] 2.33 ± 0.34 [4.66]
21p H H OPh H 4.77 ± 0.01 7.99 ± 0.18 [1.67] 10.88 ± 0.02 [2.28]
21q H Cl OCH2(2-pyridinyl) H 1.41 ± 0.07 4.58 ± 0.08 [3.24] 2.65 ± 0.13 [1.88]
Taxol 0.003 ± 0.0003 0.43 ± 0.05 [143] 1.27 ± 0.05 [423]
Vinblastine 0.0007 ± 0.001 0.08 ± 0.01 [106.2] 0.50 ± 0.12 [679.5]
Carboplatin 3.4 ± 0.99 2.45 ± 0.65 [0.7]
a Cell growth inhibition was measured by the XTT assay25 for leukemic cells after 72-h incubation using a microplate spectrophotometer as described previously.27 Similar
in vitro results were obtained by using the Cell Counting Kit-8 for the CCK-8 assays as described by technical manual of Dojindo Molecular Technologies, Inc. (Gaithersburg,
MD; Website: www.dojindo.com). IC50 values were determined from dose–effect relationship at six or seven concentrations of each drug by using the CompuSyn software by
Chou and Martin29 based on the median-effect principle and plot using the serial deletion analysis.30,31 Ranges given for Taxol and vinblastine were mean ± SE (n = 4).
b CCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells that are 143-fold resistant to Taxol, and 423-fold resistant to vinblastine, respectively, when
comparing with the IC50 of the parent cell line.
c Numbers in the brackets are fold of cross-resistant determined by comparison with the corresponding IC50 of the parent cell line.
Table 2
The cytotoxicity of phenyl N-mustard-6-aminoquinazoline conjugates (21a–q) against human solid tumor (breast carcinoma MX-1, colon carcinoma HCT-116, lung carcinoma
H1299 and prostate carcinoma PC3) cell growth in vitroa
Compd Substitute R Cell growth inhibition (IC50 lM)
20 30 40 50 MX-1a HCT-116a H1299b PC3b
21a H F H H 10.11 ± 0.09 9.62 ± 0.12 ND ND
21b H Cl H H 7.84 ± 0.03 7.46 ± 0.02 10.49 ± 2.04 10.37 ± 0.32
21c H Br H H 6.92 ± 0.05 2.17 ± 0.03 8.04 ± 1.26 10.13 ± 0.13
21d H CF3 H H 5.30 ± 0.63 5.97 ± 0.24 ND ND
21e H H F H 3.43 ± 0.003 3.18 ± 0.03 11.60 ± 1.54 8.24 ± 1.76
21f H H Br H 6.71 ± 0.03 7.79 ± 0.36 ND ND
21g F Cl H H 4.55 ± 0.02 3.84 ± 0.0005 5.52 ± 1.59 6.29 ± 1.12
21h H Cl F H 5.38 ± 0.05 3.36 ± 0.05 NDc ND
21i H Cl Cl H 6.45 ± 0.50 2.79 ± 0.14 ND ND
21j H Br F H 7.10 ± 0.14 5.99 ± 0.63 ND ND
21k H CF3 Cl H 7.44 ± 0.58 5.34 ± 0.06 ND ND
21l H Cl OMe H 5.51 ± 0.09 5.27 ± 0.18 6.94 ± 1.71 8.02 ± 2.08
21m H OMe H H 2.59 ± 0.13 2.44 ± 0.03 8.79 ± 1.32 9.44 ± 0.87
21n H OMe OMe OMe 4.02 ± 0.03 2.24 ± 0.01 10.28 ± 1.25 10.98 ± 1.89
21o H 3-Ethynyl H H 6.27 ± 0.24 3.47 ± 0.13 ND ND
21p H H OPh H 8.47 ± 0.15 12.41 ± 0.04 ND ND
21q H Cl OCH2 (2-pyridinyl) H 4.62 ± 0.20 2.22 ± 0.54 ND ND
Cisplatin 4.95 ± 0.60 26.65 ± 4.19 ND ND
a Cell growth inhibition was measured by the SRB assay26 for solid tumor cells after 72-h incubation using a microplate spectrophotometer as described previously.27
b Cell growth inhibition was determined by the Alamar blue assay28 in a 72 h incubation using a microplate spectrophotometer as described previously.
c Not determined.
1990 B. Marvania et al. / Bioorg. Med. Chem. 19 (2011) 1987–1998(Table 1). It suggests that the N-mustard derivatives were neither a
good substrate of p-glycoprotein nor mutated tubulin.The selected compounds were further evaluated for their cyto-
toxicity in inhibiting other human solid tumors such as human
Figure 2. Representative DNA cross-linking gel shift assay for 21g, 21l, 21b, and
21e at various concentrations as indicated. Control lane shows single-stranded DNA
(SS), while cross-linking (CL) shown in all tested lanes is DNA double-stranded
cross-linking. Melphalan (1 and 5 lM) was used as a positive control.
B. Marvania et al. / Bioorg. Med. Chem. 19 (2011) 1987–1998 1991breast tumor (MX-1), colon cancer (HCT-116), human non-small
cell lung cancer (H1299), and prostate cancer (PC3) cell growth
in vitro. As shown in Table 2, one can see that these conjugates
possess good to moderate cytotoxic effects against the growth of
these cell lines tested in vitro. In comparison with the cytotoxici-
ties of the N-mustard-quinoline conjugates, previously synthesized
in our laboratory,13 the N-mustard-quinazoline conjugates are less
potent in inhibiting all tumor cell lines examined.
3.2. In vivo therapeutic activity
The in vitro cytotoxicity of the tested compound may not al-
ways directly reﬂex to its therapeutic efﬁcacy in tumor xenograft
model. In the present studies, we selected compounds 21b, 21g,
and 21h for evaluating their therapeutic efﬁcacy in nude mice
bearing human mammary carcinoma (MX-1) xenografts (Table
3). To ﬁnd a maximal tolerable dose of compound tested, we
administrated various doses to view its therapeutic effects via
intravenous injection (iv inj.). The preliminary results show that
compound 21h possessed signiﬁcant tumor growth inhibition
(72%) in comparison with the untreated control when mice were
treated successfully with the dose of 50 mg/kg, every two
days for three times (Q2D  3), 60 mg/kg (Q2D  3), and then
70 mg/kg, every two days for two times (Q2D  2). With the same
drug administration route (iv inj.), compound 21b showed a mod-
erate tumor inhibition (62%), at the doses of 30 mg/kg (Q2D  3)
and 35 mg/kg, every two days for ﬁve times (Q2D  5). Compound
21g also showed to have moderate tumor suppression (52%) at the
dose of 30 mg/kg (Q2D  3) and then 40 mg/kg (Q2D  5).
Although all the tested compounds induced a 5–7% body-weight
change during the treatment (Table 3), the body-weight of mice
readily recovered after cessation of the treatment, suggesting that
these agents have relatively low toxicity to the host.
Conjugates 21b and 21g were also selected for evaluating their
therapeutic efﬁcacy against human prostate PC-3 xenograft in
nude mice. Table 3 shows that there were 27% and 69% tumor sup-
pression by 21b and 21g, respectively, at the maximal tolerable
dose of 55 mg/kg, every two days for six times (Q2D  6) with
acceptable toxicity (about 10–11% body weight loss). Similar
observations were found that N-mustard-quinazoline conjugates
are much less potent against human breast MX-1 xenograft in mice
than that of the N-mustard-quinoline conjugates.13
3.3. DNA cross-linking study by alkaline agarose gel shift assay
The alkaline gel shift assay was performed to assess DNA cross-
linking activity of compounds 21g, 21l, 21b, and 21e (Fig. 2). The
pEGFP-N1 plasmid DNA was treated with compounds, 21g, 21l,
21b, and 21e at various concentrations as indicated (1, 10 and
20 lM). Melphalan was used as a positive control. The tested com-
pounds show moderate cross-linking behavior at lower concentra-
tions; however, at high concentrations, the cross-linking behavior
was similar to melphalan. These results revealed that the newly
synthesized N-mustard-quinazoline conjugates are capable to
induce DNA cross-linking.Table 3
Therapeutic effects and toxicity of N-mustard-quinazoline conjugates in nude mice bearin
Tumor
used
Compd Dose and schedule
MX-1 21b 30 mg/kg (Q2D  3) and then 35 mg/kg (Q2D  5)
21g 30 mg/kg (Q2D  3) and then 40 mg/kg (Q2D  5)
21h 50 mg/kg (Q2D  3), 60 mg/kg (Q2D  3), and then 70 mg/kg
(Q2D  2)
PC-3 21b 55 mg/kg (Q2D  6)
21g 55 mg/kg (Q2D  6)3.4. Cell cycle inhibition
It was reported that DNA damage induced by DNA alkylating
agents is known to cause cell cycle delay and arrest the cell cycle
progression predominantly at the G2/M boundary.22 We therefore
studied the inhibitory effect of 21b on cell cycle distribution
(Table 4). The human non-small cell lung carcinoma H1299 cells
were treated with 21b at the concentrations of 5, 10, and 20 lM
for 24 h. The cells were harvested, stained with propidium iodide
(PI) and analyzed with a ﬂow cytometer. It clearly shows that
5 lM of 21b signiﬁcantly accumulated the cells at G2/M phase,
while 10 and 20 lM of 21b prevented the cell cycle progression,
which may be due to high level of DNA cross-linking. Similar G2/
M arrest was previously observed in SW626 cells treated with mel-
phalan.23 Furthermore, increased sub-G1 populations were noticed
in cells treated with 21b at 20 lM.4. Conclusion
Recently, we have synthesized a series of N-mustard-quinoline
conjugates bearing a urea or hydrazinecarboxamide linker for anti-
tumor evaluation. We demonstrated that these conjugates exhib-
ited potent in vitro cytotoxicity and therapeutic efﬁcacy against
human xenografts. To continue our research on the developing
DNA-directed alkylating agents, we have synthesized a series of
N-mustard-quinazoline conjugates, in which the N-mustard phar-
macophore was attached at the C-6 of the 4-anilinoquinazolines
via a urea linker. A variety of substituent(s) were introduced to
the C-4 anilino moiety for studying their structure–activity rela-
tionships. The preliminary antitumor studies revealed that these
agents exhibited signiﬁcant antitumor activity in inhibiting various
human tumor cell growths in vitro. Among compounds selected for
evaluating their antitumor activity against human breast tumor
(MX-1) xenograft in nude mice, 4-[30-Cl,40-F-phenylamino]quinaz-
oline derivative (21h) is the most potent. We demonstrate that the
newly synthesized N-mustard-quinazoline conjugates are gener-
ally less potent than the N-mustard-quinoline conjugates. Studies
on the therapeutic efﬁcacy against MX-1 xenograft in nude mice
revealed that the tested compounds have moderate antitumorg human mammary carcinoma (MX-1) and prostate (PC-3) xenografts
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1992 B. Marvania et al. / Bioorg. Med. Chem. 19 (2011) 1987–1998activity, but they are less toxic to the host based on the observation
of the average body-weight changes. In the present studies we also
show that the newly synthesized compounds are able to induce
DNA cross-linking through alkaline agarose gel shift assay and
inhibited cell cycle arrest at G2/M phase.5. Experimental
5.1. General methods and materials
Compound solvents and reagents were reagent grade and used
without puriﬁcation unless otherwise noted. The melting points
were recorded on a Fargo melting point apparatus and are uncor-
rected. Column chromatography was carried out on Silica Gel
G60 (70–230 mesh, ASTM; Merck and 230–400 mesh, Silicycle
Inc.). Reaction progress was monitored using analytical thin-layer
chromatography (TLC) on 0.25 mm Merck F-254 silica gel glass
plates. Visualization was achieved by UV light (254 nm). 1H NMR
spectra were recorded with a Bruker AVANCE 600 DRX and
400 MHz spectrometer. Chemical shifts are reported in parts per
million (d) using tetramethylsilane as the internal standard with
coupling constants (J) reported in hertz (Hz). The peak shapes are
denoted as follows: s, singlet; d, doublet; t, triplet; q, quartet; m,
multiplet; dd, double doublet; br s, broad singlet. Elemental anal-
yses were performed on a Heraeus CHN–O Rapid analyzer. High
performance liquid chromatography analysis for checking purity
of synthesized compounds were recorded on a Hitachi D-2000 Elite
instrument: column, Mightysil RP-18 GP 250–4.6 (5 lL) mobile
phase, MeCN/THF (70:30 v/v); ﬂow rate, 1 mL/min; injected sam-
ple 10 lL, column temp, 27 C; wavelength, 254 nm. The purity
of all compounds was >95% based on analytical HPLC.
5.2. 4-Chloro-2-phenylquinazoline (11)
To a magnetically stirred solution of POCl3 (25 mL) at 0 C was
added portion wise 2-phenylquinazolin-4(3H)-one 10 (5.0 g). The
reaction mixture was reﬂuxed for 2 h. After completion of the reac-
tion, the excess POCl3 was removed by vacuo. The residue was
poured into a mixture of chloroform (50 mL) + ice cold water
(80 mL) + ammonia solution (20 mL). The chloroform layer was
separated and the aqueous layer was extracted with an additional
20 mL of chloroform. The united chloroform extracts were dried
over Na2SO4 and ﬁltered, and the solvent was removed by distilla-
tion to give 11, 4.5 g (87%); mp 125–127 C (lit.24 124–125 C); 1H
NMR (DMSO-d6) d 7.58–7.69 (4H, m, 4  ArH), 7.91–7.92 (2H, m,
2  ArH), 8.16–8.21 (3H, m, 3  ArH). Anal. (C14H9ClN2): C, H, N.
5.3. 2-Phenylquinazolin-4-amine (12)
A mixture of 4-chloro-2-phenylquinazolin 11 (3.0 g, 12.0 mmol)
and excess phenol was heated at 170 C for 2 h. After completion of
the reaction, the ammonia gas was passed into the reaction mass at
150 C for 1 h. After that the reaction mixture was cooled to room
temperature and poured into 5% sodium hydroxide solution. The
solid was ﬁltered and washed with water and dried to give 12,
2.0 g (74%); mp 140–141 C (lit.25 146–147 C); 1H NMR (DMSO-
d6) d 7.45–7.53 (4H, m, 4  ArH), 7.75–7.79 (2H, m, 2  ArH),
7.83 (2H, br s, exchangeable, NH2), 8.23–8.25 (1H, m, ArH), 8.45–
8.48 (2H, m, 2  ArH). Anal. (C14H11N3): C, H, N.
5.4. 1-(4-Bis(2-chloroethyl)phenyl)-3-(2-phenylquinazolin-4-yl)
urea (15)
A solution of isocyanate 14 (freshly prepared from 13, 1.5 g
4.9 mmol) in chloroform (10 mL) was added dropwise to a solution
B. Marvania et al. / Bioorg. Med. Chem. 19 (2011) 1987–1998 1993of 2-phenyl quinazolin-4-amine 12 (0.63 g, 2.8 mmol) in chloro-
form (30 mL) containing triethylamine (1 mL) at room tempera-
ture. The reaction mixture was stirred at room temperature for
1 h. The solid material was fall out from reaction mass. It was ﬁl-
tered and washed with chloroform to give 1-(4-bis(2-chloro-
ethyl)phenyl)-3-(2-phenylquinazolin-4-yl)urea 15, 0.2 g (17%);
mp 263–264 C; 1H NMR (DMSO-d6) d 3.68–3.71 (8H, m,
4  CH2), 6.81 (2H, d, J = 8.6 Hz, 2  ArH), 7.48 (2H, d, J = 8.6 Hz,
2  ArH), 7.58–7.56 (4H, m, 4  ArH), 7.94–7.95 (2H, m, 2  ArH),
8.35–8.37 (2H, m, 2  ArH), 8.72–8.74 (1H, m, ArH), 10.47, 12.02
(each 1H, s, exchangeable, 2  NH). Anal. (C25H23Cl2N5O): C, H, N.
5.5. (E)-N0-(2-Cyano-4-nitrophenyl)-N,N-dimethylformimida-
mide (17)
5-Nitroanthranilonitrile 16 (20.0 g, 122.5 mmol) was suspended
in dimethylformamide dimethylacetal (43 mL, 360.0 mmol). The
mixture was heated up to reﬂux temperature for 1.5 h. The result-
ing mixture was cooled to room temperature and refrigerated
overnight. The yellow precipitated was ﬁltered, washed with ethyl
ether to give 17, 25.0 g (96%); mp 153–154 C (lit.17 153–155 C);
1H NMR (DMSO-d6) d 3.09 (3H, s, Me), 3.17 (3H, s, Me), 7.36–
7.39 (1H, m, ArH), 8.25–8.28 (2H, m, 2  ArH), 8.47–8.48 (1H, m,
ArH). Anal. (C7H5N3O2): C, H, N.
5.6. N-(3-Fluorophenyl)-6-nitroquinazolin-4-amine (19a)
Toa solutionof (E)-N-(2-cyano-4-nitrophenyl)-N,N-dimethylfor-
mimidamide 17 (6.0 g, 2.7 mmol) and acetic acid (45 mL)was added
3-ﬂuoroaniline (18a, 3.3 g, 3.0 mmol) at room temperature. The
reaction mixture was heated up to reﬂux temperature for 1 h. After
completionof the reaction, the resultingmixturewas cooled to room
temperature. The solid separatedwasﬁlteredandwashedwithether
to give 19a, 6.5 g (83%);mp 255–256 C; 1HNMR (DMSO-d6) d 6.98–
7.03 (1H, m, ArH), 7.43–7.48 (1H, m, ArH), 7.68 (1H, d, J = 9.2 Hz,
ArH), 7.89–7.95 (2H, m, 2  ArH), 8.55 (1H, dd, J = 2.2 Hz,
J = 9.2 Hz, ArH), 8.77 (1H, s, ArH), 9.65 (1H, d, J = 2.2 Hz, ArH),
10.48 (1H, s, exchangeable, NH). Anal. (C14H9FN4O2): C, H, N.
By following the same procedure as that for 19a the following
compound were synthesized.
5.6.1. N-(3-Chlorophenyl)-6-nitroquinazolin-4-amine (19b)
Compound 19b was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (5.0 g, 2.2 mmol) and 3-
chloroaniline (18b, 3.2 g, 2.5 mmol) in acetic acid (40 mL): yield
6.2 g (90%); mp 285–286 C (lit.17 278–281 C); 1H NMR (DMSO-
d6) d 7.22–7.47 (1H, m, ArH), 7.43–7.47 (1H, m, ArH), 7.83–7.85
(1H, m, ArH), 7.95 (1H, d, J = 9.2 Hz, ArH), 8.07–8.08 (1H, m,
ArH), 8.56 (1H, dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.78 (1H, s, ArH),
9.65 (1H, d, J = 2.2 Hz, ArH), 10.48 (1H, s, exchangeable, NH). Anal.
(C14H9ClN4O2): C, H, N.
5.6.2. N-(3-Bromophenyl)-6-nitroquinazolin-4-amine (19c)
Compound 19c was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (5.0 g, 2.2 mmol) and 3-
bromoaniline (18c, 4.3 g, 2.5 mmol) in acetic acid (40 mL): yield
7.2 g (91%); mp 282–283 C (lit.17 267–270 C); 1H NMR (DMSO-
d6) d 7.35–7.41 (2H, m, 2  ArH), 7.90–7.92 (1H, m, ArH), 7.94 (1H,
d, J = 9.1 Hz, ArH), 8.18–8.19 (1H, m, ArH), 8.56 (1H, dd, J = 2.2 Hz,
J = 9.1 Hz, ArH), 8.77 (1H, s, ArH), 9.64 (1H, d, J = 2.2 Hz, ArH),
10.46 (1H, s, exchangeable,NH).Anal. Calcd forC14H9BrN4O2: C,H,N.
5.6.3. N-(3-(Triﬂuoromethyl)phenyl)-6-nitroquinazolin-4-
amine (19d)
Compound 19d was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (5.0 g, 2.2 mmol) and 3-(triﬂuoromethyl)aniline (18d, 4.0 g, 2.5 mmol) in acetic acid
(40 mL): yield 6.5 g (85%); mp 210–211 C (lit.26 209–211 C); 1H
NMR (DMSO-d6) d 7.52–7.54 (1H, m, ArH), 7.65–7.69 (1H, m,
ArH), 7.97 (1H, d, J = 9.1 Hz, ArH), 8.25–8.29 (2H, m, 2  ArH),
8.59 (1H, dd, J = 2.2 Hz, J = 9.1 Hz, ArH), 8.79 (1H, s, ArH), 9.67
(1H, d, J = 2.2 Hz, ArH), 10.61 (1H, s, exchangeable, NH). Anal.
(C15H9F3N4O2): C, H, N.
5.6.4. N-(4-Fluorophenyl)-6-nitroquinazolin-4-amine (19e)
Compound 19e was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (4.0 g, 1.5 mmol) and 4-
ﬂuoroaniline (18e, 2.2 g, 2.0 mmol) in acetic acid (30 mL): yield
5.0 g (96%); mp 257–258 C; 1H NMR (DMSO-d6) d 7.28–7.32 (2H,
m, 2  ArH), 7.84–7.88 (2H, m, 2  ArH), 7.96 (1H, d, J = 9.2 Hz,
ArH), 8.58 (1H, dd, J = 2.5 Hz, J = 9.2 Hz, ArH), 8.72 (1H, s, ArH),
9.66 (1H, d, J = 2.5 Hz, ArH), 10.51 (1H, s, exchangeable, NH). Anal.
(C14H9FN4O2): C, H, N.
5.6.5. N-(4-Bromophenyl)-6-nitroquinazolin-4-amine (19f)
Compound 19f was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (3.0 g, 1.3 mmol) and 4-
bromoaniline (18f, 2.6 g, 1.5 mmol) in acetic acid (25 mL): yield
4.0 g (84%); mp 279–280 C; 1H NMR (DMSO-d6) d 7.62–7.65 (2H,
m, 2  ArH), 7.86–7.89 (2H, m, 2  ArH), 7.97 (1H, d, J = 9.2 Hz,
ArH), 8.57–8.60 (1H, dd, J = 2.4 Hz, J = 9.2 Hz, ArH), 8.76 (1H, s,
ArH), 9.67 (1H, d, J = 2.4 Hz, ArH), 10.51 (1H, s, exchangeable,
NH). Anal. (C14H9BrN4O2): C, H, N.
5.6.6. N-(2-Fluoro-3-chlorophenyl)-6-nitroquinazolin-4-amine
(19g)
Compound 19g was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (5.0 g, 2.2 mmol) and 2-
ﬂuoro-3-chloroaniline (18g, 3.6 g, 2.5 mmol) in acetic acid
(35 mL): yield 5.5 g (75%); mp 224–226 C; 1H NMR (DMSO-d6) d
7.30–7.34 (1H, m, ArH), 7.52–7.56 (2H, m, 2  ArH), 7.74–8.01
(1H, m, ArH), 8.57–8.65 (2H, m, 2  ArH), 9.55 (1H, s, ArH), 10.73
(1H, s, exchangeable, NH). Anal. (C14H8ClFN4O2): C, H, N.
5.6.7. N-(3-Chloro-4-ﬂuorophenyl)-6-nitroquinazolin-4-amine
(19h)
Compound 19h was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (3.0 g, 1.3 mmol) and 3-
chloro-4-ﬂuoroaniline (18h, 2.2 g, 1.5 mmol) in acetic acid
(20 mL): yield 4.0 g (91%); mp 280–281 C (lit.27 274–277 C); 1H
NMR (DMSO-d6) d 7.45–7.50 (1H, m, ArH), 7.81–7.83 (1H, m,
ArH), 7.94 (1H, d, J = 9.2 Hz, ArH), 8.14–8.17 (1H, m, ArH), 8.55
(1H, dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.74 (1H, s, ArH), 9.60 (1H, d,
J = 2.2 Hz, ArH), 10.50 (1H, s, exchangeable, NH). Anal.
(C14H8ClFN4O2): C, H, N.
5.6.8. N-(3,4-Dichlorophenyl)-6-nitroquinazolin-4-amine (19i)
Compound 19i was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (6.0 g, 2.7 mmol) and
3,4-dichloroaniline (18i, 4.9 g, 3.0 mmol) in acetic acid (45 mL):
yield 8.0 g (86%); mp 297–298 C; 1H NMR (DMSO-d6) d 7.65–
7.67 (1H, m, ArH), 7.89–7.96 (2H, m, 2  ArH), 8.27–8.28 (1H, m,
ArH), 8.54–8.57 (1H, m, ArH), 8.79 (1H, s, ArH), 9.61–9.62 (1H, m,
ArH), 10.49 (1H, s, exchangeable, NH). Anal. (C14H8Cl2N4O2): C, H,
N.
5.6.9. N-(3-Bromo-4-ﬂuorophenyl)-6-nitroquinazolin-4-amine
(19j)
Compound 19j was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (4.0 g, 1.5 mmol) and 3-
bromo-4-ﬂuoroaniline (18j, 4.0 g, 2.0 mmol) in acetic acid
(30 mL): yield 6.0 g (90%); mp 260–261 C (lit.27 257–258 C); 1H
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7.95 (1H, d, J = 9.2 Hz, ArH), 8.25–8.26 (1H, m, ArH), 8.56 (1H, dd,
J = 2.2 Hz, J = 9.2 Hz, ArH), 8.75 (1H, s, ArH), 9.61 (1H, d,
J = 2.2 Hz, ArH), 10.48 (1H, s, exchangeable, NH). Anal. (C14H8
BrFN4O2): C, H, N.
5.6.10. N-(4-Chloro-3-(triﬂuoromethyl)phenyl)-6-nitroquina-
zolin-4-amine (19k)
Compound 19k was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (3.0 g, 1.3 mmol) and 4-
chloro-3-(triﬂuoromethyl)aniline (18k, 2.8 g, 1.4 mmol) in acetic
acid (30 mL): yield 4.5 g (90%); mp 221–222 C; 1H NMR (DMSO-
d6) d 7.77–7.79 (1H, m, ArH), 7.98 (1H, d, J = 9.2 Hz, ArH), 8.32–
8.34 (1H, m, ArH), 8.43–8.44 (1H, m, ArH), 8.58 (1H, dd, J = 2.2 Hz,
J = 9.2 Hz, ArH), 8.81 (1H, s, ArH), 9.63 (1H, s, J = 2.2 Hz, ArH),
10.53 (1H, s, exchangeable, NH). Anal. (C15H8ClF3N4O2): C, H, N.
5.6.11. N-(3-Chloro-4-methoxyphenyl)-6-nitroquinazolin-4-
amine (19l)
Compound 19l was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (5.0 g, 2.2 mmol) and 3-
chloro-4-methoxyaniline (18l, 3.9 g, 2.5 mmol) in acetic acid
(40 mL): yield 6.8 g (91%); mp 290–291 C; 1H NMR (DMSO-d6) d
3.90 (3H, s, Me), 7.21–7.23 (1H, m, ArH), 7.75–7.77 (1H, m, ArH),
7.91 (1H, d, J = 9.2 Hz, ArH), 7.99–8.00 (1H, m, ArH), 8.52 (1H, dd,
J = 2.4 Hz, J = 9.2 Hz, ArH), 8.70 (1H, s, ArH), 9.60 (1H, d,
J = 2.4 Hz, ArH), 10.38 (1H, s, exchangeable, NH). Anal.
(C15H11ClN4O3): C, H, N.
5.6.12. N-(3-Methoxyphenyl)-6-nitroquinazolin-4-amine (19m)
Compound 19m was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (5.0 g, 2.2 mmol) and 3-
methoxyaniline (18m, 3.0 g, 2.5 mmol) in acetic acid (35 mL): yield
6.0 g (89%); mp 241–242 C; 1H NMR (DMSO-d6) d 3.82 (3H, s, Me),
6.78–6.81 (1H, m, ArH), 7.32–7.37 (1H, m, ArH), 7.49–7.53 (2H, m,
2  ArH), 7.93 (1H, d, J = 9.2 Hz, ArH), 8.54–8.57 (1H, dd, J = 2.2 Hz,
J = 9.2 Hz, ArH), 8.74 (1H, s, ArH), 9.66 (1H, d, J = 2.2 Hz, ArH), 10.38
(1H, s, exchangeable, NH). Anal. (C15H12N4O3): C, H, N.
5.6.13. N-(3,4,5-Trimethoxyphenyl)-6-nitroquinazolin-4-amine
(19n)
Compound 19n was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (5.0 g, 2.2 mmol) and
3,4,5-trimethoxyaniline (18n, 4.6 g, 2.5 mmol) in acetic acid
(40 mL): yield 5.5 g (68%); mp 274–275 C; 1H NMR (DMSO-d6) d
3.81 (3H, s, Me), 3.69 (6H, s, 2 Me), 7.27 (2H, s, 2  ArH), 7.93
(1H, d, J = 9.2 Hz, ArH), 8.56 (1H, dd, J = 2.2 Hz, J = 9.2 Hz, ArH),
8.72 (1H, s, ArH), 9.64 (1H, d, J = 2.2 Hz, ArH), 10.32 (1H, s,
exchangeable, NH). Anal. (C17H16N4O5): C, H, N.
5.6.14. N-(3-Ethynylphenyl)-6-nitroquinazolin-4-amine (19o)
Compound 19o was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (3.0 g, 1.3 mmol) and 3-
ethynylaniline (18o, 1.6 g, 1.3 mmol) in acetic acid (30 mL): yield
3.8 g (95%); mp 271–272 C; 1H NMR (DMSO-d6) d 4.25 (1H, s,
CH), 7.30–7.32 (1H, m, ArH), 7.44–7.48 (1H, m, ArH), 7.92–7.95
(2H, m, 2  ArH), 8.05–8.06 (1H, m, ArH), 8.54–8.57 (1H, m, ArH),
8.76 (1H, s, ArH), 9.65–9.66 (1H, m, ArH), 10.48 (1H, s, exchange-
able, NH). Anal. (C16H10N4O20.5): C, H, N.
5.6.15. N-(4-Phenoxyphenyl)-6-nitroquinazolin-4-amine (19p)
Compound 19p was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)-N,N-dimethylformimidamide 17 (5.0 g, 2.2 mmol) and 4-
phenoxyaniline (18p, 4.6 g, 2.5 mmol) in acetic acid (40 mL): yield
6.0 g (73%); mp 296–298 C (lit.27 293–294 C); 1H NMR (DMSO-d6)
d 7.06–7.08 (2H, m, 2  ArH), 7.11–7.13 (2H, m, 2  ArH), 7.17–7.19 (1H, m, ArH), 7.42–7.46 (2H, m, 2  ArH), 7.85–7.87 (2H, m,
2  ArH), 7.94 (1H, d, J = 9.2 Hz, ArH), 8.57 (1H, dd, J = 2.4 Hz,
J = 9.2 Hz, ArH), 8.71 (1H, s, ArH), 9.67 (1H, d, J = 2.4 Hz, ArH),
10.55 (1H, s, exchangeable, NH). Anal. (C20H14N4O3): C, H, N.
5.6.16. N-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)-6-nitroqui-
nazolin-4-amine (19q)
Compound 19q was synthesized from (E)-N-(2-cyano-4-nitro-
phenyl)- N,N-dimethylformimidamide 17 (3.0 g, 1.3 mmol) and
3-chloro-4-(pyridine-2-ylmethoxy)aniline (18q, 3.2 g, 1.3 mmol)
in acetic acid (30 mL): yield 5.0 g (89%); mp 241–242 C; 1H NMR
(DMSO-d6) d 5.32 (2H, s, CH2), 7.30–7.33 (1H, m, ArH), 7.39–7.40
(1H, m, ArH), 7.60–7.62 (1H, m, ArH), 7.74–7.75 (1H, m, ArH),
7.88–7.95 (2H, m, 2  ArH), 8.04–8.05 (1H, m, ArH), 8.55–8.57
(1H, m, ArH), 8.62–7.63 (1H, m, ArH), 8.73 (1H, s, ArH), 9.62–9.63
(1H, m, ArH), 10.43 (1H, s, exchangeable, NH). Anal.
(C20H14ClN5O32H2O): C, H, N.
5.7. N4-(3-Fluorophenyl)quinazolin-4,6-diamine (20a)
A mixture of N-(3-ﬂuorophenyl)-6-nitroquinazolin-4-amine
19a (6.0 g, 21.1 mmol) and iron (8.13 g, 147.8 mmol) were sus-
pended in aqueous ethanol (600 mL, 70% v/v) containing acetic
acid (16.3 mL, 295.4 mmol). The mixture was heated up to reﬂux
temperature for 2 h. After completion of the reaction, the reaction
mixture was cooled to room temperature and alkalinized by addi-
tion of concentrated ammonia solution (120 mL). The insoluble
material was removed by ﬁltration through Celite, and the ﬁltrate
was evaporated under reduce pressure. The resulting solid was
washed with 10% K2CO3 solution and ﬁnally with water and dried
to give 20a, 4.0 g, (75%); mp 188–189 C; 1H NMR (DMSO-d6) d
5.62 (2H, s, exchangeable, NH2), 6.84–6.88 (1H, m, ArH), 7.25–
7.28 (1H, m, ArH), 7.35–7.40 (2H, m, 2  ArH), 7.54–7.56 (1H, m,
ArH), 7.67–7.69 (1H, m, ArH), 7.93–7.96 (1H, m, ArH), 8.39 (1H, s,
ArH), 9.47 (1H, s, exchangeable, NH). Anal. (C14H11FN40.8H2O):
C, H, N.
By following the same procedure as that for 20a the following
compound were synthesized.
5.7.1. N4-(3-Chlorophenyl)quinazolin-4,6-diamine (20b)
Compound 20b was synthesized from N-(3-chlorophenyl)-6-
nitroquinazolin-4-amine 19b (5.0 g, 16.6 mmol) and iron (6.3 g,
116.2 mmol) in aqueous ethanol (400 mL, 70% v/v) containing ace-
tic acid (13.3 mL, 232.4 mmol): yield 3.5 g (78%); mp 175–176 C
(lit.17 186–189 C); 1H NMR (DMSO-d6) d 5.62 (2H, s, exchangeable,
NH2), 7.09–7.11 (1H, m, ArH), 7.25–7.28 (1H, m, ArH), 7.34–7.39
(2H, m, 2  ArH), 7.54–7.56 (1H, m, ArH), 7.82–7.85 (1H, m, ArH),
8.12–8.13 (1H, m, ArH), 8.39 (1H, s, ArH), 9.46 (1H, s, exchangeable,
NH). Anal. (C14H11ClN4): C, H, N.
5.7.2. N4-(3-Bromophenyl)quinazolin-4,6-diamine (20c)
Compound 20c was synthesized from N-(3-bromophenyl)-6-
nitroquinazolin-4-amine 19c (6.0 g, 17.3 mmol) and iron (6.69 g,
121.7 mmol) in aqueous ethanol (600 mL, 70% v/v) containing ace-
tic acid (13.9 mL, 243.4 mmol): yield 4.2 g (78%); mp 204–206 C
(lit.17 203–204 C); 1H NMR (DMSO-d6) d 5.62 (2H, s, exchangeable,
NH2), 7.22–7.35 (4H, m, 4  ArH), 7.54–7.56 (1H, m, ArH), 7.88–
7.90 (1H, m, ArH), 8.24–8.25 (1H, m, ArH), 8.38 (1H, s, ArH), 9.44
(1H, s, exchangeable, NH). Anal. (C14H11BrN4): C, H, N.
5.7.3. N4-(3-(Triﬂuoromethyl)phenyl)quinazolin-4,6-diamine
(20d)
Compound 20d was synthesized from N-(3-(triﬂuoro-
methyl)phenyl)-6-nitroquinazolin-4-amine 19d (6.0 g, 17.9 mmol)
and iron (6.9 g, 125.0 mmol) in aqueous ethanol (600 mL, 70% v/v)
containing acetic acid (14.3 mL, 250.0 mmol): yield 3.4 g (63%);
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NH2), 7.29–7.31 (1H, m, ArH), 7.39–7.42 (2H, m, 2  ArH), 7.58–
7.63 (2H, m, 2  ArH), 8.24–8.26 (1H, m, ArH), 8.37–8.38 (1H, m,
ArH), 8.42 (1H, s, ArH), 9.62 (1H, s, exchangeable, NH). Anal.
(C15H11F3N4): C, H, N.
5.7.4. N4-(4-Fluorophenyl)quinazolin-4,6-diamine (20e)
Compound 20e was synthesized from N-(4-ﬂuorophenyl)-6-
nitroquinazolin-4-amine 19e (4.0 g, 14.0 mmol) and iron (5.4 g,
98.5 mmol) in aqueous ethanol (400 mL, 70% v/v) containing acetic
acid (11.2 mL, 196.0 mmol): yield 3.5 g (97%); mp 185–186 C; 1H
NMR (DMSO-d6) d 5.60 (2H, s, exchangeable, NH2), 7.30–7.32
(2H, m, 2  ArH), 7.40–7.56 (3H, m, 3  ArH), 7.71–7.73 (2H, m,
2  ArH), 8.30 (1H, s, ArH), 9.29 (1H, s, exchangeable, NH). Anal.
(C14H11FN41.3H2O): C, H, N.
5.7.5. N4-(4-Bromophenyl)quinazolin-4,6-diamine (20f)
Compound 20f was synthesized from N-(4-bromophenyl)-6-
nitroquinazolin-4-amine 19f (4.0 g, 11.5 mmol) and iron (4.4 g,
80.5 mmol) in aqueous ethanol (400 mL, 70% v/v) containing acetic
acid (5 mL, 162.0 mmol): yield 3.2 g (88%); mp 210–211 C; 1H
NMR (DMSO-d6) d 5.63 (2H, s, exchangeable, NH2), 7.27–7.29
(2H, m, 2  ArH), 7.53–7.56 (3H, m, 3  ArH), 7.90–7.92 (2H, m,
2  ArH), 8.38 (1H, s, ArH), 9.45 (1H, s, exchangeable, NH). Anal.
(C14H11BrN40.2H2O): C, H, N.
5.7.6. N4-(2-Fluoro-3-chlorophenyl)quinazolin-4,6-diamine
(20g)
Compound 20g was synthesized from N-(2-ﬂuoro-3-chloro-
phenyl)-6-nitroquinazolin-4-amine 19g (5.0 g, 15.7 mmol) and
iron (6.0 g, 110.0 mmol) in aqueous ethanol (500 mL, 70% v/v) con-
taining acetic acid (12.5 mL, 219.0 mmol): yield 3.0 g (67%); mp
257–258 C; 1H NMR (DMSO-d6) d 5.65 (2H, s, exchangeable,
NH2), 7.25–7.27 (3H, m, 3  ArH), 7.43–7.44 (1H, m, ArH), 7.54–
7.56 (2H, m, 2  ArH), 8.24 (1H, s, ArH), 9.42 (1H, s, exchangeable,
NH). Anal. (C14H10ClFN4): C, H, N.
5.7.7. N4-(3-Chloro-4-ﬂuorophenyl)quinazolin-4,6-diamine
(20h)
Compound 20h was synthesized from N-(3-chloro-4-ﬂuoro-
phenyl)-6-nitroquinazolin-4-amine 19h (2.0 g, 6.2 mmol) and iron
(2.4 g, 44.0 mmol) in aqueous ethanol (200 mL, 70%v/v) containing
acetic acid (5 mL, 57.9 mmol): yield 1.4 g (83%); mp 255–256 C
(lit.27 263–265 C); 1H NMR (DMSO-d6) d 5.62 (2H, s, exchangeable,
NH2), 7.24–7.27 (1H, m, ArH), 7.34–7.35 (1H, m, ArH), 7.38–7.43
(1H, m, ArH), 7.53–7.54 (1H, m, ArH), 7.83–7.84 (1H, m, ArH),
8.22–8.22 (1H, m, ArH), 8.36 (1H, s, ArH), 9.50 (1H, s, exchangeable,
NH). Anal. (C14H10ClFN4): C, H, N.
5.7.8. N4-(3,4,-Dichlorophenyl)quinazolin-4,6-diamine (20i)
Compound 20i was synthesized from N-(3,4,-dichlorophenyl)-
6-nitroquinazolin-4-amine 19i (7.0 g, 20.8 mmol) and iron (8.0 g,
146.2 mmol) in aqueous ethanol (600 mL, 70% v/v) containing ace-
tic acid (16.6 mL, 291.0 mmol): yield 5.5 g (86%); mp 243–244 C;
1H NMR (DMSO-d6) d 5.66 (2H, s, exchangeable, NH2), 7.27–7.30
(1H, m, ArH), 7.34–7.35 (1H, m, ArH), 7.56–7.61 (2H, m, 2  ArH),
7.91–7.93 (1H, m, ArH), 8.34–8.35 (1H, m, ArH), 8.42 (1H, s, ArH),
9.55 (1H, s, exchangeable, NH). Anal. (C14H10Cl2N4): C, H, N.
5.7.9. N4-(3-Bromo-4-ﬂuorophenyl)quinazolin-4,6-diamine
(20j)
Compound 20j was synthesized from N-(3-bromo-4-ﬂuoro-
phenyl)-6-nitroquinazolin-4-amine 19j (6.0 g, 16.5 mmol) and iron
(6.36 g, 115.0 mmol) in aqueous ethanol (600 mL, 70% v/v) con-
taining acetic acid (13.2 mL, 231.0 mmol): yield 3.5 g (64%); mp
225–226 C (lit.27 224–225 C); 1H NMR (DMSO-d6) d 5.61 (2H, s,exchangeable, NH2), 7.25–7.27 (1H, m, ArH), 7.31–7.32 (1H, m,
ArH), 7.35–7.40 (1H, m, ArH), 7.53–7.55 (1H, m, ArH), 7.88–7.89
(1H, m, ArH), 8.30–8.31 (1H, m, ArH), 8.36 (1H, s, ArH), 9.45 (1H,
s, exchangeable, NH). Anal. (C14H10BrFN4): C, H, N.
5.7.10. N4-(4-Chloro-3-(triﬂuoromethyl)phenyl)quinazolin-4,6-
diamine (20k)
Compound 20k was synthesized from N-(4-chloro-3-(triﬂuoro-
methyl)phenyl)-6-nitroquinazolin-4-amine 19k (4.0 g, 10.8 mmol)
and iron (4.2 g, 75.8 mmol) in aqueous ethanol (400 mL, 70% v/v)
containing acetic acid (8.6 mL, 151.0 mmol): yield 2.0 g (56%);
mp 265–266 C; 1H NMR (DMSO-d6) d 5.67 (2H, s, exchangeable,
NH2), 7.27–7.29 (1H, m, ArH), 7.33–7.34 (1H, m, ArH), 7.56–7.58
(1H, m, ArH), 7.68–7.70 (1H, m, ArH), 8.29–8.31 (1H, m, ArH),
8.40–8.41 (1H, m, ArH), 8.48 (1H, s, ArH), 9.69 (1H, s, exchangeable,
NH). Anal. (C15H10ClF3N4): C, H, N.
5.7.11. N4-(3-Chloro-4-methoxyphenyl)quinazolin-4,6-diamine
(20l)
Compound 20l was synthesized from N-(3-chloro-4-methoxy-
phenyl)-6-nitroquinazolin-4-amine 19l (6.0 g, 18.0 mmol) and iron
(6.9 g, 126.0 mmol) in aqueous ethanol (600 mL, 70% v/v) contain-
ing acetic acid (14.4 mL, 252.0 mmol): yield 3.7 g (69%); mp 235–
237 C; 1H NMR (DMSO-d6) d 3.58 (3H, s, Me), 5.57 (2H, s,
exchangeable, NH2), 7.15–7.16 (1H, m, ArH), 7.24–7.26 (1H, m,
ArH), 7.33–7.34 (1H, m, ArH), 7.52–7.54 (1H, m, ArH), 7.73–7.54
(1H, m, ArH), 8.02–8.03 (1H, m, ArH), 8.32 (1H, s, ArH), 9.32 (1H,
s, exchangeable, NH). Anal. (C15H13ClN4O): C, H, N.
5.7.12. N4-(3-Methoxyphenyl)quinazolin-4,6-diamine (20m)
Compound 20m was synthesized from N-(3-methoxyphenyl)-
6-nitroquinazolin-4-amine 19m (5.5 g, 18.5 mmol) and iron
(7.2 g, 130.0 mmol) in aqueous ethanol (600 mL, 70% v/v) contain-
ing acetic acid (14.8 mL, 260.0 mmol): yield 3.2 g (75%); mp 182–
183 C; 1H NMR (DMSO-d6) d 3.77 (3H, s, Me), 5.57 (2H, s,
exchangeable, NH2), 6.63–6.66 (1H, m, ArH), 7.23–7.27 (2H, m,
2  ArH), 7.36–7.37 (1H, m, ArH), 7.49–7.58 (3H, m, 3  ArH),
8.35 (1H, s, ArH), 9.28 (1H, s, exchangeable, NH). Anal.
(C15H14N4O0.2H2O): C, H, N.
5.7.13. N4-(3,4,5-Trimethoxyphenyl)quinazolin-4,6-diamine
(20n)
Compound 20n was synthesized from N-(3,4,5-trimethoxy-
phenyl)-6-nitroquinazolin-4-amine 19n (5.0 g, 14.0 mmol) and
iron (5.4 g, 98.3 mmol) in aqueous ethanol (500 mL, 70% v/v) con-
taining acetic acid (11.2 mL, 196.5 mmol): yield 2.9 g (64%); mp
220–221 C; 1H NMR (DMSO-d6) d 3.66 (3H, s, Me), 3.79 (6H, s,
2 Me), 5.54 (2H, s, exchangeable, NH2), 7.22–7.25 (1H, m, ArH),
7.34–7.35 (3H, m, 3  ArH), 7.51–7.53 (1H, m, ArH), 8.33 (1H, s,
ArH), 9.19 (1H, s, exchangeable, NH). Anal. (C17H18N4O3): C, H, N.
5.7.14. N4-(3-Ethynylphenyl)quinazolin-4,6-diamine (20o)
Compound 20o was synthesized from N-(3-ethynylphenyl)-6-
nitroquinazolin-4-amine 19o (4.5 g, 15.5 mmol) and iron (5.9 g,
108.0 mmol) in aqueous ethanol (450 mL, 70% v/v) containing ace-
tic acid (12.4 mL, 217.0 mmol): yield 2.5 g (62%); mp 110–111 C;
1H NMR (DMSO-d6) d 4.17 (1H, s, CH), 5.60 (2H, s, exchangeable,
NH2), 7.16–7.18 (1H, m, ArH), 7.24–7.27 (1H, m, ArH), 7.35–7.39
(2H, m, 2  ArH), 7.53–7.56 (1H, m, ArH), 7.90–7.92 (1H, m, ArH),
8.08–8.09 (1H, m, ArH), 8.37 (1H, s, ArH), 9.39 (1H, s, exchangeable,
NH). Anal. (C16H12N41.2H2O): C, H, N.
5.7.15. N4-(4-Phenoxyphenyl)quinazolin-4,6-diamine (20p)
Compound 20p was synthesized from N-(4-phenoxyphenyl)-6-
nitroquinazolin-4-amine 19p (6.0 g, 16.7 mmol) and iron (6.4 g,
117.0 mmol) in aqueous ethanol (600 mL, 70% v/v) containing ace-
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(lit.27 89–90 C); 1H NMR (DMSO-d6) d 5.40 (2H, s, exchangeable,
NH2), 6.97–6.99 (2H, m, 2  ArH), 7.09–7.11 (2H, m, 2  ArH),
7.30–7.39 (3H, m, 3  ArH), 7.47–7.49 (2H, m, 2  ArH), 7.67–
7.78 (3H, m, 3  ArH), 8.51 (1H, s, ArH), 9.50 (1H, s, exchangeable,
NH). Anal. (C20H16N4O): C, H, N.
5.7.16. N4-(3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)
quinazolin-4,6-diamine (20q)
Compound 20q was synthesized from N-(3-chloro-4-(pyridin-
2-ylmethoxy)phenyl)-6-nitroquinazolin-4-amine 19q (6.0 g,
14.7 mmol) and iron (5.6 g, 103.0 mmol) in aqueous ethanol
(600 mL, 70% v/v) containing acetic acid (11.7 mL, 205.0 mmol):
yield 2.5 g (40%); mp 238–239 C; 1H NMR (DMSO-d6) d 5.28 (2H,
s, CH2), 5.57 (2H, s, exchangeable, NH2), 7.23–7.24 (2H, m, 2  ArH),
7.31–7.37 (2H, m, 2  ArH), 7.51–7.53 (1H, m, ArH), 7.58–7.60 (1H,
m, ArH), 7.71–7.73 (1H, m, ArH), 7.86–7.88 (1H, m, ArH), 8.06–8.07
(1H, m, ArH), 8.32–8.33 (1H, m, ArH), 8.60 (1H, s, ArH), 9.33 (1H, s,
exchangeable, NH). Anal. (C20H16ClN5O): C, H, N.5.8. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-ﬂuorophe-
nylamino)quinazolin-6-yl)urea (21a)
To a solution of N4-(3-ﬂuorophenylamino)quinazolin-4,6-dia-
mine (20a, 0.99 g, 3.9 mmol) in dry THF (40 mL) containing trieth-
ylamine (2.7 mL) was added a solution of isocyanate 14 (freshly
prepared from 13, 3.00 g, 9.7 mmol) in dry THF (15 mL) at room
temperature. After being stirred for 1 h at room temperature, the
solid was ﬁltered and washed with dry THF. The ﬁltrate was evap-
orated to dryness in vacuo. The residue was puriﬁed by column
chromatography using CHCl3/MeOH (100:2 v/v) as an eluent. The
fractions containing the main product were combined and evapo-
rated to dryness. The residue was recrystallized from CHCl3 to give
21a, 0.99 g, (50%); mp 190–191 C (dec); 1H NMR (DMSO-d6) d
3.69–3.71 (8H, m, 4  CH2), 6.73 (2H, d, J = 9.0 Hz, 2  ArH),
6.89–6.94 (1H, m, ArH), 7.34 (2H, d, J = 9.0 Hz, 2  ArH), 7.37–
7.43 (1H, m, ArH), 7.66–7.67 (1H, m, ArH), 7.75–7.77 (1H, m,
ArH), 7.87–7.92 (2H, m, 2  ArH), 8.45–7.46 (1H, m, ArH), 8.55
(1H, s, ArH), 8.57, 8.83, 9.85 (each 1H, s, exchangeable, 3  NH).
Anal. (C25H23Cl2FN6OH2O): C, H, N.
By following the same procedure as that for 21a the following
compound were synthesized.
5.8.1. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-chloro-
phenylamino)quinazolin-6-yl)urea (21b)
Compound 21bwas synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(3-chlorophenyl)quinazolin-4,6-dia-
mine (20b, 0.70 g, 2.6 mmol) in dry THF (35 mL) containing trieth-
ylamine (1.8 mL): yield 0.90 g (65%); mp 172–173 C (dec); 1H
NMR (DMSO-d6) d 3.69–3.71 (8H, m, 4  CH2), 6.73 (2H, d,
J = 8.8 Hz, 2  ArH), 7.14–7.17 (1H, m, ArH), 7.34 (2H, d,
J = 8.8 Hz, 2  ArH), 7.38–7.42 (1H, m, ArH), 7.76 (1H, d,
J = 9.1 Hz, ArH), 7.81–7.83 (1H, m, ArH), 7.89 (1H, dd, J = 2.2 Hz,
J = 9.1 Hz, ArH), 8.06–8.07 (1H, m, ArH), 8.46 (1H, d, J = 2.2 Hz
ArH), 8.55 (1H, s, ArH), 8.59, 8.85, 9.83 (each 1H, s, exchangeable,
3  NH). Anal. (C25H23Cl3N6OH2O): C, H, N.5.8.2. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-bromo-
phenylamino)quinazolin-6-yl)urea (21c)
Compound 21cwas synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(3-bromophenyl)quinazolin-4,6-dia-
mine (20c, 0.82 g, 2.6 mmol) in dry THF (35 mL) containing trieth-
ylamine (1.8 mL): yield 0.80 g (57%); mp 165–166 C (dec); 1H
NMR (DMSO-d6) d 3.71–3.73 (8H, m, 4  CH2), 6.75–6.77 (2H, m,
2  ArH), 7.32–7.38 (4H, m, 4  ArH), 7.77–7.79 (1H, m, ArH),7.91–7.94 (2H, m, 2  ArH), 8.21–8.22 (1H, m, ArH), 8.48–8.49
(1H, m, ArH), 8.57 (1H, s, ArH), 8.61, 8.87, 9.85 (each 1H, s,
exchangeable, 3  NH). Anal. (C25H23BrCl2N6O1.5H2O): C, H, N.
5.8.3. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-(triﬂuoro-
methyl)phenylamino)quinazolin-6-yl)urea (21d)
Compound 21dwas synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(3-(triﬂuoromethyl)phenyl)quinazo-
lin-4,6-diamine (20d, 0.79 g, 2.6 mmol) in dry THF (35 mL)
containing triethylamine (1.8 mL): yield 0.75 g (51%); mp 210–
211 C (dec); 1H NMR (DMSO-d6) d 3.70–3.71 (8H, m, 4  CH2),
6.74 (2H, d, J = 8.8 Hz, 2  ArH), 7.34 (2H, d, J = 8.8 Hz, 2  ArH),
7.43–7.45 (1H, m, ArH), 7.60–7.64 (1H, m, ArH), 7.76–7.78 (1H,
m, ArH), 7.87–7.89 (1H, m, ArH), 8.20–8.22 (1H, m, ArH), 8.29–
8.31 (1H, m, ArH), 8.50–8.51 (1H, m, ArH), 8.56 (1H, s, ArH), 8.58,
8.85, 9.98 (each 1H, s, exchangeable, 3  NH). Anal.
(C26H23Cl2F3N6O0.5H2O): C, H, N.
5.8.4. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(4-ﬂuorophe-
nylamino)quinazolin-6-yl)urea (21e)
Compound 21ewas synthesized from 14 (freshly prepared from
13, 3.00 g, 9.7 mmol) and N4-(4-ﬂuorophenyl)quinazolin-4,6-dia-
mine (20e, 0.99 g, 3.9 mmol) in dry THF (40 mL) containing trieth-
ylamine (2.7 mL): yield 1.0 g (53%); mp 223–224 C (dec); 1H NMR
(DMSO-d6) d 3.69–3.71 (8H, m, 4  CH2), 6.74 (2H, d, J = 9.0 Hz,
2  ArH), 7.19–7.24 (2H, m, 2  ArH), 7.34 (2H, d, J = 9.0 Hz,
2  ArH), 7.73 (1H, d, J = 9.0 Hz, ArH), 7.80–7.83 (2H, m, 2  ArH),
7.88 (1H, dd, J = 2.0 Hz, J = 9.0 Hz, ArH), 8.42 (1H, d, J = 2.0 Hz,
ArH), 8.46 (1H, s, ArH) 8.56, 8.79, 9.75 (each 1H, s, exchangeable,
3  NH). Anal. (C25H23Cl2FN6O): C, H, N.
5.8.5. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(4-bromophe-
nylamino)quinazolin-6-yl)urea (21f)
Compound 21f was synthesized from 14 (freshly prepared from
13, 1.50 g, 4.8 mmol) and N4-(4-bromophenyl)quinazolin-4,6-dia-
mine (20f, 0.61 g, 1.9 mmol) in dry THF (30 mL) containing triethyl-
amine (1.3 mL): yield 0.40 g (36%); mp 220–221 C (dec); 1H NMR
(DMSO-d6) d 3.69–3.71 (8H, m, 4  CH2), 6.73 (2H, d, J = 9.0 Hz,
2  ArH), 7.33 (2H, d, J = 9.0 Hz, 2  ArH), 7.56 (2H, d, J = 8.8 Hz,
2  ArH), 7.74 (1H, d, J = 9.0 Hz, ArH), 7.84 (2H, d, J = 8.8 Hz,
2  ArH), 7.89 (1H, dd, J = 9.0 Hz, J = 2.0 Hz, ArH), 8.47 (1H, d,
J = 2.0 Hz, ArH), 8.50 (1H, s, ArH), 8.59, 8.84, 9.80 (each 1H, s,
exchangeable, 3  NH). Anal. (C25H23BrCl2N6O1.5H2O): C, H, N.
5.8.6. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(2-ﬂuoro-3-
chlorophenylamino)quinazolin-6-yl)urea (21g)
Compound 21gwas synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(2-ﬂuoro-3-chlorophenyl)quinazolin-
4,6-diamine (20g, 0.75 g, 2.6 mmol) in dry THF (35 mL) containing
triethylamine (1.8 mL): yield 0.97 g (69%); mp 210–211 C (dec);
1H NMR (DMSO-d6) d 3.68–3.71 (8H, m, 4  CH2), 6.73 (2H, d,
J = 9.0 Hz, 2  ArH), 7.25–7.29 (1H, m, ArH), 7.33 (2H, d,
J = 9.0 Hz, 2  ArH), 7.45–7.54 (2H, m, 2  ArH), 7.72–7.73 (1H,
m, ArH), 7.82–7.84 (1H, m, ArH), 8.41–8.42 (1H, m, ArH), 8.46
(1H, s, ArH) 8.58, 8.87, 9.86 (each 1H, s, exchangeable, 3  NH).
Anal. (C25H22Cl3FN6O0.5H2O): C, H, N.
5.8.7. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-chloro-4-
ﬂuorophenylamino)quinazolin-6-yl)urea (21h)
Compound 21hwas synthesized from 14 (freshly prepared from
13, 0.53 g, 1.7 mmol) and N4-(3-chloro-4-ﬂuorophenyl)quinazolin-
4,6-diamine 20h (0.20 g, 0.6 mmol) in dry THF (20 mL) containing
triethylamine (0.5 mL): yield 0.14 g (37%); mp 200–201 C (dec);
1H NMR (DMSO-d6) d 3.67–3.75 (8H, m, 4  CH2), 6.73 (2H, d,
J = 9.0 Hz, 2  ArH), 7.34 (2H, d, J = 9.0 Hz, 2  ArH), 7.41–7.46
(1H, m, ArH), 7.74–7.88 (3H, m, 3  ArH), 8.14–8.17 (1H, m, ArH),
B. Marvania et al. / Bioorg. Med. Chem. 19 (2011) 1987–1998 19978.45–8.46 (1H, m, ArH), 8.52 (1H, s, ArH), 8.57, 8.83, 9.85 (each 1H,
s, exchangeable, 3  NH). Anal. (C25H22Cl3FN6O): C, H, N.
5.8.8. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3,4-dichloro-
phenylamino)quinazolin-6-yl)urea (21i)
Compound 21i was synthesized from 14 (freshly prepared from
13, 1.00 g, 3.2 mmol) and N4-(3,4,-dichlorophenyl)quinazolin-4,6-
diamine (20i, 0.40 g, 1.3 mmol) indryTHF (25 mL) containing trieth-
ylamine (0.9 mL): yield 0.55 g (71%); mp 225–226 C (dec); 1H NMR
(DMSO-d6) d 3.67–3.73 (8H, m, 4  CH2), 6.74 (2H, d, J = 8.8 Hz,
2  ArH), 7.34 (2H, d, J = 8.8 Hz, 2  ArH), 7.61–7.63 (1H, m, ArH),
7.75–7.77 (1H, m, ArH), 7.87–7.90 (2H, m, 2  ArH), 8.28–8.29 (1H,
m, ArH), 8.47–8.48 (1H, m, ArH), 8.57 (1H, s, ArH) 8.58, 8.86, 9.91
(each 1H, s, exchangeable, 3  NH). Anal. (C25H22Cl4N6O): C, H, N.
5.8.9. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-bromo-4-
ﬂuorophenylamino)quinazolin-6-yl)urea (21j)
Compound 21j was synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(3-bromo-4-ﬂuorophenyl)quinazolin-
4,6-diamine (20j, 0.87 g, 2.6 mmol) in dry THF (35 mL) containing
triethylamine (1.8 mL): yield 0.25 g (17%); mp 175–176 C (dec);
1H NMR (DMSO-d6) d 3.73–3.75 (8H, m, 4  CH2), 6.76 (2H, d,
J = 8.8 Hz, 2  ArH), 7.36 (2H, d, J = 8.8 Hz, 2  ArH), 7.41–7.43
(1H, m, ArH), 7.77 (1H, d, J = 9.2 Hz, ArH), 7.87–7.90 (2H, m,
2  ArH), 8.26 (1H, dd, J = 2.2 Hz, J = 9.2 Hz, ArH), 8.48 (1H, d,
J = 2.2 Hz ArH), 8.54 (1H, s, ArH), 8.63, 8.89, 9.86 (each 1H, s,
exchangeable, 3  NH). Anal. (C25H22BrCl2FN6O1.5H2O): C, H, N.
5.8.10. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(4-chloro-3-
(triﬂuoromethyl)phenylamino)quinazolin-6-yl)urea (21k)
Compound 21kwas synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(4-chloro-3-(triﬂuoromethyl)phenyl)
quinazolin-4,6-diamine (20k, 0.80 g, 2.6 mmol) in dry THF (35 mL)
containing triethylamine (1.8 mL): yield 0.80 g (52%); mp 220–
221 C (dec); 1H NMR (DMSO-d6) d 3.67–3.73 (8H, m, 4  CH2),
6.73 (2H, d, J = 8.8 Hz, 2  ArH), 7.34 (2H, d, J = 8.8 Hz, 2  ArH),
7.71–7.73 (1H, m, ArH), 7.76–7.92 (1H, m, ArH), 7.85–7.88 (1H, m,
ArH), 8.27–8.31 (1H, m, ArH), 8.43–8.44 (1H, m, ArH), 8.51–8.52
(1H,m,ArH), 8.56 (1H, s,ArH)8.57, 8.87, 10.05 (each1H, s, exchange-
able, 3  NH). Anal. (C26H22Cl3F3N6O0.5H2O): C, H, N.
5.8.11. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-chloro-4-
methoxyphenylamino)quinazolin-6-yl)urea (21l)
Compound 21l was synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(3-chloro-4-methoxyphenyl)quinazo-
lin-4,6-diamine (20l, 0.78 g, 2.6 mmol) in dry THF (35 mL) contain-
ing triethylamine (1.8 mL): yield 1.0 g (69%); mp 168–169 C (dec);
1H NMR (DMSO-d6) d 3.69–3.72 (8H, m, 4  CH2), 3.87 (3H, s, Me),
6.73 (2H, d, J = 8.6 Hz, 2  ArH), 7.17–7.19 (1H, m, ArH), 7.34 (2H,
d, J = 8.6 Hz, 2  ArH), 7.72–7.73 (2H, m, 2  ArH), 7.85–7.87 (1H,
m, ArH), 7.96–7.97 (1H, m, ArH), 8.42–8.43 (1H, m, ArH), 8.47
(1H, s, ArH) 8.56, 8.79, 9.70 (each 1H, s, exchangeable, 3  NH).
Anal. (C26H25Cl3N6O2H2O): C, H, N.
5.8.12. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-methoxy-
phenylamino)quinazolin-6-yl)urea (21m)
Compound 21m was synthesized from 14 (freshly prepared
from 13, 2.50 g, 8.1 mmol) and N4-(3-methoxyphenyl)quinazolin-
4,6-diamine (20m, 0.87 g, 3.2 mmol) in dry THF (35 mL) containing
triethylamine (2.2 mL): yield 1.1 g (65%); mp 159–160 C (dec); 1H
NMR (DMSO-d6) d 3.69–3.71 (8H, m, 4  CH2), 3.78 (3H, s, Me),
6.68–7.70 (1H, m, ArH), 6.73 (2H, d, J = 9.0 Hz, 2  ArH), 7.26–
7.28 (1H, m, ArH), 7.33 (2H, d, J = 9.0 Hz, 2  ArH), 7.45–7.46 (1H,
m, ArH), 7.52–7.53 (1H, m, ArH), 7.73 (1H, d, J = 9.0 Hz, ArH),
7.90 (1H, dd, J = 2.1 Hz, J = 9.0 Hz, ArH), 8.42 (1H, d, J = 2.1 Hz,
ArH), 8.50 (1H, s, ArH) 8.57, 8.81, 9.65 (each 1H, s, exchangeable,
3  NH). Anal. (C26H26Cl2N6O2H2O): C, H, N.5.8.13. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3,4,
5-trimethoxyphenylamino)quinazolin-6-yl)urea (21n)
Compound 21nwas synthesized from 14 (freshly prepared from
13, 1.00 g, 3.2 mmol) and N4-(3,4,5-trimethoxyphenyl)quinazolin-
4,6-diamine (20n, 0.42 g, 1.3 mmol) in dry THF (25 mL) containing
triethylamine (0.9 mL): yield 0.49 g (66%); mp 154–155 C (dec);
1H NMR (DMSO-d6) d 3.33 (3H, s, Me), 3.67–3.72 (8H, m,
4  CH2), 3.80 (6H, s, 2 Me), 6.74 (2H, d, J = 9.0 Hz, 3  ArH),
7.28 (2H, s, 2  ArH), 7.34 (2H, d, J = 9.0 Hz, 2  ArH), 7.73 (1H, d,
J = 8.9 Hz, ArH), 7.85–7.88 (1H, dd, J = 2.0 Hz, J = 8.9 Hz, ArH), 8.42
(1H, d, J = 2.0 Hz, ArH), 8.49 (1H, s, ArH) 8.56, 8.81, 9.58 (each
1H, s, exchangeable, 3  NH). Anal. (C28H30Cl2N6O4H2O): C, H, N.
5.8.14. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-ethynyl-
phenylamino)quinazolin-6-yl)urea (21o)
Compound 21owas synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(3-ethynylphenyl)quinazolin-4,6-dia-
mine (20o, 0.68 g, 2.6 mmol) in dry THF (35 mL) containing trieth-
ylamine (1.8 mL): yield 0.75 g (52%); mp 164–165 C (dec); 1H
NMR (DMSO-d6) d 3.67–3.73 (8H, m, 4  CH2), 4.19 (1H, s, CH),
6.73 (2H, d, J = 8.8 Hz, 2  ArH), 7.20–7.21 (1H, m, ArH), 7.34 (2H,
d, J = 8.8 Hz, 2  ArH), 7.37–7.41 (1H, m, ArH), 7.73–7.76 (1H, m,
ArH), 7.88–7.90 (2H, m, 2  ArH), 8.03–8.04 (1H, m, ArH), 8.44–
8.45 (1H, m, ArH), 8.52 (1H, s, ArH) 8.58, 8.82, 9.78 (each 1H, s,
exchangeable, 3  NH). Anal. (C27H24Cl2N6OH2O): C, H, N.
5.8.15. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(4-phenoxy-
phenylamino)quinazolin-6-yl)urea (21p)
Compound 21pwas synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(4-phenoxyphenyl)quinazolin-4,6-
diamine (20p, 0.85 g, 2.6 mmol) in dry THF (35 mL) containing tri-
ethylamine (1.8 mL): yield 0.30 g (33%); mp 143–144 C (dec); 1H
NMR (DMSO-d6) d 3.31–3.71 (8H, m, 4  CH2), 6.72–6.74 (2H, m,
2  ArH), 7.01–7.07 (4H, m, 4  ArH), 7.10–7.14 (1H, m, ArH),
7.32–7.41 (4H, m, 4  ArH), 7.71–7.73 (1H, m, ArH), 7.81–7.90 (3H,
m, 3  ArH), 8.41–8.42 (1H, m, ArH), 8.46 (1H, s, ArH) 8.58, 8.80,
9.73 (each 1H, s, exchangeable, 3  NH). Anal. (C31H28Cl2N6O2H2O):
C, H, N.
5.8.16. 1-(4-(Bis(2-chloroethyl)amino)phenyl)-3-(4-(3-chloro-4-
(pyridin-2-ylmethoxy)phenylamino)quinazolin-6-yl)urea (21q)
Compound 21qwas synthesized from 14 (freshly prepared from
13, 2.00 g, 6.5 mmol) and N4-(3-chloro-4-(pyridin-2-ylmeth-
oxy)phenyl)quinazolin-4,6-diamine (20q, 0.98 g, 2.6 mmol) in dry
THF (35 mL) containing triethylamine (1.8 mL): yield 0.90 g (56%);
mp 156–157 C (dec); 1H NMR (DMSO-d6) d 3.68–3.74 (8H, m,
4  CH2), 5.30 (2H, s, CH2), 6.74 (2H, d, J = 9.0 Hz, 2  ArH), 7.25–
7.27 (1H, m, ArH), 7.34 (2H, d, J = 9.0 Hz, 2  ArH), 7.37–7.39 (1H,
m, ArH), 7.58–7.60 (1H, m, ArH), 7.69–7.74 (2H, m, 2  ArH), 7.86–
7.91 (2H, m, 2  ArH), 8.01–8.02 (1H, m, ArH), 8.42–8.42 (1H, m,
ArH), 8.48 (1H, s, ArH), 8.60–8.61 (1H, m, ArH) 8.57, 8.80, 9.72 (each
1H, s, exchangeable, 3  NH). Anal. (C31H28Cl3N7O21.5H2O): C, H, N.
5.9. Biological experiments
5.9.1. Cytotoxicity assays
The effects of the newly synthesized compounds on cell growth
were determined in T-cell acute lymphocytic leukemia CCRF-CEM)
and their resistant subcell lines (CCRF-CEM/Taxol and CCRF-CEM/
VBL) by the XTT assay28 and human solid tumor cells (i.e., breast
carcinoma MX-1 and colon carcinoma HCT-116) by the SRB assay29
in a 72 h incubation using a microplate spectrophotometer as de-
scribed previously.30 After the addition of phenazine methosul-
fate-XTT solution at 37 C for 6 h, absorbance at 450 and 630 nm
was detected on a microplate reader (EL 340; Bio-Tek Instruments
Inc., Winooski, VT). The cytotoxicity of the newly synthesized
1998 B. Marvania et al. / Bioorg. Med. Chem. 19 (2011) 1987–1998compounds against non-small cell lung cancer H1299, human
prostate cancer PC3, were determined by the Alamar blue assay31
in a 72 h incubation using a microplate spectrophotometer as de-
scribed previously. After the addition of Alamar blue solution, it
was incubated at 37 C for 6 h. Absorbance at 570 and 600 nm
was detected on a microplate reader. IC50 values were determined
from dose–effect relationship at six or seven concentrations of
each drug using the CompuSyn software by Chou and Martin32
based on the median-effect principle and plot.33,34 Ranges given
for Taxol and vinblastine were mean ± SE (n = 4).
5.9.2. In vivo studies
Athymic nudemice bearing the nu/nu genewere used for human
breast tumor MX-1 and prostate PC-3 xenograft. Outbred Swiss-
background mice were obtained from the National Cancer Institute
(Frederick, MD). Male mice 8 weeks old or older weighing about
22 g were used for the experiments. Drug was administrated via
the tail vein by iv injection.27 Tumor volumeswere assessedbymea-
suring length width  height (or width) by using caliper. Vehicle
used was DMSO (50 lL) and Tween 80 (40 lL) in saline (160 lL).
Themaximal tolerabledoseof the tested compoundwasdetermined
and applied for the in vivo antitumor activity assay. All animal stud-
ieswere conducted in accordancewith theguidelinesof theNational
Institutes of Health Guide for the Care and Use of Animals and the
protocol approved by theMemorial Sloan-Kettering Cancer Center’s
Institutional Animal Care and Use Committee.
5.9.3. Alkaline agarose gel shift assay
Formation of DNA cross-linking was analyzed by alkaline aga-
rose gel electrophoresis. In brief, puriﬁed pEGFP-N1 plasmid DNA
(1500 ng) was mixed with various concentrations (1–20 lM) of
21g, 21l, 21b and 21e in 40 lL binding buffer (3 mM sodium chlo-
ride/1 mM sodium phosphate, pH 7.4, and 1 mM EDTA). The reac-
tion mixture was incubated at 37 C for 2 h. At the end of reaction,
the plasmid DNA was linearized by digestion with BamHI and fol-
lowed by precipitation with ethanol. The DNA pellets were dis-
solved and denatured in alkaline buffer (0.5 N NaOH–10 mM
EDTA). An aliquot of 20 lL of DNA solution (1000 ng) was mixed
with a 4 lL of 6 alkaline loading dye and then electrophoretically
resolved on a 0.8% alkaline agarose gel with NaOH–EDTA buffer at
4 C. The electrophoresis was carried out at 18 V for 22 h. After
staining the gels with an ethidium bromide solution, and the
DNA was then visualized under UV light.
5.9.4. Flow cytometric analysis
The effects of 21b on cell cycle distribution were analyzed with
a ﬂow cytometer as described previously.35 Brieﬂy, human non-
small cell lung carcinoma H1299 cells were treated with 21b at
5, 10, and 20 lM for 24 h. The attached cells were then trypsinized,
washed with phosphate buffer saline (PBS), and ﬁxed with ice-cold
70% ethanol for 30 min. The cells were stained with 4 lg/mL propi-
dium iodide (PI) in PBS containing 1% Triton X-100 and 0.1 mg/mL
RNase A. The stained cells were then analyzed using the FACS SCAN
ﬂow cytometer (Becton Dickinson, San Joes, CA, USA). The percent-
age of the cells in each cell cycle phase was determined using the
ModFit LT 2.0 software based on the DNA histograms.
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